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ABSTRACT OF THESIS
Trilostane and epostane are synthetic steroids which inhibit the 3/5 “
hydroxysteroid dehydrogenase enzyme. This enzyme is part of a system 
which catalyses an essential step in the synthesis of biologically 
active steroids. In animals and man trilostane preferentially 
inhibits adrenal steroid synthesis whilst epostane inhibits 
placental/ovarian steroid synthesis.
The synthesis of radiolabelled trilostane and epostane are 
described. Stability investigations showed these radiolabelled 
compounds to be susceptible to degradation, although trilostane less 
so than epostane. Careful handling procedures were essential for 
metabolism studies.
Animal studies showed no difference in the overall excretion and
14
distribution of radioactivity for [ Cl -trilostane and
14
[ C] -epostane. However the site specific localisation of active 
components within adrenals and ovaries reflected the in vivo organ 
selectivity observed for these compounds.
In man a major plasma metabolite of trilostane was shown to be 17- 
ketotrilostane which is intrinsically twice as active as parent 
compound with regard to 3/5 -hydroxysteroid dehydrogenase inhibition. 
A specific, sensitive and accurate HPIC assay was developed which 
enabled the measurement of trilostane and 17-ketotrilostane in 
plasma. Plasma concentrations of 17-ketotrilostane in male 
volunteers were approximately three-fold higher than trilostane, and 
consequently this metabolite may be an important contributor to the 
clinical efficacy of this drug.
Micronisation of both trilostane and epostane was shown to be 
appropriate in order to maximise the oral systemic availability of 
these corrpounds. However even with micronised formulations 
considerable inter-and irrtra— subject variability was noted. For 
trilostane, variability in absorption, coupled with individual 
differences in the metabolism to the more active 17-ketotrilostane, 
may in part account for the variable efficacy encountered in 
clinical trials.
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SUMMARY OF CHAPTER 1
The chemistry and biochemical actions of trilostane and epostane 
are presented. In vitro and in vivo data established the 
mechanism of action of these compounds as inhibitors of the 
3 (3 -hydroxysteroid dehydrogenase enzyme. Trilostane is shown to 
be more effective in inhibiting adrenal steroid synthesis than 
epostane. Epostane is an effective inhibitor of ovarian/placental 
steroid synthesis. The potential clinical uses of these compounds 
are discussed.
1.1 GENERAL INTROIXfCITON
Trilostane and epostane were prepared at the Sterl ing-Winthrop 
Research Institute, Rensselaer, New York, as part of a continuing 
program involving the synthesis and reactions of steroidal 
heterocycles. Both compounds were initially found to inhibit
5
adrenal function due to competitive inhibition of A -3 @ -
hydroxysteroid dehydrogenase. This enzyme transforms C and C
5 4
A -3^ -hydroxysteroids to the corresponding A -3- ketosteroids in
5 4the presence of NAEH- and 3-oxosteroid A ' - isamerase. This is an 
essential step in the biosynthesis of biologically active steroids 
and occurs in most endocrine tissues.
Neither compound exhibits steroid hormone agonist activity at 
effective inhibitory doses and tissue selectivity has been 
observed for each agent. Trilostane is an effective inhibitor of 
adrenal steroidogenesis in laboratory animals and man. In 
contrast, epostane inhibits ovarian/placental steroid synthesis 
more effectively than adrenal steroid synthesis. The organ 
selectivity of each agent formed the basis for the use of 
trilostane in the human as an inhibitor of excessive corticoid 
biosynthesis and investigation of epostane as a menstrual 
regulator/interceptive agent/inducer of parturition in animals as 
well as human. In addition to the use of trilostane for 
treatment of adrenal cortical hyperfunction clinical studies at
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the onset of this project indicated a beneficial effect of the 
combination of trilostane and a glucocorticoid administered to 
post-menopausal women with breast cancer. This indication was 
postulated to occur via inhibition of the steroidal aromatase 
enzyme.
The efficacy of trilostane has been somewhat variable during 
clinical trials, whilst for epostane the response to treatment has 
been more consistent.
In order to understand this apparent separation of activity from 
two such closely related structures and the variable clinical 
response it was essential to investigate the metabolism and 
pharmacokinetics of these compounds in animals and particularly in 
man.
1.2 CHEMISTRY
Trilostane and epostane are non-proprietary names approved by the 
United States Adopted Names Council (USAN) and World Health 
Organisation (INN) for the compounds, (4a,5Q',17jQ ) -4,5-epoxy-3, 
17-dihydroxyandrost-2-ene-2-carbonitrile, and (4Ce ,5a ,17^ )-4,5- 
epoxy-3,17 -dihydroxy-4,17 -dimethylandrost-2 -ene-2 -carbonitrile, 
respectively (Fig. 1). The compounds, also known by the Sterling 
Research codes Win 24,540 and Win 32,729 are closely related 
synthetic steroids derived from testosterone. The molecular
- 11-
Figure 1 Structures of trilostane and epostane
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formulas are C H NO and C H NO and molecular weights 329.4 
20 27 3 22 31 3
and 357.5, respectively. Nuclear magnetic resonance (NMR) and 
infra red (IR) spectra of these compounds have shown that they are 
mixtures of keto and enol tautomers (11). For simplicity only the 
enol tautomers will be used in illustrations throughout this 
thesis.
The epoxide of these conpounds is of the alpha configuration and 
is obligatory for the inhibition of the 3 ft -hydroxysteroid 
dehydrogenase enzyme (11). Two polymorphic forms of epostane have 
been identified and designated as Form I and Form II (18). All 
investigations have been conducted with the lower melting 
polymorph, Form I. No evidence of polymorphism for trilostane has 
been found (19).
1.3 BIOCHEMICAL ACTIONS OF TRILOSTANE AND EPOSTANE
The inhibitory actions of trilostane and epostane upon different 
endocrine glands have been investigated in a number of in vitro 
and in vivo studies.
1.3.1 Effects on the adrenal cortex: The adrenal gland consists of two
parts which are embryologically and functionally distinct, the
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inner medulla and the surrounding cortex. Histologically, the 
adrenal cortex consists of three layers, the outer zona 
glamerulosa, a broken, scattered layer of cells immediately 
beneath the capsule of the gland, the central zona fasciculata and 
the innermost zona reticularis. The most Important steroids 
produced by the adrenal cortex are the glucocorticoid, cortisol 
and the mineralocorticoid, aldosterone. Oestrogens are also 
synthesised in the cortex but only in minor quantities and adrenal 
androgens, though produced in relatively large amounts have only a 
weak physiological action. Cortisol, androgens and oestrogens are 
synthesised primarily in the zona fasciculata-zona reticularis and 
aldosterone is produced in the zona glamerulosa. The main 
metabolic steps in the production of different hormones in the 
adrenal cortex are shown in figure 2. The level of circulating 
adrenocorticoids is under homeostatic control via adrenocortico- 
trqphic hormone (ACIH) for glucocorticoids and the renin- 
angiotensin system for mineralocorticoids.
1.3.1.1 In vitro studies on adrenal enzyme inhibition; In isolated rat
adrenal microsames, trilostane competitively inhibited the
production of progesterone from pregnenolone with a K
i
(dissociation constant for the enzyme-inhibitor complex) =2.3 x
-7
10 M (6). Trilostane was however ineffective in blocking the
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Fig. 2 Biosynthesis of adrenal steroids
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conversion of cholesterol to pregnenolone and progesterone to 
other steroids in adrenal mitochondria, thus locating the site of 
action at the 3 ft -hydroxysteroid dehydrogenase level. In a 
similar system, epostane was shown to inhibit rat adrenal 3 ft - 
hydroxysteroid enzyme with a = 2.0 x Hf^M (9). Further 
evidence for 3 @ -hydroxysteroid dehydrogenase inhibition was
gained in bovine adrenal glands. In mitochondria from bovine
-7 . . . .adrenal cortex 1 x 10 M trilostane significantly reduced
pregnenolone metabolism without inhibiting cholesterol side chain
cleavage (12). Moreover, in further studies (13), the in vitro
conversion of tritiated pregnenolone to other steroids was 65.3%
in the absence of trilostane. This conversion was reduced to
—846.9% in the presence of 2 x 10 M trilostane and to 18.9% at the
-7concentration of 2 x 10 M trilostane.
-7Trilostane (2 x 10 M) decreased cortisol synthesis and release 
both in non-stimulated and ACIH stimulated ovine adrenal tissue 
(14). Further studies of ovine adrenal have confirmed these 
effects for trilostane and also demonstrated that 11 -
hydroxysteroid dehydrogenase activity was stimulated (8). 
However, when human adrenal adenomas were examined, trilostane 
inhibited the 3 ft -hydroxysteroid dehydrogenase but the lift -enzyme 
was unaffected.
- 16-
Cortisol synthesis was reduced in ACIH stimulated dispersed guinea 
pig adrenal cells (15). 50% inhibition was obtained by the
addition of 1.3 x 10 Si trilostane. The same degree of inhibition 
was achieved with 0.44 x 10 Si epostane.
In an anaesthetised dog model # the rapid iv infusion of 10 mg/kg 
trilostane to dogs constantly infused with ACIH (0.2 iu/min) 
caused a marked reduction in the cortisol and corticosterone 
content of the adrenal vein within 5 minutes of administration, 
and was maintained for the duration of the 4 h experiment (16). 3
steroids, pregnenetriol, 17-hydroxypregnenolone and pregnenolone 
increased in concentrations in the adrenal vein during the 
infusion period. This indication of 3 -hydroxysteroid 
dehydrogenase inhibition was confirmed by histochemical studies in 
which the 3 -hydroxysteroid dehydrogenase in the adrenal glands 
of dogs given 1.25 mg/kg trilostane intravenously, was reduced 
compared with the enzyme activity of control animals (17).
In adrenal adenoma tissue slices (obtained from Cushings Syndrome 
patients) the addition of 2 x 10 Si trilostane to the incubation 
medium reduced the conversion of pregnenolone to other steroids 
from 40% in controls to 10.7%. The utility of trilostane for the 
control of glucocorticoid excess was therefore indicated.
1.3.1.2 In vivo studies on adrenal cortical hormone secretion: Oral
treatment of intact male rats with trilostane (2-200 mg/kg) for 
two weeks caused a dose-dependent increase in circulating 
pregnenolone in the presence and absence of ACIH stimulation. 
Corticosterone levels however were suppressed only after ACIH 
administration (6). In the same study a single oral trilostane 
dose of 12.5 mg/kg significantly inhibited corticoid production in 
ACIH stimulated pseudopregnant rats. Epostane was only found to 
be effective in suppressing circulating corticosterone levels in 
the pseudopregnant rat after ACIH stimulation at doses greater 
than 20 mg/kg orally (20).
Trilostane was shown to depress circulating plasma aldosterone 
levels in male rats maintained on a low sodium diet after ACIH 
stimulation (6). Treatment of male rats with trilostane (25 mg/kg 
x 3 orally) in combination with furosemide (a diuretic which 
enhances urinary sodium excretion and potassium loss) 
significantly reduced the diuretic-induced kaliuresis without 
altering urine volume or sodium (21). Doses of 50 mg/kg x 3 
orally were required to produce similar results for epostane. In 
the deoxycorticosterone acetate (DOCA) - treated adrenalectomised 
rat, trilostane was ineffective alone or in combination with DOCA, 
in altering electrolyte excretion (21). In contrast
- 18-
spironolactone reversed DOCA - induced sodium retention. These 
studies indicated that trilostane inhibits mineralocorticoid 
biosynthesis rather than the action of the sodium-retaining 
corticoids, which is consistent with 3 ft -hydroxysteroid 
dehydrogenase inhibition.
The effect of trilostane and epostane on ACIH-stimulated cortisol 
production in intact female rhesus monkeys has been examined (22). 
Trilostane significantly inhibited ACIH-induced cortisol secretion 
at an oral dose of 10 mg/monkey and further reduced cortisol 
levels at doses of 50 and 250 mg/monkey. Epostane inhibited 
ACIH-stimulated cortisol secretion at a dose of 250 mg/monkey but 
did not significantly reduce cortisol levels at doses of 10 and 
50 mg/monkey (9, 20). The greater affinity of trilostane for 
inhibiting adrenal steroid synthesis compared to epostane has also 
been observed in human (30). In a comparative study of early 
human pregnancy the effects of trilostane and epostane on the 
adrenal were assessed by changes in the ratio of plasma cortisol 
to plasma dehydroepiandrosterone (DHEA) concentrations. 
Trilostane caused a 50% reduction in the cortisol/DHEA ratio 
following a 30 mg oral dose. A similar reduction was only 
observed with epostane following a 100 mg oral dose.
Treatment of Cushing's syndrome patients (6 pituitary—dependent 
Cushing's Disease and one adrenocortical carcinoma) with 
trilostane in various dosage regimens (200-1000 mg/day orally) 
significantly reduced cortisol and 17-hydroxycorticosteroid 
urinary excretion rates (23). Plasma cortisol levels also 
declined. Conversely, DHEA-sulphate levels in plasma increased 
and urinary output increased. A significant reduction in urinary 
excretion of 3 a. -5 @ -hydroaldosterone, 3 a -5 fi -hydrodeoxy 
corticosterone and 18-hydroxy 3 a -5jg hydrodeoxycorticosterone was 
noted with treatment. These observations indicated that 
trilostane is an effective inhibitor of the 3fi -hydroxysteroid 
dehydrogenase enzyme system in human adrenal gland. However, 
although effectiveness in the treatment of Cushing' s syndrome 
patients has been confirmed (24, 25) a number of studies have 
shown that the response of Cushings syndrome patients is variable 
(24, 26, 27). Investigations in normal healthy human volunteers 
have also given conflicting data upon the effect of trilostane on 
adrenal steroidogenesis (28, 29, 31).
1.3.2 Actions on other endocrine organs
1.3.2.1 Effects on the ovarv/placenta: In pseudopregnant rats given ACIH,
trilostane decreased progesterone levels after a 500 mg/kg oral 
dose (6). Epostane was also effective in suppressing progesterone
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levels in pseudopregnant rats after ACIH stimulation, but at much 
lower doses i.e. 20 mg/kg (9). Marked separation of tissue 
selectivity has also been reported for trilostane and epostane 
with respect to interceptive activity in the rat. The minimum 
effective dose for 100% termination on day 10 of pregnancy in the 
rat was approximately 50 and 500 mg/kg (as a single oral dose) for 
epostane and trilostane, respectively (6, 9, 11). The ability of 
both agents to interrupt pregnancy was found to be dose dependent 
and could be blocked by the concomitant administration of 
progesterone.
Administration of 100 IU human chorionic gonadotrophin (HOG) to 
cycling rhesus monkeys induced a rise in progesterone levels which 
remained elevated above control levels for several days. Oral 
administration of 500 mg/monkey of trilostane, along with HOG 
resulted in a prompt decline in progesterone levels (22). 
Administration of only 100 mg/monkey of epostane, in addition to 
HOG on day 22 of the menstrual cycle resulted in a sharp reduction 
in progesterone levels 24 hours later. Neither trilostane nor 
epostane significantly altered the length of the menstrual cycles 
compared to the monkeys treated with HOG alone (32).
Trilostane was 100% effective in terminating pregnancy in monkeys 
(n = 6) when administered orally at a dose of 500 mg/monkey for
five days starting on approximately day 25 of gestation, but was 
not effective when given at a dose of 100 mg/monkey. When drug 
administration started on day 50 of gestation, trilostane at a 
dose of 500 mg/monkey terminated pregnancy in 13 out of 17 (76%) 
monkeys an effect that was prevented by concurrent administration 
of progesterone (22). When epostane was administered orally 
starting on day 50 of gestation, only a dose of 50 mg/monkey was 
required to terminate pregnancy in 26 of 34 (76%) animals. A dose 
of 100 mg/monkey of epostane for five days interrupted pregnancy 
in 18 of 24 animals (75%) and pregnancy was terminated in all 
monkeys (n = 6) treated with 250 mg/monkey (9). The interceptive 
effect of epostane in rhesus monkeys was also prevented by the 
concurrent administration of progesterone (20).
Equivalent doses of trilostane and epostane were evaluated in 
early human pregnancy (30). Patients and controls (less than 12 
weeks pregnant) were given a single oral dose (25-120 mg) of 
either drug and the resultant hormonal changes monitored over 8 h. 
A consistent fall in plasma progesterone concentrations occurred 
at all doses and, at the highest doses (100 or 120 mg), fell to 
less than 50% of pre-treatment levels. However, whilst with 
trilostane the associated increase in plasma concentrations of 
pregnenolone was always accompanied by a rise in plasma DHEA 
concentrations, with epostane there appeared to be no adrenal
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effect at the lower dosage levels (25 or 50 mg). Tissue 
selectivity of trilostane and epostane in human tissue, as with 
monkey, was therefore suggested.
In further studies of epostane in early human pregnancy 3 groups 
of pregnant women (5-8 weeks, 8-12 weeks, and 12-18 weeks of 
pregnancy) and 15 women in the luteal phase of the menstrual cycle 
were studied in a single dose, randomised, double-blind study 
(63). Each woman received a placebo, 50 mg epostane or 100 mg 
epostane. In the pregnant group as a whole there was a 
significant decline in serum progesterone after both 50 mg and 100 
mg of epostane. The percentage fall increased with both dosage 
and advancing gestation. Similar falls in serum oestradiol were 
observed and both effects were only temporary, returning toward 
pre-treatment values within 24 h of dosing. In the luteal phase 
group a significant decline in serum progesterone was observed 
after 100 mg epostane but the serum oestradiol was not 
significantly different from the pre-treatment concentrations. 
Serum cortisol did not differ from control values, indicating a 
lack of effect on adrenal steroidogenesis. The same workers also 
investigated multiple dosage regimens of epostane in similar 
groups of women (64). In women of 12-18 weeks gestation treatment 
with 100 mg epostane every 6 h for 1 day lowered progesterone
concentrations to 12% of the pre-treatment value by 21 hours after 
drug administration. Serum oestradiol concentration fell in 
parallel to serum progesterone levels but cortisol levels remained 
at pre-treatment values. In women of 8-12 weeks gestation 
treatment with epostane, 100 mg 8-hourly for 5 days, lowered 
progesterone levels to 19% of the pre-treatment value. Oestradiol 
concentrations also fell after epostane treatment but the 
magnitude of the fall was lower. Again, no evidence for adrenal 
inhibition of cortisol production was observed. In the women in 
the luteal phase of the menstrual cycle (days 19-21), serum 
progesterone concentrations fell significantly after treatment 
with epostane, 100 mg 8-hourly for 5 days, and did not recover 
before the subsequent menstrual bleed. There was no change in 
serum oestradiol or cortisol levels. The menstrual cycle of this 
group of women (n = 8) was shortened on average by 2.8 days.
1.3.2.2 Effects on the testis: The effect of trilostane upon gonadal
steroidogenesis in male rats was assessed following treatment with 
both ACIH and HOG. Whilst plasma corticosterone levels were 
significantly reduced at a dose of 1.25 mg of trilostane/kg 
orally, a dose of 20 mg/kg was required to decrease testosterone 
levels by 50% (6). Similarly, epostane caused a reduction in mean 
plasma testosterone levels when administered to rats at doses of
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25, 50 or 100 mg/kg (35). The effect of trilostane on
testosterone synthesis was also examined after multiple dosing 
(33). In rats treated with 150 mg or 300 mg/kg/day for 7 or 14 
days trilostane decreased plasma testosterone levels significantly 
(P < 0.05). In contrast, basal testosterone levels in healthy 
human volunteers were not changed following 240 mg/day treatment 
with trilostane for 14 days. However, serum EHEA-sulphate was 
stimulated above the normal range. Trilostane did impair the 
testosterone response to luteinising hormone release hormone 
(IHRH), although luteinising hormone (IH) and follicle stimulating 
hormone (FSH) response to IHRH were unaffected.
In a further study of human volunteers trilostane was given 
initially at 240 mg/day, increasing at weekly intervals by 240 
mg/day up to 960 mg/day (34). When chromatography was used to 
remove trilostane and metabolites from the assay system, serum 
testosterone was found to fall on trilostane therapy (P < 0.01) 
and was accompanied by a rise in IH. The responses of FSH and IH 
to IHRH were unaffected by treatment and there was no change in 
sex hormone binding globulin (SHBG) levels.
-25-
1.4 THERAPEUTIC USES
1.4.1 Trilostane
1.4.1.1 Cushings syndrome: Cushing's syndrome occurs whenever peripheral
tissues are chronically exposed to excess quantities of cortisol. 
Apart from administration of exogenous ACIH or glucocorticoids, 
the causes fall into two main groups:-
1. Excessive secretion of ACIH either from the pituitary 
(Cushings Disease) or from non-endocrine tumours (ectopic ACIH 
syndrome). Cushings Disease accounts for about 80% of all 
Cushing's syndrome cases.
2. Benign or malignant tumours of the adrenal cortex.
The treatment of choice in Cushings syndrome is generally
surgical, directed at the adrenal or pituitary gland as 
appropriate. However, drug therapy is useful in lowering 
corticosteroid levels prior to surgery and in treating
patients who are considered unfit for operation.
Whilst clinical studies with trilostane have been successful in 
the treatment of Cushing's syndrome (23, 24, 25, 26) the notable 
feature throughout the clinical experience has been the individual
variability in response. For example, in an 11 year old girl
-26-
given a greater maximum dose than that recommended for adults 
(i.e. 960 mg/24 h) cortisol levels were not restored to the normal 
range (27). In contrast, a patient maintained on 960 mg 
trilostane/day for 5 days resulted in an Addisonian crisis 
(adrenocortical insufficiency). Often the failure of treatment 
has been attributed to compensatory ACIH feedback mechanism, 
overcoming the 30 -hydroxysteroid dehydrogenase block in cortisol 
synthesis. Variable absorption or metabolism of the drug was hot 
considered as a causative factor.
1.4.1.2 Primary hyperaldosteronism: Aldosterone is the major
mineralocorticoid excreted by the human adrenal cortex and its 
main target organ is the kidney where it acts on the renal tubule 
to increase sodium resorption and potassium excretion. At least 
four stimuli are known to influence aldosterone production, 
namely: angiostensin II, ACIH and plasma concentration of sodium 
and potassium. Normally, homeostasis is maintained by a negative 
feed-back mechanism, in which a rise in plasma potassium 
concentration stimulates aldosterone production which in turn 
stimulates increased potassium excretion in the urine.
Excessive aldosterone production may be 'primary' or 'secondary'. 
Primary hyperaldosteronism includes a spectrum of disorders of the 
glomerulosa cells of the adrenal cortex manifest as 'autonomous*
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over-production of aldosterone. Hypersecretion of aldosterone is 
the common feature of these conditions. The existence of a 
discrete adrenal adenoma in adults causing primary 
hyperaldosteronism was first reported by Conn in 1955 (Conn's 
syndrome) and the clinical features of this condition have been 
well documented. Hypokalaemia is the most common biochemical 
feature but the normal fall in aldosterone levels does not occur 
because secretion of the hormone is relatively autonomous. In 
these circumstances, the positive correlation of aldosterone with 
its stimulus (potassium) is reversed. The diagnosis is confirmed 
by the characteristic findings of excess aldosterone, low plasma 
renin and potassium and associated hypertension.
As well as being associated with a benign aldosterone-secreting 
adenoma, the syndrome of primary hyperaldosteronism can occur in 
the absence of a discrete tumour. In such cases, the cause may be 
micronodular hyperplasia or simple hypertrophy of the zona 
glomerulosa, though, sometimes, there seems to be no histological 
lesion in the adrenal cortex. In all these instances, the overall 
picture is the same as that associated with an 
aldosterone-secreting adenoma but the biochemical abnormalities 
seem to be less severe.
In primary hyperaldosteronism excessive secretion of aldosterone 
is generally accompanied by raised blood pressure and low levels 
of renin, angiotensin II and potassium. Plasma sodium levels are 
either normal or elevated. Total exchangeable potassium is 
reduced. Clinical symptoms include hypertension, muscle weakness 
and nocturia, though many have few or minor symptoms.
In the treatment of primary aldosteronism due to discrete tumours, 
surgical intervention is usually indicated, but operative risks 
may be reduced by pre-operatively restoring total body potassium 
and blood pressure to normal. Hypertension may be controlled by 
salt and water depletion with a diuretic and administration of the 
aldosterone antagonist spironolactone. In some instances, this 
treatment has also been used as an alternative to surgery.
Diuretics of this type may correct the excessive sodium and water 
retention and potassium loss and consequently lower blood 
pressure. Aldosterone secretion is rarely improved and may even 
increase. Spironolactone is not without side effects: skin
rashes, drowsiness and ataxia have been reported and, with 
long-term treatment, gynaecomastia can occur. Other 
'potassium-sparing' diuretics such as triamterene or amiloride
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have also been employed to manage the biochemical abnormalities 
associated with primary aldosteronism but they are less potent 
than spironolactone and, like it, do not reduce the secretion of 
aldosterone.
Trilostane has been used in the treatment of primary aldosteronism 
and produced a marked decrease in plasma aldosterone, reversed the 
hypokalaemia and reduced the elevated blood pressure in patients 
(n = 7) with this condition (38).
In a further study, trilostane was shown to reduce the elevated 
levels of aldosterone in five patients with primary 
hyperaldosteronism within 2 weeks of therapy (39). The 
normalisation of serum potassium and blood pressure required a 
longer period (up to 12 weeks).
1.4.1.3 Low-renin essential hypertension: Low renin essential
hypertension patients have low plasma renin activity associated 
with 'normal' aldosterone levels and constitute some 30% of all 
patients with essential hypertension. When given trilostane, 
30 mg four times daily for 6 weeks, eight out of ten patients with 
low-renin essential hypertension responded to therapy, with 
decreases in blood pressure (40).
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1.4.1.4 Metastic breast cancer: Breast cancer patients can be divided
into two groups based upon their oestrogen receptor status; those
containing a significant level (>5 fmol of receptor protein per
milligram of protein per milligram of breast tissue) of oestrogen
receptors (ER+) and those below this limit (ER-), although
definitions of positive and negative do vary, ^proximately two
thirds of primary breast cancers are ER+ and as such may respond
to therapy which 'removes1 the hormonal stimulus which provokes
< .hormone-responsive tumour growth. Tamoxifen is the first-line 
>
agent currently used in postmenopausal women with advanced breast 
cancer (43). The mechanism of action of this anti-oestrogen is 
thought to be by binding to the oestrogen receptor. Tamoxifen is 
not yet licensed for use in pre- menopausal women, but one third 
of unselected women and 60% of ER+ women respond objectively to 
the drug regardless of menopausal status (44).
Other compounds that are used in breast cancer endocrine therapy 
interfere with the biosynthesis of oestrogens, thereby removing 
the stimulus for ER+ tumour growth.
The main sources of oestrogens in pre-menopausal women are the 
ovaries, while in postmenopausal women oestrogens are derived from 
aramatisation of androgens in the peripheral tissues (41, 42).
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Aromatisation is catalysed by the aromatase enzyme (45) which 
converts the phenolic "A" ring of an androgen to the unsaturated 
or aramatised "A" ring of an oestrogen (see Fig. 2) at several 
sites in the body, including adipose tissue (46) muscle, liver and 
breast cancer tissue itself (47). The androgen androstenedione, 
which is synthesised and secreted by the adrenal cortex, is 
aramatised to oestrone, which is subsequently reduced to 
oestradiol (48). Testosterone is also directly aramatised to 
oestradiol, but the aramatisation of androstenedione is thought to 
account for the majority of oestradiol produced in postmenopausal 
women.
The use of trilostane in postmenopausal women with hormone- 
dependent metastatic breast cancer was therefore considered on the 
basis of inhibiting androstenedione production, the main precursor 
of cirulating oestrogen in this patient group.
At the onset of this project the results from a clinical trial 
were published demonstrating the beneficial effect of trilostane 
therapy (49). Postmenopausal women with metastatic breast cancer 
were treated with trilostane, initially 240 mg daily increasing 
after 3 days to 480 mg daily and after a further 3 days to 960 mg 
daily. After 3 days at this dose dexamethasone 1 mg daily was 
added (replacement glucocorticoid) and this combination was 
continued until disease progression occurred. Partial remission
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was seen in 6 (26%) and stabilisation of previously progressive 
disease in a further 13% of the first 23 patients studied. This 
success rate was as good as other endocrine agents. DHEA-sulphate 
levels and androstenedione levels increased while oestrone levels 
decreased in patients receiving trilostane alone. After the 
addition of dexamethasone further falls in oestrone and oestradiol 
concentrations were seen, and DHEA-sulphate and androstenedione 
returned to basal levels or below. The interpretation of these 
results was that the aramatase enzyme was inhibited. Since it had 
already been demonstrated that trilostane per se has no effect on 
placental aramatase (50)f this suggested a metabolite of trilostane 
was responsible for this action or that aramatase enzymes differ.
After this initial study conflicting data about the usefulness of 
trilostane in breast cancer have appealed. In a study in which 
trilostane alone was given to 41 postmenopausal women with 
advanced breast cancer (51) only one patient responded to 
trilostane and in a further six the disease was stabilised. It 
was suggested that additional corticosteroid might be necessary to 
prevent a reflex rise in ACIH due to trilostane therapy. In a 
more extensive trial in 97 postmenopausal patients in which 
trilostane was again administered with dexamethasone (52), an 
objective response rate in eighteen patients (25%) and
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stabilisation of disease in a further 21 patients (32%) was 
observed. No biochemical data was produced in this study. 
However a more critical evaluation of the role of concurrent 
glucocorticoid administration was suggested.
1.4.2 Epostane
1.4.2.1 Interceptive agent: Progesterone is required for both the
maintenance of a secretory endometrium during the menstrual cycle 
and for the continuation of human pregnancy. At the end of the 
menstrual cycle a decline in progesterone production by the corpus 
luteum occurs and this induces menstruation. The removal of the 
corpus luteum before the luteoplacental shift (at about 49 days 
gestation) results in a dramatic fall in serum progesterone 
concentration producing progressive uterine activity and abortion 
(56). Uterine contractions only occurred when the serum 
progesterone concentration fell to 32 nmol I-1 (10 ng ml”1) and 
abortion when circulating progesterone was less than 13 nmol l”1 
(4 ng ml 1). Consequently, drugs which inhibit ovarian 
steroidogenesis should disrupt hormone production in the luteal 
phase and prevent implantation. Similarly in early pregnancy 
inhibition of ovarian and placental steroidogenesis should result 
in a critical degree of progesterone 'withdrawal' and subsequent 
abortion. Termination of pregnancy of up to 12 weeks duration is
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commonly achieved by suction curettage after dilation of the 
cervix under local or general anaesthesia. Although the direct 
complications of this are slight, there is no clear view of the 
long term consequences. There are indications that rapid dilation 
of the cervix can damage the structure of the tissue, with the 
risk of spontaneous abortion in subsequent pregnancy (62). The 
advantage of drug-induced abortion is that natural dilation is 
mimicked, as a result of which damage to the cervix can be 
prevented. Epostane has this potential.
An early clinical study with epostane was conducted in the first
trimester of human pregnancy (53). Epostane was administered
every 8 h for 3 days to women 8-11 weeks pregnant (and who had
been scheduled for surgical termination of pregnancy within 24 h
of completion of the study). In comparison to a control group
there were significant falls in serum progesterone and oestradiol
concentrations. Uterine activity in the epostane-treated group
was enhanced and was postulated to occur because of the decline in
progesterone levels. In a follow-up study the effect of epostane
in combination with prostaglandin-E for induction of abortion in
2
early first-trimester pregnancy was studied in a group of twenty 
women awaiting termination of pregnancy (54). The first group 
received FGE2 alone, administered vaginally as a lipid— based
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pessary (3 x 10 ng at 2 h intervals). The remaining three groups 
received epostane at differing doses for 5 days, and were treated 
with PGE^ on the fourth day. Significant falls in serum
progesterone and oestradiol occurred in the epostane-treated 
patients. Abortion was induced in one of the five control 
patients and in three of ten patients treated with low doses 
(300-400 mg) of epostane. At the highest dose (600 mg) of 
epostane j serum progesterone and oestradiol showed the greatest 
decline to 8% and 21% of pre-treatment values, a prompt and 
sustained pressure response occurred to FGE2 and abortion was 
induced in all five patients. Thus progesterone suppression by 
epostane appeared to sensitise the myometrium to exogenous 
prostaglandin and such a combined treatment was postulated to have 
a role in the management of mid-trimester abortion.
In a group of 26 healthy women (gestation less than 8 weeks) 
epostane (200 mg) was administered 4 times daily. 83% of the 
women who completed treatment (n = 23) aborted completely, and all 
demonstrated rapid decreases in HOG, progesterone and oestradiol 
(58). In a larger study with 50 patients a similar epostane 
dosage regimen resulted in the same success rate (82%) in 
producing termination of the pregnancy (59). In a further study 
of 56 women, with a gestational length of less than 49 days from 
the last menstrual period, epostane was given in the same dose of
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200 mg x 4 for seven days (60). The treatment resulted in 84% 
complete abortions (90% among women completing the therapy).
Epostane has also been used to facilitate mid-trimster termination 
of pregnancy in a double-blind, placebo controlled trial (61).
Epostane 100 mg x 3 was administered for 3 consecutive days to 5
women of 13-18 weeks gestation prior to admission to hospital.
Another 5 women received a placebo control. Following admission
to hospital oxytoxin was administered intravenously for up to 1 h,
after which time PGE (1.5 mg) was introduced into the extra
2
amniotic space. Mean peripheral progesterone levels had fallen by 
74% after 72 h in the patients treated with epostane. The mean (+ 
SD) induction- abortion interval in the treatment group was 490 + 
271 min compared with 1432 + 640 in the control group.
Intrauterine pressure recording demonstrated increased sensitivity 
to FGE2 after epostane treatment but no charge in oxytocin 
sensitivity. The utility of epostane as a ’priming' agent in the 
treatment of mid-trimester termination of pregnancy was therefore 
demonstrated.
1.4.2.2 Veterinary use: The management of the reproduction of domestic
animals, whether they are companion or food-producing animals, is 
of major concern for the veterinary profession. The economic 
impact of unwanted pets or the presence of calves, lambs, or pigs
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at depressed market times is of major consequence.
In veterinary medicine, a popular approach for controlling 
reproduction in companion animals has been surgical sterilisation. 
For animals that are maintained intact for breeding purposes, 
control measures have been limited. Pharmaceutical agents 
designed to control oestrus are utilized with same success. 
However, a substantial number of dogs experience mismating and 
require a pregnancy interceptive agent.
Reproductive control in large or food-producing animals has taken 
three primary directions:
1. oestrus control
2. pregnancy termination
3. parturition induction
Oestrus regulation, a recent development in veterinary medicine, 
has gained popularity with the introduction of prostaglandins. 
Oestrus regulation is utilized for two reasons:
1. by regulating oestrus, time and labour can be saved at 
breeding time
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2. with conception occurring at approximately the same time for a 
group of animals, parturition will occur at about the same 
time, again saving time and money.
Pregnancy termination is further divided into elective abortion 
and parturition induction. Pregnancy termination occurs
occasionally because of mismating but more generally is applied to 
feedlot heifers to optimise weight gain and carcass quality, and 
eliminate penalty at processing. Oestrogens are currently used 
with limited success and are being discouraged by regulatory 
agencies. Fenprostalene has been licensed recently for this 
indication but cost is a primary deterrent. Surgical
sterilisation and abortion are employed but are time-consuming and 
barely cost effective.
Parturition induction is a relatively untapped area in veterinary 
medicine. Prior to effective ways of regulating oestrus, inducing 
parturition was impractical. However, advances in oestrus
regulation have established a need for a reliable inducing agent. 
Since the latter days of gestation in most food-producing animals 
are not dependent on a viable corpus luteum, very few agents can 
reliably induce parturition. Corticosteroids have been used but 
side effects such as retained placenta make them undesirable 
agents.
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In controlled studies, epostane has been found to terminate 
pregnancy in the dog, induce parturition and control oestrus in 
the pig, and induce parturition in sheep.
Epostane, offers veterinary medicine a wide range of potential 
applications. The proposed clinical uses include; 1) pregnancy 
interception in the canine, 2) pregnancy interception in food- 
producing animals, 3) oestrus regulation in food-producing animals 
and horses, 4) induction of parturition, and 5) enhanced fecundity 
in all species. Differences in reproductive physiology in 
domestic animals require an agent that operates at a fundamental 
step common to all. Epostane appears to operate at this step, 
thereby offering versatility not currently available for 
reproductive control in veterinary medicine.
1.5 PROPOSED STUDIES
This study of trilostane and epostane as outlined below was 
undertaken (i) to explain the separation of activity of these 
closely related steroids (ii) to understand the variable efficacy 
observed in clinical trials and (iii) to provide relevant data for 
the further development of these drugs.
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1. Synthesis of radiolabelled drugs (Chapter 2)
2. Investigation of steroid stability (Chapter 3)
3. Investigation of the excretion, tissue distribution and tissue 
metabolism of trilostane and epostane in animals (Chapter 4)
4. Investigation of epostane metabolism in different animal 
species (Chapter 4)
5. Development of an analytical method for the measurement of 
trilostane in plasma (Chapter 5)
6. Investigation of the bioavailability and pharmacokinetics of 
trilostane and epostane in man (Chapter 6)
1.5.1 Organisation of thesis: Tables and figures cited in Chapters 3-6
are located in the appendices. Figures cited in the Discussion
are located; within the text. I
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CHAPTER 2
MATERIALS AND METHODS
SUMMARY OF CHAPTER
2.1 SYNTHESIS OF RADIOIAEELLED COMPOUND
2.1.1 [ 14C] -Trilostane
142.1.2 [ C]-Epostane
2.1.3 Thin layer <±Lromatographic systems for monitoring 
radiolabelled synthesis
2.1.4 Precipitation of radiolabelled compounds
2. 2 RADIOCHEMICAL RJRITY AND STABILITY STUDIES WITH
COMPOUNDS
2.2.1 [ 14C] -Trilostane
142.2.2 [ C]-Epostane
2.3 EXPERIMENTS IN VIVO
2.3.1 Animal studies
2.3.2 Human studies
2.4 DRUG ASSAY IN BODY FLUIDS
2.4.1 Trilostane
2.4.2 Epostane
2.5 INVESTIGATION OF METABOLITES
2.5.1 Isolation and identification of a trilostane
metabolite in human plasma and urine
- 42-
2.5.2 Isolation and characterisation of epostane 
metabolites from rat faeces
2.5.3 Epostane metabolite profile in different species
2.5.4 Plasma and tissue metabolite profiles of trilostane 
and epostane
2.6 RADIOACTIVITY MEASUREMENT
2.6.1 Liquid scintillation counting
2.6.2 Linear analyser (TLC) and radioactivity monitor (HPLC)
2.7 DATA ANALYSIS
2.7.1 Organ radiation dose calculations
2.7.2 Pharmacokinetic analysis
2.7.3 Statistical analysis
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SUMMARY OF CHAPTER 2
14 . 14The radiochemical synthesis of [ C]-trilostane and [ C] -epostane
are described. Chrcoratographic systems for the investigation of
radiochemical stability are detailed as well as the general
experimental procedures for animal and human studies. Analytical
methods for both compounds in biological fluids are outlined in
addition to nucleonic techniques and methods of data analysis.
- 44-
2.1 SYNTHESIS OF FADIOIAEELT.ED COMPOUNDS
2.1.1 f 14C1 -Trilostane
14The synthesis of radiolabelled trilostane from 4- C testosterone 
was achieved following the 4-stage reaction scheme shown in Fig.
3. The reaction sequence is that used in the manufacturing 
process for non-radiolabelled drug.
142.1.1.1 Starting material; [4- C]-Testosterone, 46 u moles, in 57.5 ml 
benzene/ethanol (9:1 v/v) was added to non-radiolabelled
testosterone (478 u moles), and the mixture dried under reduced
pressure at 40°C to a solid with a specific activity of 4.39 m Ci
-1 . TM .mmol . A 1 Drierite 1 (anhydrous calcium sulphate) column was
attached to the neck of the round bottom vessel, and stored at 
—20°C overnight prior to the first reaction step.
142.1.1.2 Preparation of 2-hvdroxvmethvlene-4-r C1-17p -hvdroxv-androst-4-
14en-3-one: [4- C]-Testosterone (0.476 m mole) was dissolved in
anhydrous THF (3 ml) under an N2 atmosphere. The mixture was 
cooled for 15 minutes on a salt/ice bath prior to the addition of 
sodium hydride in oil (1.38 m moles, 2.9 equivalents) and a 
catalytic amount of methanol (15 ul). The mixture was stirred for
10 mins (4°C), methyl formate added (2.6 m moles, 5.46
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14Fig. 3 . Chemical synthesis of f4- Cl -Trilostane
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-46-
equivalents) and then stirred for a further 1 h on the salt/ice 
bath. The reaction mixture was then allowed to come to ambient 
temperature and left overnight to stir under N^ . The reaction was
complete after 24 h as determined by thin layer chromatography 
(TLC) using solvent system SI described in Section 2.1.3. Glass 
distilled water (2 ml) was added to the reaction mixture and the 
THF removed under reduced pressure. A further portion of water 
(10 ml) was added and then the solution was acidified to pH 1 by 
the addition of 5M HC1. A yellow solid precipitated, which was 
collected by suction filtration, dried in a vacuum oven at 40°C 
overnight, to give'140.2 mg product (0.444 m moles). The product 
co-chromatographed with a 2-hydroxymethylene -17 
hydroxyandrost-4-en-3-one reference standard by TLC (SI).
The yield for the reaction stage was 93%.
142.1.1.3 Preparation of T4- C1-Androsta-2.4-diene-r2.3-d1 isoxazol-17^?
-ol; To a stirred mixture of 2-hydroxymethylene-4-[14C]-17j3 
-hydroxyandrosta-4-en-3-one (0.444 m moles) in glacial acetic acid 
(1.2 ml), was added an aliquot (0.2 ml) of a solution prepared by 
dissolving sodium acetate trihydrate (1.53 g) and hydroxylamine 
hydrochloride (0.87 g) in water (4 ml). A further portion (0.5 
ml) of glacial acetic acid/water (6:1 v/v) was added and the
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reactants stirred overnight at ambient temperature. TLC (SI, S2) 
after 2 h indicated that the reaction had gone to completion.
Glass distilled water (5 ml) was added dropwise to the reaction 
mixture with stirring, which was then extracted twice with ethyl 
acetate (5 ml). The ethyl acetate phases were combined and washed 
twice with a saturated solution of sodium bicarbonate (10 ml), 
twice with glass distilled water (10 ml) and then dried over 
anhydrous magnesium sulphate. The ethyl acetate was evaporated 
under reduced pressure at 40°C.
TLC analysis (SI) showed that the yellow product obtained (124 mg) 
contained inpurities besides the desired product. Purification 
was required before the next stage of synthesis.
The product was dissolved in ethyl acetate (15 ml) and absorbed 
onto 3.5 g silica which was added to the top of a dry packed 
silica column (35 g silica, bed height 13 cm, bed diameter 2.5 
cm). The column was eluted with 100 ml of the following solvent 
mixtures with 20 ml fractions collected from the column:
i) Ethyl acetate/cyclchexane 30/70 v/v
ii) -Ethyl acetate/cyclohexane 40/60 v/v
iii) Ethyl acetate/cyclohexane 50/50 v/v
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. . 14Fractions 4-8 containing [4- C] -Androsta-2,4-diene- [ 2,3-d] 
-isoxazol-17 fi -ol were pooled, evaporated to dryness under reduced 
pressure and further dried in a 40°C vacuum overnight.
A white crystalline solid was obtained (55.9 mg, 0.178 m moles) 
which co-chromatographed with a reference standard in 2 TLC 
systems (SI, S2). The yield for this stage was 40% with the 
overall yield being 37%.
142.1.1.4 Preparation of T4- C1-4Q! ,5 ce Epoxvandrost-2-ene-f 2,3 -d 1
_ . 14isoxazol-17 fi -ol: To a solution of [4- C]-Androsta-2,4-
diene-[2,3-d] isoxazol-17 fi -ol (0.178 m moles) on a salt/ ice
bath, was added pre-cooled m-dhloroperbenzoic acid (0.295 m moles,
1.67 equivalents) in dichloromethane (1.25 ml). The reaction
mixture was stirred on an ice/salt bath for 0.5 h, allowed to come
to room temperature, and then stirred for 26 h until the reaction
was demonstrated to have gone to completion by TLC (S2).
A portion (0.3 ml) of a solution prepared by dissolving sodium 
sulphate (100 mg) in distilled water (1 ml) was added to the 
reaction mixture. The products were transferred to a separating 
funnel with dichloromethane (5 ml) and the organic phase washed 
with aqueous 1M sodium bicarbonate (1 x 10 ml), dried over 
anhydrous magnesium sulphate, and evaporated to dryness under 
reduced pressure.
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The resultant white crystalline solid was further dried in a 
vacuum oven at 40°C to yield 48.5 mg (0.147 moles) product, which 
co-chrcmatographed with a synthetic reference standard by TLC
(S2).
The yield for this stage was 83% with the overall yield being 31%.
2.1.1.5 Preparation of f4-14C1 -(4 0. 5 0L ,17 fi )-4,5-epoxy-3.17- dihvdroxy
14androst-2-ene-2-carbonitrile: A solution of [4- C]-4a ,5a
epoxy androst-2-ene-[2,3-d]-isoxazol- 17 ft -ol (0.147 m moles) in 
anhydrous THF (1 ml) was stirred at ambient temperature with a 
solution of potassium hydroxide (93.4 mg in 1.5 ml THF/water (3:1 
by vol) under an atmosphere of N2. TLC analysis (S2) showed the 
reaction was complete at 47 h after additional quantities of 
potassium hydroxide solution were added (36.9 mg in 600 ul).
The reaction mixture was acidified to approximately pH 3 by 
dropwise addition of aqueous 1M hydrochloric acid, before cooling 
on a salt/ice bath for 1 h. The reaction mixture was reduced to 
half volume under reduced pressure, and then cooled for a further 
1 h period. A white precipitate formed which was filtered, washed 
with water and dried in a vacuum oven at 40°C overnight to give
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25.6 mg of product (0.078 m moles). The product
co-chrcmatographed with a reference standard in HPLC and TLC 
systems (see section 2.2.1) and was 96% radiochemically pure (see 
section 2.2.2).
The yield for this stage was 53% with the overall yield for the 
synthesis being 16%.
2.1.2 f14C1-Epostane
In collaboration with the Radiochemical Section, Sterling-
Winthrqp Research Centre, the synthesis of radiolabelled epostane
from 17-methyltestosterone was achieved following a 6-stage
. . 14reaction sequence. The procedure utilized [ C] -formaldelyde as 
the source of the radiolabel and is illustrated in Fig. 4.
14 o .2.1.2.1 Preparation of P Cl-17p -hvdrow-17-methvl-4-(phenvlthicmethvl) -
androst-4 -ene-3 -one: To a round bottomed flask was added
17-methylestosterone (1 g, 3.31 m moles), 38% formaldehyde
solution (0.114 ml, 1.55 m moles) and thiophenol (0.53 ml, 4.90 m 
14moles). [ C]-formaldehyde (40 mCi, 2.54 m moles) was then added, 
washed in with 4 ml ethanol and a further portion of formaldehyde 
(0.114 ml, 1.55 m moles), followed by triethylamine (0.548 ml,
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Fig. 4 14Chemical synthesis of f Cl-Epostane
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3.95 in moles). The resulting mixture was heated at reflux for 68 
hours and then cooled to room temperature. The yellow solution 
was quenched in 0.5M potassium hydroxide solution (40 ml) and 
stirred for 3 h. The precipitated product was collected by 
suction filtration, washed with water (3 x 20 ml), n-hexane
(20 ml) and dried under vacuum at 40°C for 48 h. The product 
(1.358 g, 3.20 m moles) co-chromatographed with a synthetic 
reference standard by TLC (S3) (The yield for the reaction stage 
was 97%).
142.1.2.2 Preparation of f4- Cl-17-dimethvltestosterone; Raney nickel
catalyst (10 ml) was successively washed with water (5 x 80 ml)
and acetone (3 x 80 ml) under an N2 atmosphere. The catalyst was
resuspended in acetone (40 ml) and a solution of 
14[ C] -17 ft -hydroxy-17-methyl-4- (phenylthiomethyl) -androst-4-ene-3- 
-one (1.358 g, 3.2 m moles) jln acetone (40 ml). The mixture was 
stirred at room temperature under N2 for 18 h, after which the 
reaction was shown to be complete by TLC (S3).
The acetone solution was decanted off from the catalyst and the
catalyst washed with further acetone (6 x 50 ml). The original
acetone solution plus washings were combined, filtered through 
TMhiflo filter aid and then concentrated under reduced pressure to
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give a colourless oil. The oil was dissolved in cyclohexane/ethyl 
acetate (70/30 v/v, 20 ml) and added to the top of a column 
comprising of silica (300 g) pre-conditioned with the same 
solvent. The column was eluted with cyclohexane/ethylacetate 
(70/30 v/v) and fractions (50 ml) collected. The fractions were 
monitored by TLC (S3) and fractions 8-15 contained the desired 
product as single spot material. These fractions were combined 
and evaporated to dryness under reduced pressure to give a white 
crystalline solid (951 mg, 3.0m moles).
_ 14
2.1.2.3 Preparation of 17 p -hvdroxv-2-hvdroxvmethvlene-f4- Cl-17-
14dimethvlandrost-4 -en-3 -one: A solution of [4- C]-17-
methyltestosterone (951 mg, 3.0 m moles) in dried distilled 
tetrahydrofuran (7 ml) and methanol (14 ul) was stirred at room 
temperature and sodium hydride (60% dispersion in oil, (346 mg, 
5.19 m moles) added, followed by methylformate (750 ul, 11.968 m 
moles). The resulting suspension was stirred at room temperature 
for 24 h under N2« The reddish/brown mixture was quenched by the 
addition of water (10 ml) and the tetrahydrofuran carefully 
removed under reduced pressure. The slightly cloudy solution was 
filtered through a glass fibre filter paper and the pH of the 
filtrate adjusted to 3.0 using 5M HC1. The resulting yellow 
slurry was stirred for a further 1 h, the solid removed by
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filtration under suction, washed with water (3 x 10 ml) and then
dried under reduced pressure at 60°C for 24 h. The product (966 
mg, 2.8 m moles) co-chrcmatographed with a reference standard by 
TLC (S3).
14 .2.1.2.4 Preparation of f4- Cl -17-dimethvlandrosta-2,4-diene f2,3-d~l
isoxazol-17 fi -ol; A mixture of 17@ -hydroxy-2- hydroxymethylene-
14[4- C]-17 dirrethylandrost-4-en-3-one (966 mg , 2.8 m moles) and
glacial acetic acid (8.5 ml) was stirred while an aqueous solution
(1.33 ml) containing sodium acetate trihydrate (447 mg, 3.29 m
moles) and hydroxylamine hydrochloride (228 mg, 3.30 m moles) was
added. The mixture was stirred overnight at ambient temperature.
Distilled water (8 ml) was slowly added, left for 3 h stirring,
and the resulting solid collected by filtration under suction,
washed with water (2 x 20 ml) and n-hexane (10 ml) and dried
overnight at 60°C. This yielded 912 mg (2.7 m mole) of a yellow
14crystalline solid, [4- C]-17- dimethylandrosta-2,4-diene- [2,3-d] 
isoxazol-17 ft -ol, as confirmed with a reference standard by TLC
(S3).
142.1.2.5 Preparation of 4a ,5Of-epoxy-r4- Cl, 17-dimethyl androst-2- eno 
T2,3-dl isoxazol-17 fi -ol: A solution of [4-14C]-17-
dimethylandrosta-2,4-diene-[2,3-d] isoxazol-17 -ol (912 mg, 2.7 m 
moles) in dichloromethane (12 ml) was cooled to 5°C in an
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ice/water bath, m-chloroperbenzoic acid (630 mg, 2.92 m moles) 
was added to the mixture, stirred at 5°C for one hour, then 
overnight at ambient temperature. The reaction was shown to be 
complete by TLC (S2).
The excess acid was decomposed by the addition of a solution of 
sodium sulphite (80 mg) in water (2 ml). The two-phase mixture 
was stirred for 20 min., filtered through a glass fibre filter 
paper under suction and the cake washed with didhloromethane (5 
ml). The filtrate was washed with saturated sodium bicarbonate 
solution (4 x 25 ml) followed by water (2 x 25 ml) and brine (25 
ml). The aqueous portions were combined and extracted with 
dichloramethane (2 x 20 ml). The dichloromethane extracts were 
combined, charcoal (100 mg) and anhydrous sodium sulphate (250 mg) 
added, and the slurry stirred for 15 mins before being filtered 
under suction through a glass fibre filter paper. The cake was 
washed with dichloramethane (20 ml). The filtrate was evaporated 
to dryness under reduced pressure to yield 1100 mg of crude 
product. The product was pre-absorbed onto silica by dissolving 
in dichloramethane (25 ml), adding silica (10 g) and evaporating 
to dryness under reduced pressure. The residual solid was added 
to a silica column (250 g), eluted with cyclohexane/ethyl acetate 
(70/30 by vol) and fractions (10 ml) collected.
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TIC analysis (S3) of these fractions showed that fractions 17-21
14 .contained 4 OL , 5 ce -epoxy-[4 -C], 17-dimethylandrost-2-eno[2,3-d]
isoxazol-17- j3 -ol contained as a single spot material. These 
fractions were combined and evaporated to dryness under reduced 
pressure to yield 300 mg (0.8 m moles) of a white solid.
. . . 14The radiochemical purity of this precusor to [ C]-epostane was
checked by HPLC and found only to be 80%. Purification was 
achieved by semi-preparative high performance liquid 
chromatography (HPLC), following unsuccessful attempts by 
preparative TIC.
High performance liquid chromatography purification method; 5 mg
14crude 4 Qf ,5 Of -epoxy-[4- C], —- 17-dimethylandrost-2-ene- 
[ 2,3-d] -isoxazol-17 ft -ol was dissolved in methanol (4 ml) and then 
glass distilled water (2 ml) added. The total volume was injected 
onto the column at a flow rate of 1 ml min 1. After 6 minutes, 
i.e. when all the material was on the column, the flow rate was 
increased to 4 ml min 1. Separation was achieved using a 5 u 
Hypersil ODS column (25 cm x 1 cm id) with an eluent composition 
of 63% methanol and 37% water. Radioactivity was monitored using 
a Berthold LB503 flow detector with a solid scintillant cell.
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14The fraction corresponding to 4 a ,5a -epoxy-[4- C]-17- 
dimethylandrost-2-ene-[2,3-d]-isoxazol-17 -ol was collected from 
the outlet of the radioactivity monitor and then the eluent 
changed to 100% methanol and run for a further 10 minutes. The 
system was re-equilibrated for 15 minutes at the starting 
conditions prior to a further injection.
. . 14The fractions containing 4 a ,5 a -epoxy-[4- C]-17-
dimethylandrosta-2-ene-[ 2,3-d] -isoxazol-17 ft -ol were taken to 
dryness under reduced pressure at 60°C and the resultant white 
crystalline product stored at -20°C. The radiochemical purity was 
shown to be 99% by HPLC and TLC. The overall yield for the 
purification process was 65%.
2.1.2.6 Preparation of (4a ,5a . 17ft )-4,5-epoxv-3,17-dlhvdroxv-f4-14C1,17 
-dimethvlandrost-2-ene-2-carbonitrile (epostane]: To a round
bottomed flask (5 ml) was added 4 a ,5 a -epoxy-[4-14C]-17- 
dimethylandrosta- 2-ene-[2,3-d]-isoxazol-17 ft -ol (40 mq, 0.112 m 
moles), dried distilled tetrahydrofuran (3 ml) and sodium 
methoxide (17 irg, 0.315 m moles). The mixture was stirred under 
N2 at room temperature for 3 hours, then added dropwise to a 
solution of 1M HC1 (1 ml) in a separating funnel.
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The mixture was extracted with ethyl acetate (2 x 10 ml) and the 
organic extracts combined. The pooled extract was washed with 
water (1 x 10 ml), dried over magnesium sulphate (2 g), filtered,
and then evaporated to dryness under reduced pressure at 40°C for
1418 hours. This yielded 32 mg (0.09 m moles) of [ C]-epostane.
14The radiochemical purity of [ C]-epostane was found to be only 
74% indicating some breakdown during the final synthetic stage. 
Purification was achieved by semi-preparative HPLC, followed by an 
ethanol recrystallisation.
High performance liquid chrcmatographv purification method: 
14[ C]-epostane crude product (32 mg) was dissolved in methanol (6
ml) and water (2.5 ml) added. Two serial injections were made
onto the HPLC system which comprised of a 5 u Hypersil ODS column
(25 cm x 1 cm id) with an eluent of 60% methanol/40% water
(containing 0.5% w/v ammonium acetate), operating at a flow of 4
ml min 1. Detection was by UV absorbance at \  = 280 ran.
14Fractions corresponding to [ C]-epostane (Retention tune 24-32 
mins) were collected, combined and the methanol removed under 
reduced pressure at 30°C. The remaining aqueous solution was 
extracted with dichloramethane (2 x 150 ml). The organic portions 
were combined and washed with water (2 x 100 ml), dried over
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magnesium sulphate (2 g), and filtered through a No. 4 sinter 
funnel. The dichloramethane was removed under reduced pressure to 
a yellow oil, which yielded a fine white powder following 
trituration with hexane (10 ml). This was dried under reduced 
pressure, at ambient temperature, in the presence of a dessicant 
(anhydrous calcium sulphate) for 18 h to yield 22 mg product. The 
radiochemical purity was shown to be 93% by HPLC.
14The purity of [ C]-epostane was increased to 95% by repeat 
purification under the same HPLC conditions described above.
14Ethanol recrvstallisation: [ C] -epostane (22 mg) and
non-radiolabelled epostane (153 mg) were heated to boiling point 
in absolute ethanol (2 ml), allowed to cool to ambient temperature 
and then chilled (ice/water) for 1 hour. The resulting white 
crystalline product was collected by suction filtration, washed 
with water (0.5 ml) and then dried under reduced pressure at 
30-40°C for 18 hours. This yielded 94 mg of [ 14C]-epostane which 
was 98% radiochemically pure (Section 2.2.2).
The mother liquor firm the first re-crystallisation was dried 
under reduced pressure, taken up in ethanol (75 op, 0.7 ml),
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heated to boiling point and re-crystallised as described above to
14 . . . .yield a further 28.5 mg [ C]-epostane with a radiochemical purity
of 97% (Section 2.2.2).
2.1.3 Thin layer chromatographic systems for monitoring radiolabelled 
synthesis: TLC was performed using normal phase (NP) silica gel
plates (G60F254, Merck No. 5175) or C1Q reverse phase (RP) plates 
(Whatman MKC^F) in the following solvent systems:
Solvent system Plate used
51 : ethyl acetate/cyclohexane (70/30 v/v)
52 : methanol/water (80/20 v/v)
53 : ethyl acetate/cyclohexane (50/50 v/v)
NP
PP
NP
Plates were visualised under UV light (254 nm) or by spraying with 
a sulphuric acid solution (20% in ethanol), heating with a hot-air 
blower, and then viewing with white or UV (366 nm) light.
2.1.3 Precipitation of radiolabelled compounds: In order that both
14 14[ C] -trilostane and [ C]-epostane were of the correct particle 
size and polymorphic form for use in animal studies, the 
radiolabelled compounds were precipitated from dimethyl formamide/
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water under controlled conditions. The radiolabelled compounds 
were separately dissolved in a small volume (2 ml) of EMF which
had been heated to 60°C and bubbled with oxygen-free-nitrogen. 
Under an atmosphere of oxygen- free nitrogen, the radiolabelled 
solutions were allowed to attain room temperature. With constant 
stirring, glass distilled water (2 ml, N2 bubbled) was added 
dropwise over a period of 45 seconds, resulting in the formation 
of white precipitate. Maintaining the solid under a nitrogen 
atmosphere at all times, the products were suction filtered and 
washed with 50% aqueous EMF (5 ml) and water (5 ml). The products 
were then vacuum dried overnight at 45°C.
Similar batches of non-radiolabelled trilostane and epostane were 
prepared under identical conditions and submitted to the 
Department of Chemistry, Analytical and Stability, Sterling- 
Winthrop Research Centre, for particle size analysis and melting 
point determinations. The purities of the radiochemical compounds 
were checked by HPLC (Section 2.2).
2.2 RADIOCHEMICAL PURITY AND STABILITY STUDIES WITH
PADTOT ABET JED COMPOUNDS
142.2.1 f cl-Trilostane
14 .The radiochemical purity of [ C]-trilostane and its stability in
organic solvents and dose formulation, was assessed using the
following HPLC and TLC systems.
HPLC systems: (I) conditions detailed in Section 2.4.1.1.
(II) Column : Whatman Partisil 5 G8 RAC (9.6 mm x 
100 mm)
Eluent : A) 0.3M sodium acetate (adjusted to 
pH 5.0 with 1M acetic acid) 
containing 5% methanol by volume 
B) Methanol
Gradient : Isocratic operation at 60% B for 15 
minutes then changed to 100% B for 
15 minutes 
Flow : 2 ml min 1 
Temp : Ambient 
Detection : (i) UV atA=280 nm
(ii) Radioactivity monitor
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14 . .TLC: [ C]-trilostane or dried extracts were dissolved in
chlorofonr/methanol/fomic acid (80/10/10 v/v) and spotted onto 
plastic-backed silica gel TLC plates (Merck 5135). The plates 
were rapidly dried under oxygen free nitrogen and developed over 
approximately 15 cm in the following solvent systems.
I Chloroform/water/glacial acetic acid/t-butanol
(65/20/10/5 v/v - lower phase)
II Chlorofoira/methanol/fonirLc acid (80/10/10 v/v)
III Chlorofonr/THF/glacial acetic acid (88/10/2 v/v)
Following development the plates were dried and put into contact 
with X-ray film (Osray M3, Agfa-Gavaert) and left for a suitable 
period of time. After localisation of the radioactivity from the 
autoradiogram, the plates were sectioned into glass scintillation 
vials, water (0.4 ml), and NE260 scintillant (10 ml) added. 
Radioactivity was measured by liquid scintillation counting 
(details given in 2.6).
142.2.2 f Cl -Epostane
14The radiochemical purity of [ C]-epostane and its stability in 
organic solvents, dose formulation and biological fluids (rat 
plasraa/urine/faeces/ bile; dog plasma/urine) were assessed using 
the following HPLC and TLC systems.
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HPLC system: Column : Ultrasphere IP (4.6 mm id x 25 cm) 
Eluent : A) Methanol/water (60/40 by volume) 
containing 0.5% w/v ammonium 
acetate and adjusted to pH 5.0 
with glacial acetic acid
B) Methanol/water (98/2 by volume) 
Gradient : Isocratic operation at 0% B for 25 
minutes then changed to 100% B for 
15 minutes
Flow
Temp
Detection
: 1 ml min 1
: 45°C
: (i) UV at A “254 nm
(ii) Radioactivity monitor
TIG: Plates were spotted and developed as for [14C]-trilostane
in the following solvent systems:
I Hexane/THF/glacial acetic acid (75/20/5 w/v)
II Chloroform/acetone/cyclohexane/glacial acetic acid 
(30/30/30/10 v/v)
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2.3 EXPERIMENTS IN VIVO
2.3.1 Animal studies
Oral doses of radiolabelled trilostane and epostane were 
administered in 0.25% (w/w) gum tragacanth in all species.
2.3.1.1. Rat: These studies were performed using pigmented Long-Evans or
Sprague Dawley CD rats, purchased from Charles River UK Limited 
(Margate, Kent). The animals were given a routine examination 
upon receipt and checked at intervals during the acclimatisation 
period before the start of the studies (minimum of 7 days). 
Tissue distribution and excretion studies utilized animals in the 
weight range 110-195 g (6-8 weeks) at dosing. For the isolation 
of metabolites, larger animals (200-275 g, 8-12 weeks) were used.
The animals were housed, and the studies performed, in rooms with 
controlled temperature (21°C ± 1°C), relative humidity (55 + 5%), 
air circulation changes (25-30 h_1) and light cycle (0700 - 1900 
h). Mains tap water was available ad libitum for drinking along 
with Rat and Mouse Maintenance diet (Labsure, K + K Greef Limited, 
Croydon, Surrey) but food was withheld from the animals 16 h prior 
to and 2 h post-dosing.
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Animals were individually identified in each study by a number 
tattoed on their tail.
For tissue distribution studies the following tissues were removed
or sampled for the determination of radioactivity levels:
adrenals; blood; bone; bone marrow; brain; brown adipose; diaphram
(trilostane only); eyes; fat; fallopian tubes; heart; kidneys;
large intestine; liver; lungs; muscle; ovaries; pituitary
(trilostane only); plasma; residual carcass; salivary gland
(trilostane only); skin (pigmented and non-pigmented); small
intestine; spleen; stomach; thymus; thyroid and uterus. The
14tissue distribution of [ C]-epostane was investigated by Mr J. 
Allen, Sterling-Winthrop Research Centre, Alnwick.
2.3.1.2 Dog: Female dogs (ca 12 kg) purchased from Alpha Sirius,
Perry-Croft Farm Kennels (Colwall, Malvern, Worcs) were used. The 
animals were given a routine examination upon receipt and 
acclimatised for at least 6 weeks before use in studies.
The dogs were housed in individual stainless steel metabolism 
cages with mesh floors and maintained under environmental
conditions as described above (2.5.1). Mains tap water was 
available ad libitum for drinking with SDS dog diet (Special Diet
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Services, Stepfield, Witham, Essex) but food was withheld from the 
animals 16 h prior to and 4 h post-dosing. Animals were 
individually identified by numbers tattoed onto the inside of the 
ear.
2.3.1.3 Pig: Studies with pigs were conducted at Huntingdon Research 
Centre, Huntingdon, Cambridgeshire (HRC) and utilized female 
animals (130 - 170 kg) obtained from R. Beedles, Shadymoor, 
Shropshire. The animals were housed in individual stainless steel 
metabolism cages with galvanised steel mesh floors designed to 
facilitate the separate collection of urine and faeces. The 
animals were offered HRC standard pig diet (3 kg/head/day) 
supplied by J. Odam Limited (Peterborough). Tap water was 
available at all times.
2.3.1.4 Monkey: Studies with cynomolgus monkeys were conducted at the 
Sterling-Winthrop Research Institute, Rensselaer, New York. The 
animals were in the weight range 3-5 kg.
2.3.2 Human studies
2.3.2.1 Subjects: Trilostane and epostane clinical studies were conducted
in medically approved male volunteers between the ages of 20 and 
47 years. Prior to the studies all volunteers were physically
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examined, including blood chemistry on liver and kidney functions, 
haematology and urinalysis. All volunteers appeared to be healthy 
and gave their written informed consent prior to participating in 
the studies.
2.3.2.2 Drug administration: Oral doses of trilostane and epostane were 
administered to the volunteers with tap water (50 ml) after 
overnight fasting. Volunteers were allowed a cup of coffee 2 h 
after drug administration and a lunch (ham salad) served after the 
3 h blood sample. Blood samples were collected according to 
protocol during the 24 h after drug administration.
Starting 24 h before the study days until after the last blood 
sample, the volunteers were not allowed to drink any alcoholic 
beverage nor smoke. The volunteers were free of other 
prescription medicines and OTC medicines for at least 20 and 7 
days respectively, prior to the start of the study.
2.3.2.3 Sample collection and analysis: After each drug administration 
blood samples (8 ml) were taken from an indwelling cannula 
positioned in either the median cubital vein or the lower cephalic 
vein. The blood was put into tubes containing lithium heparin as 
anticoagulant. Blood samples were mixed slowly by inversion and
-69-
the plasma separated immediately by centrifugation at 2000 g for 
10 min. The plasma samples were immediately stored at -20°C until 
assayed.
Trilostane and epostane were assayed by specific HPLC assay 
procedures as detailed in Sections 2.4.1.1 and 2.4.2.1 
respectively.
2.4 DRUG ASSAY IN BODY FLUIDS
2.4.1 Trilostane
2.4.1.1 HPLC assay: A specific, accurate and precise HPLC assay was
developed to determine the concentrations of trilostane, and its 
metabolite 17-ketotrilostane in human plasma (5).
The HPLC system consisted of a Waters Model 6000A pump, a Waters 
Model 710B Wisp automatic sample injector, a Waters Model 440 UV 
detector operating at 254 nm, and a Spectra Physics SP4100 data 
system. A 5 urn Hypersil ODS column (150 x 4.6 mm id) was employed 
to achieve separation of drug and metabolite with a mobile phase 
of methanol/0.1M formic acid (1:1 v/v) at a flow rate of 2 ml
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min”1. Both column and mobile phase were maintained at 30°C. 
Under these conditions the retention times for trilostane, 
17-ketotrilostane and the internal standard, ethisterone (Sigma), 
were approximately 6, 7 and 12 minutes.
Aliquots of human plasma (2.0 ml) were acidified with sodium 
acetate buffer (0.5M, pH 5.0, 1.0 ml) and extracted with
chloroform (10 ml) containing the internal standard (0.2 ug ml”1). 
After mixing and centrifugation the upper aqueous phase was 
carefully removed by aspiration and discarded, leaving the lower 
organic phase which was dried over sodium sulphate. An aliquot (5 
ml) was evaporated to dryness under a stream of 
oxygen-free-nitrogen in a dry-block heater at 45°C. The residue 
was dissolved in ethanol (50 ul) and 20 ul injected into the 
liquid chromatograph for analysis.
Plasma standards were prepared by the addition of trilostane and 
17-ketotrilostane (in 1 mM potassium hydroxide) to control human 
plasma (obtained from blood with lithium heparin as 
anticoagulant). Standards were prepared over the range 0.2 - 1.0 
ug ml 1 for trilostane and 0.25 - 2.5 ug ml”1 for
17-ketotrilostane and extracted as detailed above.
Regression analysis of the peak height ratios (trilostane : 
internal standard, 17-ketotrilostane : internal standard) obtained 
for the standards were performed to determine the linearity of the 
response with respect to concentration. The resulting regression 
lines were used to quantify the concentrations of trilostane and 
17-ketotrilostane in the unknown samples.
2.4.1.2 Cvtochemical bioassav: A cytochemical bioassay was developed for
the measurement of trilostane in human plasma by R. Eamshaw et al 
(1). This assay was based upon the inhibition of 3@ 
-hydroxysteroid dehydrogenase (3jg HSD) activity in unfixed tissue 
sections of the dioestrus rat ovary. The bioassay, whilst 
accurate and precise, is not specific since metabolites of 
trilostane active in inhibiting HSD enzyme are measured by the 
assay.
Extraction from plasma was achieved utilizing the method described 
in section 2.4.1.1.
All assays were performed by R.J. Eamshaw at the Department of 
Chemical Pathology, University of Manchester, Clinical Sciences 
Building, Hope Hospital, Salford.
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Ovaries were removed from female Sprague Dawley rats during 
dioestrous, chilled in n-hexane at -70°C and 6 urn sections taken 
using a Bright' s cryostat with a cabinet temperature of between 
-30°C and -35°C. The sections were incubated at 37°C with 
dehydrxDepiandrosterone (substrate), NADf, nitroblue tetrazolium 
(soluble dye) and a plasma extract for 60 mins. The reaction was 
stopped by immersion of the section in ice-cold water.
The amount of dye deposited in the section was measured by 
microdensitometry (Vickers M85A scanning integrating 
microdens itameter) and related to drug and metabolite 
concentration from the equation:
Absorbance a. 1/ [Drug + Metabolite].
The assay procedure is outlined schematically in Fig. 5.
2.4.2 Epostane
A previously developed HPLC assay (4) was utilized to quantify 
epostane in human plasma.
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Fig. 5 Schematic diagram of cvtochemical bioassav
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2.4.2.1 HPLC analysis: The chromatographic conditions were as follows:
Column : Whatman Partisil 5 C-8 RAC 
(9.4 mm id x 100 mm)
Eluent : 0.1M sodium acetate (adjusted 
to pH 6.5 with 0.1M acetic 
acid)/methanol (40/60 v/v)
Flow rate : 2.0 ml min 1 
Temperature : Ambient
Detection : UV at X =280 nm 
Approximate retention times : Epostane } 8.0 min
Internal standard 
13 minutes
Aliquots of human plasma (1.0 ml) were adjusted to pH 6.5 with 1M 
phosphate buffer and internal standard (4,5-epoxy -4 -ethyl-17 
-hydroxy-17 -methyl-3 -oxoandrostane-2 - carbonitrile) added. The 
buffered plasma was extracted with diethyl ether ( 2 x 5  ml) and 
the combined organic phase evaporated to dryness under a stream of 
oxygen-free-nitrogen in a dry-block at 35°C. The residue was 
dissolved in HPLC mobile phase (200 ul) and 100 ul injected into 
the liquid chromatograph for analysis.
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Silanised glassware was used throughout the extraction procedure. 
Quantitation was achieved using spiked standards as described for 
trilostane earlier (Section 2.4.1.1).
2.5 INVESTIGATION OF METABOLITES
2.5.1 Isolation and identification of a trilostane metabolite in human 
plasma and urine
2.5.1.1 Isolation: Blood samples (50 ml) were collected at 2,3 and 4 h,
from four healthy male volunteers following medication with
trilostane (4 x 60 mg Modrenal capsules). Urine was also 
collected over the 8 h period following dosing. Samples of plasma 
and urine were stored at -20°C prior to extraction.
A pooled plasma sample (100 ml) was adjusted to pH 5.0 with 0.5M 
sodium acetate buffer, pH 5.0 (50 ml). The acidified plasma was 
extracted with ether (3 x 200 ml), the extract dried over 
anhydrous sodium sulphate (50 g) and the solvent removed under 
reduced pressure at 30°C.
A pooled urine sample (100 ml) was adjusted to pH 5.0 with 1M 
acetic acid and 0.5M sodium acetate buffer, pH 5.0 (10 ml). 
f3-glucuronidase (1 ml, Helix pomatia, 102,000 Fishman units ml-1, 
Sigma) was added to the buffered urine and the mixture incubated 
overnight at 37°C.
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Following incubation the urine was extracted as described for 
plasma. Both plasma and urine extracts were dissolved in 
chloroform (0.5 ml) and applied to a silica gel column (10 cm x
1.3 cm ID bed, activity III, Woelm, Pharma FRG) prewashed with 
chloroform (25 ml). The column was eluted with chloroform (25 ml) 
and chloroform/methanol (90 : 10 v/v, 25 ml) at a flow rate of 
approximately 1 ml min 1, with fractions (5 ml) collected.
Fractions containing the metabolite were further purified by 
semi-preparative HPLC under the following conditions:
Column 
Eluent 
Flow rate 
Temperature 
Detection
5 u Hypersil ODS (250 mm x 10 mm id) 
Methanol/0.1M formic acid (1:1 v/v)
4 ml min 1
Ambient 
UV at 254 nm
The relevant fractions were collected from the HPLC column and 
dried under reduced pressure at 30°C.
2.5.1.2 Analysis of metabolites: HPLC analysis of the isolated
metabolites was performed using the assay detailed in Section
2.4.1. In addition the following mobile phases were employed:
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I Methanol/water (55/45 v/v)
II Methanol/water/1. 3M ammonium acetate (45/40/15 v/v)
TLC analysis was performed on Merck silica gel 60-F-254 plates 
using the following solvent systems:
A) Chloroform : water : acetic acid : t-butanol (65 : 20 : 10 : 
5 - lower phase)
B) Chloroform : methanol : formic acid (80 : 10 : 10)
C) Chloroform : toluene : methanol : acetic acid (60 : 30 : 5 :
5)
D) Chloroform : methanol : acetic acid (94 : 4 : 2)
E) Toluene : water : acetic acid: t-butanol (41 : 35 : 15 : 9 -
upper phase)
F) Dichloromethane : ether : acetic acid (80 : 15 : 5)
Plates were developed over a distance of 10 or 15 cm and 
visualisation was by viewing under UV light and white light (after
spraying with 3.75M sulphuric acid and charring at 100°C for 5/10 
minutes).
GC/MS was performed by Simbec Analytical Systems Limited (2,3) 
Trimethylchlorosilane (TMCS) derivatives of standards and extracts
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were prepared by reaction with N, O-bis- (trimethylsilyl) 
tri-fluoroacetamide (BSTFA) containing 1% 1MCS and chromatographed 
on a fused silica WOOT (OV73) column (15 m x 0.4 mm id) or a 
Durabond 5 column (15 cm x 0.32 mm id). Columns were conditioned 
by repeat injection of Silyl-8 (Pierce Chemical Company) prior to
leaving at 310°C overnight. Helium was used as carrier gas with a 
linear velocity of 40 ml min 1. For capillary operation the gas 
chromatograph oven was held at 80°C for one minute and the 
programmed to 305°C at 25°C/minute. Injection port, separator and 
transfer line temperatures were set at 260°C, 280°C and 280°C 
respectively.
A Finnegan 4000 quadrapole mass spectrometer was employed in the 
electron impact mode with a filament current of 300 microamps and 
70 eV electron energy at an ion source temperature of 260°C. The 
end of the capillary column was inserted directly into the mass 
spectrometer transfer line.
Data collection and analysis was performed using an INCOS 
dedicated computing system.
2.5.2 Isolation and characterisation of epostane metabolites from rat 
faeces:
2.5.2.1 Isolation: Twenty five female Sprague-Dawley rats were dosed
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14 -1orally with [ C] -epostane (ca 450 mg kg ) and placed in
individual metabolism cages to enable the separate collection of
urine and faeces. Excreta samples were collected over
solid-carbon dioxide in the 0-24 and 24 - 48 h periods post-dose
and thereafter at roam temperature up to 168 h post-dose. Samples
were maintained at -20°C prior to isolation of the metabolites.
Faecal samples (24 - 48 h) containing a major proportion of the 
administered dose were pooled, freeze-dried, and extracted with 
methanol (4 x 250 ml). The methanol extracts were combined and 
the solvent removed under reduced pressure to leave an oily 
residue. This was dissolved in water (150 ml) and methanol (10 
ml) and applied to a C-8 Sepralyte column (40 gf C-8 sepralyte 
(40 urn), Analytichem International). The column was washed with 
water (100 ml) and then eluted with methanol/water (50/50, 100 
ml), methanol/water (75/25, 100 ml, fraction FI) and finally, 
methanol (100 ml, fraction F2). The fractions were taken to 
dryness under reduced pressure and then fractions FI and F2 were 
further purified by semi-preparative HPLC. The fractions were 
dissolved in methanol (5 ml) and aliquots (1 ml) repeatedly 
injected onto the following systems:
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FI
Column : Partisil 10 ODS-3 M9 (9.4 mm id x 500 mm) 
Eluent : A) Glass Distilled water 
B) Methanol
Gradient : Isocratic at 65% B for 30 mins., then changed
to 100% B for 15 mins.
Flow : 3.5 ml min 1
Temp : Ambient
Detection : (i) Radioactivity monitor (Berthold LB503)
(ii) UV at 254 nm
F2
As above with the following gradient and flow rates:
Gradient : Isocratic at 70% B for 45 mins., then changed
to 100% B for 15 mins.
Flow : 4 ml min 1
FI was resolved into 4 major bands of radioactivity (F^  I-IV) and 
F2 into 5 major bands (F2 I-V).
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Yjq. 6 summary of r^CI-epostane metabolite isolation rrom rat
METHANOL EXTRACTION 
'f OF FREEZE DRIED FAECES
C0 -  SEPRALYTE OOILMN
50% MEOH 75% MEOH 100% MEOH
MEOH EXTRACT 
(24%)
2 4 -4 8  h  FAECES 
(38%)«-
(3% ) F I  (8%) F2 (9%)
F I ( I )  F I ( I I )  F I ( I I I )  F I ( I V )  F 2 ( I )
(27%) (0 .4% ) (0 .8% ) (0 .3% )
F la  F ib  
(0 .4% ) (0 .8% )
F 2 ( ± I ) F 2 ( I I I )
(0.1%) (1.1%)
F2a
(0.1%)
F2b
(0.5% )
F2c
(0.1%)
F2 ( IV ) F2 (V )
(1 .4% ) (1 .4 % )4%)
F2g
(0.8%)F2d
(o.i%:0 1 ) (0 .2 % ) (0 .4 % )
*  M u ltic o m p o n e n t m ix tu re s  n o t  p ro ce s s e d  f u r t h e r
-H- Per cent of dose
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Further purification of those metabolite fractions was achieved 
using a two-stage HPLC procedure. The same column was utilized in 
each stage (Ultrasphere IP, 4.6 mm id x 250 mm) but different 
mobile phases were employed. Initially the metabolite fractions 
were passed down the HPLC column using methanol/water (either 
55/45 or 60/40) and subsequently using acetonitrile/water (33/67)
at a flow rate of 1 ml min 1. The relevant fractions were 
collected from the HPLC column and dried under reduced pressure at 
45°C.
2.5.2.2 Analysis of metabolites: TLC analysis of the isolated metabolites
was performed on silica gel TLC plates (Merck No. 5735) using the 
following solvent systems.
I Chlorofonr/methanol/t-butanol/water 
(85/5/5/5 - lower phase)
II Propan-1-ol/ammonia/water (80/7/13)
GC/MS analysis of the isolated rat faecal metabolites was kindly 
performed by Dr A.M. Lawson, Clinical Research Centre, Watford 
Road, Harrow, Middlesex.
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2.5.3 Epostane metabolite -profile in different species
2.5.3.1 Sample preparation; Samples of urine from different species were 
analysed for radiolabelled metabolites by HPLC and TLC. Samples 
of urine following enzyme hydrolysis were also examined for 
metabolites.
Aliquots of urine (0.5 ml) were loaded onto pre-washed C8 
Bond-Elut cartridges (0.5 g), the cartridges washed with water 
(0.5 ml) and eluted with methanol (0.5 ml). Recoveries of 
radioactivity in the methanol extract were greater than 95%.
Faecal samples (rat only) were freeze dried overnight and then 
extracted with methanol (3 x 25 ml). The extracts were combined 
and dried with anhydrous magnesium sulphate and then rotary 
evaporated to a 3 - 10 ml volume at a temperature of 35°C. 
Recoveries of radioactivity in the methanol extracts ranged 
between 62 - 86%.
Aliquots (300 ul) of urine were adjusted to pH 5.0 with an equal 
volume of sodium acetate buffer (0.2M, pH 5.0). The samples were 
then incubated overnight at 37°C in the presence of:
(i) (3 -glucuronidase/aryl sulphatase (50 ul Helix pcsmtia H-2
enzyme, 111,000 units/ml);
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(ii) (3 -glucuronidase/aryl sulphatase plus D-saccharic acid -1, 
4-lactone (0.2M, 200 ul, a ^-glucuronidase inhibitor);
(iii) acetate buffer (control sample).
The (3 -glucuronidase activity of the enzyme preparation was 
checked by incubating aliquots of urine in the presence of 
phenolphthalein glucuronide. The formation of a violet colour 
following addition of IN NaOH demonstrated the hydrolysis of the 
conjugate to phenolphthalein. Following incubation the samples 
were loaded onto Bond-Elut cartridges and extracted as detailed 
earlier. Aliquots of each samples were assayed for radiolabelled 
metabolites by HPLC and TLC.
2.5.3.2 Chromatocrraphic analysis of metabolites: Aliquots of urine
methanol extracts were analysed by HPLC under the following 
conditions.
Column : Ultrasphere IP (25 cm x 4.6 mm id)
Eluent : A) 0.02M Acetic acid
B) Methanol
Time (mins)
Gradient x % B ------------- > y % B
10 10 10 10 
Gradient 1. 30% -- > 40% --> 60%-- > 100% -- > 100%
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Pump : 1 ml min 1 
Temp : 45°C 
Detection : 1) UV at 254 nm
2) Radioactivity monitor
Faecal methanol extracts were examined as above with the modified 
gradient system shown below:
10* 20' 101 15' 5'
Gradient 2. 30% -- > 30%--> 50%--- > 80%-- > 100%--- > 100%
Aliquots of urine and faecal methanol extracts were 
chromatographed over 15 cm on Merck 60F^^ plastic backed silica 
gel (0.2 mm) sheets in the following solvent systems:
Solvent system I : Chloroforn/methanol/t-butanol/water
(85/5/5/5 by volume - lower phase)
Solvent system II : Propan-l-ol/ammonia/water (80/7/13 by volume)
Following chromatography, the areas of radioactivity on the 
chromatograms were located precisely by autoradiography using 
Osray 3M X-ray film. Quantitation of radioactivity was achieved
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by segmentation of the chromatogram. Each segment was transferred 
to an individual liquid scintillation vial and water (0.4 ml) 
added followed by NE 260 scintillation fluid (10 ml). The 
radioactivity in the vials was then determined by liquid 
scintillation counting.
2.5.4 Plasma and tissue metabolite profiles of trilostane and epostane:
14 . 14Metabolite profiles of [ C]-trilostane and [ C] -epostane were
investigated in plasma, liver, adrenal and ovary tissue from dog.
Plasma samples (0.2 ml) were precipitated with acetonitrile (3 ml)
and the aqueous supernatant dried under reduced pressure.
. . . 14Extraction efficiencies were 80-97% for [ C] -epostane and 45-70%
14for [ C]-trilostane. Aliquots of liver homogenates (2.5 g) were 
extracted with methanol ( 2 x 5  ml) and the combined
aqueous/organic extract taken to dryness under reduced pressure.
. . . 14Extraction efficiencies were 64% for [ C]-trilostane and 60% for
14[ C] -epostane. Adrenal and ovary homogenates were freeze-dried
and then extracted with methanol ( 2 x 5  ml) followed by
acetonitrile ( 2 x 5  ml). Combined organic extracts were dried
under reduced pressure. Extraction efficiencies were 62% for 
14 . 14[ C]-trilostane and 66% for [ C]-epostane. All sample extracts 
were resuspended in methanol prior to analysis by TLC in the 
following solvent systems.
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14 .[ C]-Trilostane : Chloroform/water/acetic acid/t-butanol
(65/20/10/5 - lower phase)
14[ C] -Epostane : Chloroform/methanol/t-butanol/water
(85/5/5/5 - lower phase)
2.6 RADIOACTIVITY MEASUREMENT
2.6.1 Liquid scintillation counting-: Volumes and weights of all
biological samples were measured where appropriate. Portions of 
diluted dose solution, plasma, urine and cage washings were added 
to liquid scintillation vials. Following the addition of 10 ml of 
NE 260 scintillant (Nuclear Enterprises, Edinburgh), the samples 
were assayed for radioactivity by liquid scintillation counting. 
The skin, tail and feet from animals were digested by re-fluxing 
for 0.75 h in 2N ethanolic NaOH (ca 200 ml). Aliquots of the 
digest (200 ul) were neutralised by the addition of 1M acetic acid 
and assayed for radioactivity following the addition of NE 260.
Large tissues/organs and residual carcasses were coarsely 
homogenised with up to 3 tiroes their equivalent weight of water 
using a Waring-Blender (Waring Products, New Hartford, 
Connecticut, USA), before being more finely homogenised by an
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Ultra-Turrax Gun (Sartorius Instruments, England). Faecal samples
were homogenised in up to 4 volumes of distilled water. Small
tissues, aliquots of blood, portions of faecal and large tissue
TMhomogenates were weighed into Ccambusto-cones (Packard
Instruments, Caversham, Bucks) and the samples combusted in oxygen
using a Packard Sample Oxidiser B306. The combusted products were
TMabsorbed in Carbosorb (8 ml), mixed with Permafluor V (14 ml) 
and the radioactivity determined by liquid scintillation counting. 
Carbon-14 standards, "Spec Check" were combusted at the beginning 
of each day and at regular intervals throughout the day to check 
the carry-over between samples and to determine the efficiency of 
the combustion process. Combustion and trapping efficiencies 
during the analysis of homogenate samples were found to be in 
excess of 97%. Data are therefore uncorrected for oxidiser 
recovery.
Radioactivity was measured using a Packard Tri-Carb Model 300 CD
Spectrometer (Packard Instruments Ltd), with facilities for
computing quench-corrected disintegration per minute (dpm).
Efficiency correlation curves were routinely checked by the use of
14internal standards, ([ C]-n-hexadecane, Amersham International, 
Amersham, Bucks). The spectrometer was recalibrated when a 
deviation between the counting efficiencies (calculated from the
quench indicating parameter (QXP) and the internal standard) of 
greater than 5% was observed. All radioassays were performed in 
duplicate.
2.6.2 Assay of radioactivity on TLC plates: TLC plates were assayed for
radioactivity by either sectioning and subsequent liquid 
scintillation counting or by use of a linear analyser (RITA, 
Raytest System Ltd., Sheffield). Data was acquired with the anode 
wire set at a high voltage of 1560 v and lower and upper threshold 
windows of 50 and 150, respectively.
2.6.3 Assay of radioactivity in HPLC eluates: Eluates from the HPLC 
column were monitored by use of either a Berthold LB503 monitor 
(Berthold Instruments, St. Albans) or a Ramona V monitor (Raytest 
Instruments Ltd., Sheffield). Both monitors utilised solid 
scintillant cells (yttrium silicate) and the data analysed by 
either a Commodore 4032 computer (Berthold) or IEM-XT computer 
(Ramona) utilising the manufacturers software.
2.7 DATA ANALYSIS
2.7.1 Outran radiation dose calculations;
The administration of radiolabelled drugs to human volunteers must 
be approved by the EHSS, and in order to gain this approval an
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assessment of the radiation dose to be received by the volunteers 
from the administration of the drug must be made.
The radiation dose to be received by the body of a human volunteer
was calculated according to the recommendations of the World
Health Organisation (67), using formulae and data recommended by
the International Commission on Radiation Units and Measurements
(68). In order to obtain this dose, known as the committed
effective dose equivalent, the weighted dose equivalent of named
tissues or organs for which weighting factors are individually
specified and to the 5 most highly exposed other organs using a
14weighting factor of 0.06 are summed. In the case of C-labelled 
trilostane the weighted dose equivalents to the lung, ovary, bone 
marrow, bone, thyroid, fat, stomach, small intestine, upper large 
intestine, lower large intestine and urinary bladder were summed.
Ihe initial step in the calculation of the dose equivalents is the 
calculation of the number of transformations (A) in each source 
region from 1 Bequerel (Bq) of administered drug. These values
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were calculated free the elimination half-lives of the activity 
and from the intercept value (or maximum observed value, whichever 
is greatest) of the fraction of the administered activity present 
in the source regions:
A = C  o
K
Where : CQ = Intercept value or maximum concentration (% Dose)
K = Elimination rate constant
Therefore for lBq
A = C x t o____
0.693 x 100 
Where : t = elimination half-life (secs)
The value of a A for the contents of the gut compartments and 
urinary bladder were calculated, as recommended by Dolphin and Eve
(69), from the fraction of the administered activity passing 
through their contents and their mean residence time in them.
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Freon the values of A the dose equivalents (D, Sieverts (Sv)) to
14the target organs which in the case of C are also the source 
organs were calculated using the following formula:
D = A xAxcfcxA 
m
Where : m is the mass of the source organ (kg)
14A is the constant for C equivalent to the mean energy
-15
of radiation per nuclear transformation (7.94 x 1
kg.Gy.Bq ^ s ^
<t> is the fraction of radioactive emissions absorbed
within the source organ (1 for most tissues except.
gut and urinary bladder where it = 0.5)
14A is the amount of C-labelled drug administered (Bq).
The source organ masses used for the calculations are those 
specified by the International commission on Radiological 
Protection (70).
Each of the above was then multiplied by the appropriate weighting 
factor recommended by the International Commission on Radiological 
Protection (71) and summed to give the calculated value of the 
weighted dose equivalent commitment.
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2.7.2 Riarmacokinetic analysis: The maximum plasma concentrations
(C ) and time to achieve these (t ) were determined by- 
max max
inspection of the plasma concentration vs I time data. Plasma 
concentration vs! time data were fitted to a polyexponential 
function losing the program PKALC (65). This program utilises a 
modified version of ESTRIP (66) to fit data to the general 
equation.
Where C is the concentration of drug at time t, u is the number of 
exponential terms and a^ and b^ are the parameters to be 
determined.
Areas under the plasma concentration v time curves were calculated 
by the method of trapezoids. Because the sampling times extended 
beyond the point at which concentrations fell below the minimum 
quantifiable limit, the calculated AUC values approached that of
oO ,
AUCq and as such were used as a guide to absorption.
2.7.3 Statistical analysis: The pharmacokinetic parameters C , t
u
and AUC were compared using the student t-test.
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SUMMARY OF CHAPTER 3
14 . 14Both [ C]-trilostane and [ C]-epostane were stable as dry
powders when stored at -20°C. In organic solvents at the same
14 .temperature, [ C]-trilostane was stable over a period of 7 days
14whilst [ C]-epostane showed marked degradation. One of the 
degradation products represented the loss of the cyano group from 
the epostane molecule.
Both compounds had only short term stability (3 h) in aqueous gum
tragacanth dose formulations, although in biological fluids
14 o 14 14.
[ C] -epostane was stable at -20 C. [ C]-trilostane and [ C]-
epostane were very susceptible to degradation on silica gel tic
plates. The implications of the instability of these steroid
molecules for drug metabolism studies and animal toxicity are
discussed.
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3.1 r14C1-EPOSTANE
. . . . 143.1.1 Stability as dry powder and in organic solvents: C-epostane was
stable when stored as a dry powder at -20°C for at least 6 months
(Fig. 3.1 a). Since many radiolabelled steroids are stored in a
mixture of toluene/ethanol (90/10 v/v; Ref. 96) this organic
14mixture was investigated as storage medium for [ C]-epostane at a
temperature of -20°C. Within 10 days approximately 50%
degradation had occurred (Fig. 3.1 b). There were 2 main
degradation products, as determined by HPLC (see section 2.2.2),
one corresponding to (4 a , 5 OL , 17 ) -4,5-epoxy-17-hydroxy-4,17-
dimethyl-2,3-dioxo- androstane (a known degradation product of
epostane) and a second component which was non-UV absorbing at
14A= 254 nm and A= 280 nm. The storage of [ C]-epostane was
further investigated in acetone. Again, storage in acetone at
-20°C led to considerable (32%) degradation within 7 days (Fig.
3.2). Similar degradation problems were also observed with
14methanol and ethanol solutions of [ C] -epostane (data not shown).
3.1.2 Stability on tic plates: Comparison of the initial radiochemical
14purity determinations of [ C]-epostane by HPLC and TLC showed 
that the TLC analysis consistently gave lower purity estimates.
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TLC analysis was performed using freshly prepared acetone
14 . .solutions of [ C]-epostane on silica gel TLC plates. To
, , 14
investigate the stability of [ C]-epostane on TLC plates aliquots 
14(5 ul) of [ C] -epostane solutions in acetone or water were
applied to silica gel plates (plastic backed) and allowed to stand
for various times prior to development in solvent system I (see
section 2.2.2). The initial radiochemical purity of 
14[ C]-epostane was 95% as assessed by HPLC.
Upon immediate development, the radiochemical purity determined by 
14TLC for the [ C]-epostane acetone solution was only 80% (Fig.
143.3). This had decreased to 21% when the [ C]-epostane was left
on the TLC plate for 2 h before development. Degradation was more
14extensive with the [ C]-epostane aqueous solution. In both cases 
the major degradation product had an Rf value similar to (4cy ,5a 
,17 f] )-4,5—  epoxy-17-hydroxy-4,17-dimethyl-2,3-dioxoandrostane.
TLC data was found only to correlate well with HPLC data (i.e.
. . . . 14minimal degradation) when solutions of [ C] -epostane in organic
solvents were spotted onto a TLC plate, dried under
oxygen-free-nitrogen, and developed immediately. The most
14reproducible results were obtained when the [ C] -epostane was 
dissolved in a mixture of chloroform/methanol/ formic acid 
(80/10/10 by volume). This procedure was adopted for the routine 
TLC analysis of radiochemical purity of both steroids.
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. . .  . . 143.1.3 Stability in dose formulation: Animal studies with [ C]-epostane
required oral administration using 0.25% w/v gum tragacanth as a
14vehicle. A 1.25% w/w suspension of [ C]-epostane was prepared
using gum tragacanth in distilled water (pH 6.5). The formulation
was prepared using a mortar and pestle and the initial
radiochemical purity of radiolabelled drug was 95%. Rapid 
14degradation of [ C]-epostane was observed. The radiochemical 
14purity of the [ C]-epostane in suspension was only 76% after 
1.5 h, falling to 71% 3 h after preparation. By 24 h, further 
degradation to 42% radiochemical purity had occurred. Following
preliminary investigations, it was demonstrated that the
14 . . . .[ C]-epostane suspension could be stabilised if the suspension
was prepared using gum tragacanth in pH 5.0 citrate buffer. 
However, the use of buffered suspensions in animal dosing was not 
desirable since toxicology studies were performed using unbuffered 
suspensions. An alternative procedure for preparing the dose
formulation was therefore examined. A gum tragacanth suspension
14 . . .of [ C]-epostane in distilled water (pH 6.5) was prepared using
an Ultra-Turrax homogeniser. The radiochemical purity of the
suspension remained constant over 3 h, although degradation was
14evident after 24 h (Table 3.1). [ C]-epostane suspensions
were prepared and used within 3 h of preparation.
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3.1.4 Stability in biological fluids: Samples of rat plasma, urine,
bile and faeces and dog plasma and urine were fortified with
14 o[ C] -epostane and analysed by HPLC after storage at -20 C for up
to 1 month (Table 3.2). Some variation in the retention time of
14 . . .C-epostane was noted over the period of analysis, but in all
cases the major radioactive component co-chramatographed with a
14non-radiolabelled epostane standard. [ C]-epostane was stable in 
all the biological media examined with the exception of rat bile, 
in which approximately 3% degradation occurred over the 1 month 
storage period.
3.2 T ^ Cl -TRILOSTANE
3.2.1 Stability as dry powder and in organic solvents: Like
14 14[ C]-epostane, [ C] -trilostane was observed to be stable over a
period of at least 6 months when stored at -20°C in the dry state.
14 14However, in contrast to [ C]-epostane; [ C]-trilostane was
stable in organic solvents (acetone, ethanol) when stored at a
-20°C for up to 7 days (Fig . 3.3).
. . . . . . 143.2.2 Stability in dose formulation: The stability of [ C]-trilostane
in 0.25% w/v aqueous gum tragacanth was investigated prior to
14animal studies. As with [ C]-epostane stability was maintained
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over 3 h stored at room temperature/dark (Table 3.1), although by
24 h the radiochemical purity had decreased to 46%. In animal 
14studies with [ C]-trilostane the dose formulation was prepared 
and used within 1 h of preparation.
3.3 DISCUSSION
. . 14 . .The instability of [ C]-epostane in various organic solvents
confirmed earlier observations with non-radiolabelled compound
that degradation of the drug occurred in alcoholic solvents (77).
The appearance of a degradation product with similar
characteristics to (4 a, 5 a ,  170 ) 4,5-epoxy, 17-hydroxy-4,17-
dimethyl-2,3-dioxoandrostane (i.e. loss of the cyano moeity from
the epostane molecule) also substantiated the report that an HCN
odour was associated with the decomposition of "2 cyano-3-
14ketosteroids”. However, [ C]-trilostane was stable under these
conditions. Consequently the presence of the additional methyl
14group in the A-ring of [ C] -epostane appears to result in the 
destabilisation of this steroid.
Both compounds had only short term stability in the aqueous gum 
tragacanth dose formulations, although were sufficiently stable 
for animal studies to be performed. Despite the apparent
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lability of the cyano group in aqueous media, this has been shown 
to be without consequence in toxicology studies. Rat and monkey
studies with epostane following 10 and 100 mg kg 1 oral doses (98) 
showed that serum cyanide levels were similar to control animals. 
Urinary thiocyanate ion was also measured in the 24 hours urines 
from the rat study and showed a dose related increase. 
Consequently, any in vivo loss of the cyano group from the steroid 
molecule is eliminated from the body by the detoxifying 
thiocyanate pathway (102).
14 . 14Since [ C]-trilostane and [ C]-epostane are very unstable on
silica gel tic plates and in organic solvents, very careful
handling procedures were required in order to minimise the
potential degradation of these steroids in samples from drug
. . 14metabolism studies. The stabilisation of [ C]-trilostane and
14[ C]-epostane on tic plates by the use of a chloroform/ethanol 
formic acid mixture arose from earlier observations regarding a 
stability assay for non-radiolabelled trilostane (91). However, 
acceptable stability on TLC plates was observed so long as the 
samples (in methanol or ethanol) were dried under oxygen-free- 
nitrogen and the drying process kept to less than 30 seconds. By 
adopting this technique drug and metabolite profile studies could 
be reliably and reproducibly performed by TLC.
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SUMMARY OF CHAPTER 4
The overall excretion and tissue distribution of radioactivity for
14 14 . .[ C]-epostane and [ C]-trilostane were similar in rat and
consequently, organ selective uptake of drug related products did
not account for the pharmacological selectivity of these
compounds. However further investigation into the nature of
adrenal and ovarian radioactivity in dog demonstrated that
epostane concentrations were highest in the ovaries whilst for
trilostane and its active metabolite, 17 -ketotr ilostane,
concentrations were highest in adrenals. Thus the adrenal and
ovarian distribution pattern for epostane, trilostane and
17-ketotrilostane was consistent with the observed target organ
specificity.
14 14Based upon the [ C]-epostane and [ C]-trilostane tissue
distribution data in rat, organ radiation doses were within the
regulatory limits for human radiolabelled studies, despite slow
elimination of radioactivity from adrenals and ovaries.
. 1 4A sex difference in the urinary excretion of [ C] -epostane was 
observed. Male animals excreted less radioactivity in urine than 
females and fewer metabolites were observed. Compared to rat, dog 
and monkey (the other toxicology species), excreted a greater
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proportion of the dose in urine. A similar level of excretion was
also observed in the urine of pigs. The metabolism of 
14[ C]-epostane varied markedly between species, although rat and 
pig showed same degree of similarity.
14[ C]-epostane metabolites were isolated from rat faeces. No
14single major metabolite of [ C]-epostane was evident with the 
radioactivity being distributed amongst a large number of 
products. Of the metabolites isolated, several components 
represented A-ring reduced products.
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4.1 EXCRETION STUDIES IN THE RAT
Hie excretion of radioactivity in male rats following
. . .  14 . . .administration of [ C]-trilostane had been investigated m
earlier studies (36). However commercial interest for trilostane
had been stimulated as a result of its potential use in
post-menopausal women with breast cancer. It was therefore
14 . .appropriate to examine the excretion of [ C]-trilostane within
female animals to support further metabolism studies, in addition
. . . 1 4to examining the excretion of [ C]-epostane.
14Female rats (n = 3) were dosed orally with [ C]-trilostane (20 mg
kg 1). Separately three male and three female rats were dosed
14 — 1orally with [ C]-epostane (25 mg leg ). Animals were placed in
individual all-glass metabolism cages suitable for the separate
collection of urine and faeces. Urine samples were collected over
12 hour periods for the first 24 h and thereafter at 24 h
intervals until 72 h ([14C]-trilostane) and 120 h ([ 14C] -epostane)
post-dose. Faecal samples were collected daily over the same time
periods. All samples were collected into glass vessels cooled
with solid CO^ . After 120 h, the rats were sacrificed by CC>2
inhalation. Samples of urine, faeces, carcass and cage washings
were assayed for radioactivity as described in section 2.6.1 and
the routes and rates of excretion determined.
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144.1.1 T Cl -Trilostane: Hie mean (+ SD) total recovery of the 
administered radioactivity was 96.7 + 4.1%. Means of 27.8 + 5.6% 
and 65.4 + 2.2% of the dose were excreted in urine and faeces 
respectively, during the 72 h period after dosing (Table 4.1). 
Miost of the radioactivity (90% of the dose) was recovered within 
48 h of dosing (Fig. 4.1).
The urinary excretion of radioactivity in female animals in this 
study was twice that observed in male rats (13.7%, ref. 36).
14 . . . .4.1.2 r Cl-Epostane: The mean (+ SD) total recoveries of radioactivity
j
in male and female animals were 97.4 + 1.2% and 97.5 + 0.9% 
respectively.
14As with [ C]-trilostane, female animals excreted more 
radioactivity in urine than males. Means of 11.1 + 2.2% and 24.0 
+ 1.7% of the administered radioactivity were excreted in the 
urine of male and female rats respectively, during the 120 h 
period after dosing (Table 4.2). The majority of the 
radioactivity was excreted in faeces with means of 84.5% (males) 
and 72.3% (females) being recovered within 120 h of dosing. Most 
of the urinary and faecal elimination of radioactivity occurred 
within 48 h of dosing (Fig. 4.2).
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4.2 TISSUE DISTRIBUTION STUDIES TN THE RAT
To support the application for radiolabelled metabolism studies in 
women and to examine the adrenal/ovarian organ distribution of 
radioactivity, distribution studies were conducted in female rats. 
Pigmented animals were used to assess the melanin binding of drug 
related products.
14Twelve female pigmented rats were dosed with [ C]-trilostane (20
-1 14mg kg ) and a further twelve animals with [ C]-epostane (25 mg
kg 1) and transferred to individual grid floor cages. At 1, 24,
48 and 72 h post-dose 3 animals were exsanguinated whilst under
ether anaesthesia, and various tissues (detailed in section
2.3.1.1) were removed or sampled^and assayed for radioactivity.
144.2.1 r Cl -Trilostane: One hour after dosing there was widespread
tissue distribution of radioactivity (Table 4.3). Excluding the 
stomach and gastrointestinal tract the highest mean tissue 
concentrations were found in liver (23.0 ug equiv g-1), adrenals 
(18.7 ug equiv g”1), ovaries (9.04 ug equiv g"1) and kidneys (8.46 
ug equiv g 1). Tissue/blood concentration ratios varied between 
2.93 + 0.70 and 7.27 ± 0.93 for adrenals, ovaries and liver (Table
4.4). Concentrations of radioactivity had declined markedly by 24
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h in all tissues, although less rapidly in adrenals and ovaries 
(Fig. 4.3). Thereafter concentrations declined more slowly such 
that by 72 h post-dose tissue levels were either low (0.01 - 1.03 
ug equiv g 1) or non-detectable, with the exception of adrenals 
(5.55 ug equiv g ^  and ovaries (2.58 ug equiv g”1). The 
half-life for the elimination of radioactivity in adrenals and 
ovaries was 54 and 76 h, respectively.
144.2.2 r Cl-Epostane: The following results are presented with the kind
permission of Mr J. Allen. The tissue distribution of 
14 . . 14[ C]-epostane was similar to [ C]-trilostane (Table 4.5). The 
highest mean concentrations of radioactivity at 1 h post-dose 
(excluding the tissues of absorption) were found in liver (39.8 ug 
equiv g”1), adrenals (36.8 ug equiv g”1) and ovaries (12.4 ug 
equiv g 1).
By 24 h post-doset levels of radioactivity has declined in all 
tissues, falling to 3.12, 8.06 and 3.37 ug equiv g"~'L in liver, 
adrenals and ovaries respectively. The decline in the adrenals 
and ovary radioactivity concentrations over the first 24 h was 
less marked than that observed in other tissues (Fig. 4.4). 
Thereafter, radioactivity levels declined more slowly in all 
tissues. By 72 h post-dose,the adrenals (3.06 ug equiv g”1) and
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ovaries (1.47 ug equiv g 1) contained the highest concentrations 
of radioactivity. The half-life for the elimination of 
radioactivity in adrenals and ovaries was 34 and 40 h 
respectively.
In conclusion there were no major differences in the organ
distribution or elimination of radioactivity between
14 . 14[ C]-trilostane and [ C]-epostane.
4.2.3 Organ radiation doses for proposed human study; The rat 
quantitative tissue distribution data was used to calculate the
organ radiation dose a human volunteer would receive following an
14 . .oral dose of [ C]-trilostane (50 uCi, 1.85 MBq). For trilostane,
the radiation doses to the adrenal, bone, bone marrow, eye, liver,
lung, ovary, thyroid, fat, stomach, small intestine, upper large
intestine, lower large intestine and urinary bladder were
calculated. A summary of the weighted dose equivalents for these
tissues is shown in Table 4.6. From this data it was shown that
the intestine would receive the highest radiation dose and despite
the long elimination half-lives of radioactivity in adrenal and
ovaries, these tissues had relatively low exposure. The committed
effective dose equivalent after a single oral dose of 
14[ C]-trilostane (1.85 MBq) was calculated to be approximately
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318 uSv. This is lower than the 500 uSv upper limit recommended 
by the World Health Organisation for a Catergory 1 Project. 
Similarly, the committed effective dose equivalent for epostane 
was 320 uSv. Approval for conducting radiolabelled studies in 
female volunteers was obtained from ARSAC (Administration of 
Radioactive Substances Advisory Committee) although not eventually 
pursued.
4.3 INVESTIGATION OF ADRENAL VS OVARIAN METABOLISM IN THE DOG
Since gross differences in organ radioactivity did not explain 
the pharmacological selectivity of trilostane and epostane, the 
tissue metabolism of these compounds was investigated. Dogs were 
used for these studies so that large radioactive doses could be 
administered.
A single female beagle dog received an oral dose of 
14 -1 .[ C]-trilostane (7.1 ug kg ; 164 uCi) and a second dog received
14 -1an oral dose of [ C]-epostane (5.8 mg kg ; 129 uCi). Blood
samples were removed from each animal at 0.5, 1.0, 2.0, 3.0 and
4.0 h post-dose and the resultant plasma assayed for
radioactivity. At 4.0 h post-dose the animals were exsanguinated
under pentobarbitone anaesthesia, and the adrenals, ovaries and
liver removed. The metabolite profiles of tissue extracts were
examined by TIC.
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4.3.1 Plasma radioactivity profiles: Absorption of drug related
products was confirmed by the analysis of plasma post-dosing.
14 . .Following [ C]-trilostane administration a peak plasma
radioactivity concentration of 4.2 ug equiv g”1 was observed 1.0 h
14 . . .post-dose. After [ C]-epostane administration a peak plasma
radioactivity concentration of 8.4 ug equiv g-1 occurred 2.0 h
post-dose. By 4 h post-dose plasma radioactivity concentrations
—1 14had declined to 1.8 and 3.0 ug equiv g for [ C]-trilostane and 
14[ C]-epostane respectively.
4.3.2 Tissue concentrations of radioactivity: At 4 h after
. . .  14 14administration of [ C]-trilostane and [ C]-epostane adrenal
concentrations were 5.89 and 11.0 ug equiv g 1 respectively (Table
4.7). Concentrations in the ovaries were lower (3.71 and 9.78 ug
-1 -1 equiv g ) but in the liver higher (10.0 and 15.6 ug equiv g )
than those observed in adrenals. Tissue/plasma ratios ranged
between 2.1-5.6 for these tissues (Table 4.8), but as found in rat
14 . 14were not obviously different for C-trilostane and C-epostane.
4.3.3 Tissue metabolite profiles: Plasma, liver, adrenals and ovaries
were extracted with acetonitrile or methanol as described in 
Section 2.5.4. Extracts from these tissues were examined for 
metabolites by TLC. At the time of peak plasma radioactivity 
concentrations (2.0 h post-dose) trilostane and 17-ketotrilostane
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(an active metabolite) accounted for 14% and 8% of the plasma 
radioactivity, respectively (Fig. 4.5). The majority (59%) of the 
plasma radioactivity was associated with polar material which did 
not move from the origin. By 4 h post-dose, the region of 
radioactivity associated with trilostane and 17-ketotrilostane 
accounted for 18% of the plasma radioactivity.
14 . . .Following [ C]-epostane administration, parent drug accounted for
56% of the plasma radioactivity 2.0 h post-dose (Fig. 4.6). By 
144.0 h post-dose, C-epostane had decreased to represent only 14% 
of the plasma radioactivity.
TLC examination of tissue extracts at 4 h post-dose demonstrated
an absence of trilostane and 17-ketotrilostane, or epostane, in
liver (Fig. 4.7). In contrast to this major organ of drug
metabolism, trilostane and 17-ketotrilostane accounted for 20% and
17% of the radioactivity observed in adrenals (Fig. 4.8).
Slightly less radioactivity was associated with these components
in ovaries (11% and 14% for trilostane and 17-ketotrilostane,
14respectively). For [ C]-epostane the distributional pattern was 
reversed. In adrenal, 10% of the radioactivity was associated 
with epostane (Fig. 4.9) whilst in ovary 51% of the radioactivity 
was accounted for by epostane. This distribution pattern for
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trilostane and epostane was consistent with the organ selectivity 
noted for these agents in earlier animal studies.
4.4 EPOSTANE METABOLISM IN THE RAT
Toxicology studies with epostane were performed in rat, dog and
monkey and no significant adverse findings were observed. Since
veterinary use of epostane in food-producing animals was proposed
(i.e. oestrus control/induction of parturition), the metabolic 
14 .products of [ C]-epostane in pig (as viewed from urinary
disposition) were compared to the toxicology species,to provide a
basis for extrapolating safety data. To elucidate the metabolic
14 . . .fate of [ C]-epostane in rat, the isolation and identification of
the faecal metabolites was undertaken (the major route of 
excretion for this steroid).
4.4.1 Metabolic profiles in urine and faeces
4.4.1.1 Rat: Urine and faecal samples, collected during the rat excretion
study, were examined by a combination of HPUC and TUC for
metabolites as described in Section 2.5.3. A sex difference in 
the quantities of radioactivity excreted in urine had been
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observed; male rats excreting much less of the dose than female
animals (see section 4.1.2). This sex difference was also
apparent in the metabolic profiles (Fig. 4.10). Nine major
metabolite peaks were observed in female urine (0-12 h) by HFLC
analysis. The largest of the metabolite peaks (U ) accounted for
5
15% of the urinary radioactivity (2.5% of the dose). In male 
urine, 5 metabolites were observed and corresponded in retention 
time to same of those observed in female urine. The major
metabolite in male urine (Ug) accounted for 46% of the urinary 
radioactivity (2.4% of the dose).
TLC analysis confirmed the metabolite profile observed by HPLC.
TLC analysis of female urine revealed 8 radiolabelled components
in solvent system I and 9 in solvent system II. In male urine, up 
to 5 components were observed in the same solvent systems. 
Negligible levels of urinary radioactivity (0.01-0.1% of the dose 
%) were associated with parent drug.
The metabolic profiles in urine were analysed by TLC before and 
after ft -glucuronidase/aryl sulphatase hydrolysis. There was 
little or no change in the distribution of radioactivity in both 
male and female urine following enzyme treatment.
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The HPLC radioactivity profiles of the 0-24 h faecal extracts were
similar for males and females and showed the presence of 2 major
peaks (F and F ) along with a smaller, more polar component, F 
2 3 1
(Fig. 4.11). F3 corresponded in retention time to an epostane 
standard and represented 17.8% and 16.7% of the dose in males and 
females respectively. F2 accounted for 7.4-9.7% of the dose and 
FI 2.4-4.6% of the dose.
TIC analysis in two solvent systems (I and II, see section
142.5.2.2) tentatively confirmed the presence of [ C]-epostane at 
8-11% of the dose.
In the HPLC and both TLC systems, a considerable proportion of the 
dose (10-17%) was associated with non-discrete zones of 
radioactivity.
4.4.1.2 Species comparison of urinary metabolic profiles ; Urine samples
14 . . .from [ C]-epostane excretion studies in dog, pig and monkey were
received for HPLC and TLC analysis of metabolites to assess the 
variation in metabolism across species. A summary of the 
administered doses and urinary radioactivity recoveries are 
presented in Table 4.9 and compared to the data in rat.
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Total urinary excretion of radioactivity was lower in the female 
rat (24.0 + 17%) than in other species examined (40.1 + 6.0%; dog 
to 47.0 + 7.4%; monkey) . However, initial urinary excretion rates 
were similar in the female animals of all species (20-28%).
Comparison of the metabolites in female rat, dog, pig and monkey 
urine (0-24 h) showed marked species variation in the metabolism 
14of [ C]-epostane (Fig. 4.12). Although only partially resolved 
in the HPLC system,rat and pig urine contained at least 9-12 
components with no single major metabolite, indicating extensive 
metabolism. In dog, fewer components were observed although again 
these were only partially resolved in the HPLC system. Monkey 
urine contained mainly polar components as evidenced by the short 
retention time on the HPLC column. Rat, pig and dog urines were 
unaffected by ft -glucuronidase/aryl-sulphatase enzyme and were 
unaffected by storage at -20°C over a period of several months. 
In contrast, monkey urine when reanalysed after storage at -20°C, 
showed a different metabolic profile (Fig. 4.13). Treatment with 
-glucuronidase/aryl-sulphatase completely removed the more 
polar components at the beginning of the chromatogram, and this 
hydrolysis was inhibited by saccharo-4-lactone. The presence of 
glucuronide conjugates in monkey urine was therefore indicated.
TLC analysis of rat, dog, pig and monkey urine confirmed the
14relative complexity of the metabolism of [ C]-epostane in the 
different species.
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To summarise, the metabolism in pig as viewed from urinary 
profiles, most resembled the metabolism in rat, although 
quantitative differences in the metabolites were evident. The 
; metabolism* data generated in rat may therefore be appropriate to 
support the use of epostane in the veterinary control of oestrus 
and induction of parturition.
.4.2 Isolation of metabolites; Female rats (n = 25) were dosed orally
14 -1with [ C]-epostane at a dose level of approximately 450 mg kg ,
and urine and faeces collected up to 96 h post-dose. Samples from
6 animals were assayed for radioactivity to determine the rate of
excretion (Table 4.10). As observed with the lower dose of 25 mg
-1 14 . .kg [ C]-epostane in female rat, most of the radioactivity was
excreted in faeces, although at a slower rate. HPLC analysis of 
the 24-48 h faecal extracts, containing the major proportion of
the dose, showed the presence of 2 major components designated FI
and F2. Further fractions were isolated from FI and F2 as
described in Section 2.5.2.
In total 9 metabolite fractions (Fla-F2g) were purified and
characterised by TLC. These metabolites, in addition to synthetic 
reference standards of possible metabolites, were supplied for 
mass spectral analysis. Following conversion to trimethylsily 1
derivatives all the samples were analysed by capillary GC/MS. 
Epostane itself gave multiple peaks on derivatisation and none of 
these could be attributed to epostane. Mass spectra for these 
derivatives are presented in Figs. 4.14-4.25 .
Three of the reference standards were different isomers of the 
compound (2 7/ 37, 4a, 5a, 17j$ )-4,5-epoxy-3,17-dihydroxy-4,17- 
dimethyl androstane-2-carbonitrile (Figs. 4.14-4.16). A 
theoretical fragmentation pattern for the TMS derivatives of these 
isomers is presented in Fig. 4.26. It is of interest to note that 
for the 20! , 3a isomer the m/e ion at 446 is apparently more 
stable and further fragmentation to ia/e ions at 393 and 303 is 
limited. The ions at m/e 393 and 303 were also prominent in the 
mass spectrum of (20! , 3 7 , 40! , 50! , 17ft )-4,5-epoxy-4,17- 
dimethyl androstane- 2,3,17-triol (Fig. 4.17). All these 
standards gave the same base ion at ra/e 143 (Fig. 4.26). The 
spectrum of (2 0! , 3a , 40! , 5a , 160! , 17fi )-4,5-epoxy
3,16,17-trihydroxy 4,17-dimethylandrostane- 2-carbonitrile (Fig. 
4.18) gave a base ion at my'e 73 representing IMS. A prominent ion 
at m/e 218 is likely to be due to the stable radical-cation 
fragment as illustrated in Fig. 4.18.
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All metabolic fractions contained either as the base peak or as a 
major peak the ion at ir/e 143. Consequently it is likely that 
none of the metabolites represent hydroxylated products in the 
d-ring of the steroid molecule. Metabolite Fla (Fig. 4.19) had an 
identical mass spectrum to the reference standard (2a. , 3a , 4a , 
5 a , 1 7 )  -4,5-epoxy 3,17-dihydroxy-4,17-dimethyl androstane- 
2-carbonitrile (Fig. 4.14). Metabolites Fib, F2a and F2d (Fig. 
4.20) had similar mass spectra to the compound (2a, 3 7 , 4a ,5a, 
17 ft )-4,5-epoxy- 4,17-dimethyl androstane-2,3,17-triol (Fig.
4.17). Metabolite fractions F2b, F2c, F2e, F2f and F2g (Figs. 
4.21-4.25) had different spectra to the available reference 
standards although F2c had, on the basis of HPLC and TLC evidence, 
been assigned as epostane. However, since epostane apparently 
decomposes under the derivatising conditions the mass spectrum for 
F2c (Fig. 4.22) does not discount this possibility.
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CHAPTER 5
TRHOSTANE : TMJG ASSAY DEVELOPMENT AND METABOLITE ISOLATION
SUMMARY OF CHAPTER
5.1 HPLC
5.2 ISOLATION AND IDENTIFICATION OF 17-KETOTRIIOSTANE IN 
PLASMA AND URINE
5.3 COMPARISON OF CYTOCHEMICAL AND HPLC ANALYTICAL METHODS
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SUMMARY OF CHAPTER 5
An analytical method for the measurement of trilostane in human 
plasma was essential for the drugs clinical development. Initial 
HPLC investigation of plasma extracts from volunteers dosed with 
trilostane revealed the presence of a metabolite which was 
isolated and identified as 17-ketotrilostane. This metabolite was 
also shown to be excreted in urine as the glucuronide conjugate.
Both trilostane and 17-ketotrilostane were quantified by the HPLC 
assay with acceptable accuracy and precision down to a limit of
detection of 0.03 ug ml 1 (trilostane) and 0.05 ug ml”1 (17- 
ketotrilostane) . In order to further validate the assay a 
collaborative study was undertaken to compare the HPLC analytical 
procedure with an independently developed cytochemical bioassay. 
Since this Hatter method measured total 3 @ -hydroxysteroid 
dehydrogenase inhibitory activity it was not expected to be 
specific if active metabolites of trilostane were present in 
plasma. In fact, the intrinsic potency of 17-ketotrilostane was 
shown to be approximately double that of trilostane. Taking into 
consideration the increased potency of 17-ketotrilostane, 
excellent agreement between the HPLC and cytochemical bioassay was 
observed. It was concluded that 17-ketotrilostane was the only 
important active metabolite of trilostane in plasma.
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5.1 HPLC
In order to monitor drug levels in human bioavailability and 
pharmacokinetic studies an analytical method for measuring 
trilostane in plasma was required.
A radioimmunoassay for trilostane in plasma had been developed 
with a detection limit of 2 ng ml 1 and was claimed to be specific 
(55). However the antiserum for the assay was raised by 
conjugation of trilostane with bovine serum albumin through the 
17-hydroxy functional group. This radioimmunoassay was therefore 
suspected to have little specificity for trilostane metabolites of 
the 17-hydroxy group, a common point of metabolism for androstanes 
(82).
A high performance liquid chromatographic procedure was therefore 
developed for trilostane. Briefly, this method involved 
chloroform extraction of acidified (pH 5.0) plasma, reconstitution 
of the dried organic phase in ethanol, and injection of the 
extract onto a reverse-phase C1Q column with methanol and 0.1M 
formic acid (1:1) as eluent (full details given in section 
2.4.1.1).
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HPLC examination of plasma extracts from volunteers given a 
trilostane dose revealed that the chromatograms contained two 
peaks, assigned to trilostane and a metabolite which were absent 
from extracts of control plasma (Fig. 5.1). The metabolite was 
isolated and identified to be 17-ketotrilostane (see section 5.2). 
Preliminary investigations in healthy volunteers suggested that 
the plasma concentrations of trilostane and 17-ketotrilostane 
following an oral dose of trilostane (120 mg) were likely to be in 
the ranges 0-1 ug ml 1 and 0-2.5 ug ml 1, respectively.
Two sets of plasma samples were prepared with trilostane and 
17-ketotrilostane within these ranges. One set, prepared in 
quadruplicate was analysed upon preparation whilst the other, 
prepared in triplicate, was analysed after 7 days storage in the 
laboratory freezer. All assays were performed under single-blind 
conditions.
The efficiency for the extraction of trilostane and 
17-ketotrilostane from plasma was determined by comparing the peak 
heights obtained from extracted samples with those obtained by 
injection of unextracted samples. The mean extraction 
efficiencies (+ SD) were 82 + 6% and 76 + 12% for trilostane and 
17-ketotrilostane, respectively and were independent of 
concentration (0.2-2.5 ug ml 1).
Regression analysis of the plasma standards (Figs. 5.2 and 5.3) 
showed a linear relationship between peak height ratio and
concentration over the ranges 0-1 ug ml""1 (trilostane) and 0-2.5 
ug ml""1 (17-ketotrilostane). Typically regression coefficients 
were 0.9980 and 0.9990 for trilostane and 17-ketotrilostane 
respectively.
The concentrations of trilostane and 17-ketotrilostane in the 
prepared plasma samples, estimated by inverse prediction from the 
regression equation, and allowing for the contribution of a very 
small endogenous component present in the control plasma, are 
summarised in Tables 5.1 and 5.2. Storage of plasma for 1 week 
had no effect on the assayed concentrations (Figs. 5.4 and 5.5). 
The accuracy of the assay, defined by ranges of the mean percent 
differences from the nominal concentration values, varied from 
-6.7% to 7.9% for trilostane, and -7.9% to 6.5% for 
17-ketotrilostane. The minimum quantifiable level (MQL) of the 
assays was estimated as the concentration whose lower 80% 
confidence limit just encompassed zero (56). These were 0.03 and 
0.05 ug ml 1, for trilostane and 17-ketotrilostane, respectively.
5.2 ISOLATION AND IDENTIFICATION OF 17-KETOTRILOSTANE 
IN PLASMA AND URINE
HPLC analysis of plasma samples from volunteers who had received 
an oral dose of trilostane (120 mg) showed the presence of two 
components which appeared only in post-dose samples. One
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component was identical in retention time to parent drug. The 
second component varied in a time-dependent manner similar to 
trilostane and was therefore assigned as a metabolite (see 
Fig. 5.1). The metabolite had a similar retention time to 
17-ketotrilostane which had been observed as a major metabolite of 
trilostane in rat plasma (37).
When the HPLC analytical procedure was applied to urine samples 
taken from volunteers no trilostane or 17-ketotrilostane was 
observed. However, following incubation with @ -glucuronidase 
(Helix Pomatia) small amounts of trilostane and larger quantities 
of 17-ketotrilostane were evident (Fig. 5.6).
The plasma and deconjugated urinary metabolites were isolated as 
detailed in section 2.5.1. Briefly, acidified (pH 5.0) plasma and 
urine samples were extracted with ether, the extracts passed down 
a silica gel column and subsequently purified by semi-preparative 
HPLC. The partially purified metabolite fractions from the silica 
gel column were assayed in 3 HPLC systems and 6 different TLC 
systems (section 2.5.1.2). Co-chromatography of 17-ketotrilostane 
and the isolated plasma and urinary metabolites were demonstrated. 
Moreover, following TLC analysis both the isolated metabolites and 
17-ketotrilostane turned a characteristic grey/brown colour after 
spraying with 20% sulphuric acid and heating for 5 mins.
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After further purification of the metabolites by semi-preparative 
HPLC the purity of these metabolite fractions was assessed by TLC 
(urinary metabolite only) and also by analytical HPLC in 
conjunction with a diode array detector. UV scans (over the 
wavelength range of 200 nm to 400 nm) taken at the beginning, apex 
and end of the metabolite peaks showed completely overlapping 
spectra and suggested peak homogeneity.
Confirmation of the identity of 17-ketotrilostane was obtained by 
GC/MS analysis. Under the GC conditions employed (section
2.5.1.2) both trilostane and 17-ketotrilostane trimethylsilyl 
(IMS) derivatives eluted as sharp peaks, separated by 17 seconds 
with retention times approximately 11.5 minutes. The mass spectra 
of the IMS derivatives of trilostane and 17-ketotrilostane are 
shown in Fig. 5.7. Trilostane existed as a ditrimethylsilyl 
derivative whilst 17-ketotrilostane existed as a 
monotrimethylsilyl derivative with molecular weights of 473 and 
399 respectively. Both compounds showed a characteristic loss of
a methyl group to give relatively intense M+ -15 fragments at m/e 
384 arising from cleavage of a methyl —  silicon bond. The TMS 
derivatives of the isolated plasma and urine metabolites eluted 
with similar retention times to 17-ketotrilostane IMS and gave 
essentially identical mass-spectra to the reference standard 
(Figs. 5.8 and 5.9).
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5.3 COMPARISON OF CYTOCHEMICAL AND HPLC METHODS
A cytochemical bioassay (CBA) was independently developed for the 
measurement of trilostane in plasma (1). However this analytical 
procedure was not specific in the sense that any metabolites of 
trilostane active in inhibiting 3 ft BSD would be measured. The 
relative potency of 17-ketotrilostane was assessed by bioassay and 
was shown to be 1.71 times (95% confidence limits 1.4-2.1) more 
potent than trilostane (100).
Subsequently, the two assays were compared by analysing plasma 
samples from 4 fasted volunteers who had received an oral dose of 
trilostane (120 mg). Blood samples were taken pre-medication and 
at 1, 2, 3, 4, 5, 6 and 8 h post-medication. The prepared plasma 
was divided into two aliquots, one for assay by HPLC and the other 
by CBA.
HPLC results for trilostane and 17-ketotrilostane are presented in 
Table 5.3 and the corresponding trilostane equivalents (CBA) are 
presented in Table 5.4. Taking into account the relative potency 
of 17-ketotrilostane, the molar sum of trilostane equivalents from 
the HPLC data and CBA data are compared in Fig. 5.10. The 
excellent agreement between the assays was characterised with a 
correlation coefficient of 0.947 (n = 18, P > 0.99) (Fig. 5.11). 
Consequently, 17-ketotrilostane was the only important active 
metabolite of trilostane present in plasma with respect to - 
hydroxysteroid dehydrogenase activity.
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SUMMARY OF CHAPTER 6
Human volunteer studies were conducted to examine the effect of 
trilostane and epostane particle size upon the systemic 
availability of these compounds after oral administration.
17-ketotrilostane concentrations were 2-3 fold higher than
trilostane concentrations at the optimum particle size of 10 urn
2 - 1  . . .(~ 2 m g ) and followed a similar time course. Trilostane
therefore undergoes first-pass metabolism to yield the principal 
active metabolite, 17-ketotrilostane (with respect to 3/3 
-hydroxysteroid dehydrogenase inhibition). A similar surface area 
requirement was shown to be appropriate for the optimum systemic 
availability of epostane. However even at the optimum particle 
size, considerable variability was observed in plasma trilostane, 
17-ketotrilostane and epostane concentrations.
Linear kinetics was demonstrated for trilostane up to a 240 mg 
dose. From these data multiple dose predictions of therapeutic 
plasma trilostane and 17-ketotrilostane were made for the dosage 
regimens employed in clinical trials. Analysis of clinical trial 
samples confirmed the predictions that no significant accumulation 
of drug or metabolite would occur upon long term therapy with 
trilostane.
Epostane plasma concentration data could not be described by a 
simple exponential function.
- 1 3 0 -
6.1 THE INFLUENCE OF PARTICLE SIZE ON THE SYSTEMIC
AVAILABILITY OF TRILOSTANE AND EPOSTANE FOLLOWING ORAL 
ADMINISTRATION
6.1.1 Trilostane: Trilostane was originally formulated for oral
administration in soft gelatin capsules containing 60 mg 
trilostane in addition to maize starch, lactose and magnesium 
stearate excipients. The influence of the particle size of 
trilostane raw material used within the capsules upon the in-vivo 
absorption was investigated in two separate human volunteer 
studies. The first study, conducted in medically approved male 
volunteers (n = 8) utilised trilostane raw material with median 
relative volume diameter particle sizes of 10 um, 45 urn or 100 urn 
(Coulter determination). The second study in a separate panel of 
8 volunteers (n = 8) investigated 4 um particle size raw material 
in comparison to 10 um. These batches of trilostane were also 
characterised by surface area measurement (Strbhlein) and were 2.2
2-1 2-1 m g and 7.3 m g  , respectively.
Following administration of 120 mg trilostane (ie 2 x 60 mg 
capsules) blood samples were taken at 0.5, 1.0, 2.0, 3.0, 4.0,
5.0, 6.0, 8.0, 10.0 and 24 (initial study only) hours post-dose. 
Both studies were conducted on a randomised cross-over basis with 
1 week washout periods between dosing. Plasma samples were
-131-
assayed for trilostane and its active metabolite 17-ketotrilostane 
by HPLC as detailed in Section 2.4.1. Mean plasma trilostane and 
17-ketotrilostane concentrations are presented as a function of 
time in Figs 6.1-6.4. Considerable variation was noted between 
individuals and for the purposes of clarity only the error bars 
for the 10 um data are presented. 17-ketotrilostane 
concentrations were generally 2-3 fold higher than trilostane 
concentrations and followed a similar time course. Since 
17-ketotrilostane had been shown to be an active metabolite the 
area under the concentration v time curve for trilostane and 
17-ketotrilostane was combined, taking into consideration the 
increased potency of the metabolite (Table 6.1). There were no 
significant differences between the 4 um and 10 um formulations. 
However, in comparison to these formulations the relative 
availability of the biologically active components was 
significantly reduced (p < 0.05) to 58% and 27% for the 45 um and 
100 um particle size materials respectively.
6.1.2 Epostane: Unlike trilostane, epostane was formulated as a tablet
containing either 50 mg or 100 mg active ingredient, although the 
excipients were similar between formulations. The influence of 
raw material particle size (as assessed by median volume diameter 
and surface area measurements) on the absorption of epostane was 
investigated. Three different grades of epostane raw material
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2 - 1were examined (1) 0.6 m g /14.4 um median volume diameter (2) 3.8
2-1  . . 2-1 m g /15.3 um median volume diameter and (3) 7.0 m g /10.4 um
median volume diameter.
Healthy male volunteers (n = 8) were dosed orally with epostane 
(400 mg) and blood samples collected at 0.5, 1.0, 1.5, 2.0, 3.0,
4.0, 6.0, 8.0, 10.0 and 24.0 h after dosing. The study was
conducted on a randomised cross-over basis with at least 7 days 
between each dose. Plasma samples were assayed for epostane by 
HPDC as detailed in Section 2.4.2. As with trilostane 
considerable inter-individual variation was observed in the data
(Fig 6.5). There was no significant differences between the
2-1 2-1 3.8 m g and 7.0 m g formulations. However the larger particle
2-1 . . .size material (0.6 m g ) gave significantly lower values
2 — l(p < 0.01) and AUC values (p < 0.02) than the 3.8 m g
formulation (Table 6.2).
In conclusion, these formulation studies in healthy volunteers
demonstrated that particle size is important for the systemic
availability of both trilostane and epostane. A particle surface
2 -1area within the range 2-5 m g was shown to be appropriate for 
the production of both doseforms. However even within this range 
considerable inter-individual differences were evident. 
Trilostane was shown to undergo first-pass metabolism to give the 
active metabolite, 17-ketotrilostane whose plasma concentrations 
were 2-3 fold higher than parent compound.
6.2 THE FHARMAOOKENETICS OF TRILOSTANE AND EPOSTANE
FOLLOWING ORAL ADMINISTRATION
6.2.1 Trilostane
6.2.1.1 120 mcr oral dose: Using the optimum particle size trilostane
formulation (10 um) the pharmacokinetics of trilostane following 
an oral dose was investigated in ten medically approved male 
volunteers. Blood samples were taken at half-hourly intervals for 
the first 4 hours and at 5, 6, 8 and 24 hours following
administration of 120 mg trilostane. Plasma samples were analysed 
for trilostane and 17-ketotrilostane by HPLC as detailed in 
Section 2.4.1., and the resultant concentration data are presented 
in Fig. 6.6 (mean + SD). As previously observed there was 
considerable variation between volunteers in the plasma trilostane 
and 17-ketotrilostane concentrations. In an attempt to reduce the 
variability, all available data from volunteers receiving a 10 um 
particle size trilostane formulation were combined. (NB all 
studies performed under standardised conditions). Mean (± SD) 
data from twenty five volunteers are presented in Fig. 6.7. For
trilostane the C of the mean data was 0.43 ug ml”1 and occurred max 3
at 2.0 h post-dose. Similarly, 17-ketotrilostane also reached 
maximum levels (1.12 ug ml”1) at 2.0 h post-dose.
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Using a polyexponential fitting function (see Section 2.7.2) it
Twas found that the concentration of trilostane (Cp ) could be 
represented by the biexponential equation
CpT = 1.143e”°*529t - 1.143e“1,235t
KTand the concentration of 17-ketotrilostane (Cp ) by
c F  = 4.676e”°’530t - 4.676e”1,028t
The lag times were 0.33 h and 0.48 h for trilostane and 
17-ketotrilostane respectively. The degree of the goodness of fit
(as indicated by the sum of squared deviations (F), and
. . . . 2coefficient of determination (r )) of the above equations to the
mean concentration-time data for trilostane and 17-ketotrilostane 
are indicated in Table 6.3. A plot of the observed versus 
estimated plasma concentration versus time profiles is shown in 
Fig. 6.8.
6.2.1.2 240 mcr oral dose: Since the dosage regimens employed in the
clinic ranged up to 240 ug x 4 times daily the plasma levels of 
trilostane and 17-ketotrilostane following a single 240 mg oral 
dose was investigated to confirm linear kinetics and to enable
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predictions of the likely concentrations following multiple
dosing. Healthy male volunteers (n = 8) received 240 mg
trilostane (4 x 60 mg capsules) and blood samples taken at 0.5,
1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0 and 24 h post-dose.
Plasma samples were analysed for trilostane and 17-ketotrilostane
by HPLC as detailed in Section 2.4.1., and the mean plasma
concentration v time profiles presented in Fig. 6.9 (NB due to an
episode of ernes is in one volunteer 45 mins after administration
the data are only presented for 7 volunteers). Mean (+ SD) C
max
-1 -1 
was 1.19 + 0.31 ug ml and 2.43 + 0.90 ug ml for trilostane and
17-ketotrilostane, respectively (Table 6.4). Comparison of the
data following 240 mg and 120 mg oral doses (Table 6.5), after
normalisation for body weight, showed that the ratio for C wasJ ' max
2.0 and 1.8 for trilostane and 17-ketotrilostane, respectively.
The ratio of the AUC 240/120 mg was 2.9 and 2.5 for trilostane and 
17-ketotrilostane, respectively. Within the variability of the 
plasma concentrations following administration of trilostane 
doseforms, these data suggested linear kinetics for this compound.
6.2.1.3 Multiple dose predictions; In the clinic, ascending dose regimens 
are employed rising to either 480 mg or 960 mg daily in divided 
doses. These doses are given typically at 6 hourly intervals or 
at 8 am, 12 noon, 4 pm and 8 pm respectively. Assuming that
sequential doses are linearly superimposable, predicted plasma 
concentrations for the top dose of 960 mg losing the regimens 
outlined above ace depicted in Figs. 6.10 and 6.11. For the 
purposes of illustration it was assumed that the first dose 
administered is 240 mg trilostane at time zero. In figure 6.10, 
the concentration v time profiles have been plotted for trilostane 
and 17-ketotrilostane when 240 mg of trilostane are administered
every 6 hoars. The peak concentrations of 2.37 ug ml 1 for
-117-ketotrilostane and 0.90 ug ml for trilostane occur 2 h after 
dosing, whilst the corresponding trough concentrations are 0.37 
and 0.10 ug ml 1 respectively. In Fig. 6.11, similar 
concentration v time prefiles have been plotted for the case in 
which trilostane is administered at four hourly intervals during 
the day. The peak concentrations are 2.61 for 17-ketotrilostane 
and 0.96 for trilostane and occur 2 h after dosing. The 
corresponding trough concentrations during the day are 1.55 and 
0.30 ug ml 1, although immediately prior to the first morning dose 
both trilostane and 17-ketotrilostane have almost been cleared 
from the system.
6.2.1.4, Plasma levels in patients: In patients being treated with
trilostane for hypertension plasma samples were analysed for 
trilostane and 17-ketotrilostane at single , time points during the 
post-dose treatment periods. The results are illustrated in Fig.
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6.12. All patients showed a general increase in trilostane and
17-ketotrilostane levels in response to increased dosage with the
exception of patient 4. These values generally fall within the
multiple dose predictions of C and C at steady state and'
max min
confirm that long-term trilostane treatment does not lead to 
significant accumulation of drug, as predicted from the single 
dose kinetics. However, it was noted in same of these patients 
that the ratio of 17-ketotrilostane to trilostane was lower than 
that observed in healthy human volunteers.
6.2.1.5 Urinary excretion: Urine samples were collected over the periods
0-2, 2-4, 4-6, 6-8 and 8-24 hours following oral administration of 
120 mg trilostane to 8 healthy male volunteers. Aliquots of urine 
were analysed directly using the HPLC procedure detailed in 
Section 2.4.1. Further urine aliquots were adjusted to pH 5.0, 
hydrolysed with ft -glucuronidase/aryl sulphatase enzyme (Helix 
pamatia) for 17 hours at 37°C, and then analysed using the HPLC 
method. Individual urinary excretion data for 'free1 and 
'conjugated1 trilostane and 17-ketotrilostane are presented in 
Tables 6.6 and 6.7 respectively. Only small quantities of 
trilostane or conjugated trilostane (0.1-0.6% of the dose) were 
excreted in the 24 h period following dosing. 17-ketotrilostane 
was present in larger quantities (0.4-2.1% of the dose) and 
conjugated 17-ketotrilostane accounted for 0.1-8.3% of the dose.
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6.2.2 Epostane: Data from the bioavailability study described earlier,
(Section 6.1.2) were not suitable for pharmacokinetic analysis due
to the low number of volunteers (n = 8) and the variability
observed. A further bioavailability study was conducted with
epostane (200 mg oral dose) in 24 volunteers. Plasma assays were
conducted by Mr P. Powles and the following epostane concentration
v time data are quoted with permission (Fig. 6.13). As observed
with the initial study, large inter-subject variation was noted in
plasma epostane concentrations (Fig. 6.13). Mean (+ SD) C was
max
-1
0.25 + 0.12 ug ml and occurred at a t of 2.1 + 1.4 (h). The — max ~ '
AUC^q was 0.66 + 0.32 ug ml 1 h. The mean plasma epostane data 
could not be represented by a simple exponential function and no 
further interpretation of this data was attempted.
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7.1 Absorption and bioavailability: Previous studies with
14 .[ C]-trilostane in rat and monkey indicated that the drug was
well absorbed following oral administration (36). Comparison of
the per cent dose excreted in urine after an oral dose and
intravenous administration showed that 74% and 85% of the dose was
absorbed in rat and monkey, respectively. Similarly animal
14studies have shown that [ C]-epostane is also well absorbed.
Preliminary work in female rat indicated that 99% of an oral 
14[ C] -epostane dose was absorbed, as determined from the dose
corrected areas under the blood radioactivity concentration vs
time curves (78). The almost complete absorption of 
14[ C]-epostane in rat was demonstrated in a subsequent study using
female biliary cannulated rats (79). This study showed that 93.5
+ 4.5% of an oral dose was recovered in bile over 72 h, mainly
within the first 24 h post- dose. In female dog (80), 86.3 ±
1415.3% of an oral [ C]-epostane dose was absorbed. In the same
study parent drug was also measured following oral and intravenous
. . .  14 . . . .administration of [ C]-epostane, and the absolute bioavailability
(fraction of the dose reaching the systemic circulation) was 
estimated to be 99 + 24%.
The total extent of absorption of these steroids in humans has not 
been examined and would require the dosing of radiolabelled drugs 
to be investigated. Approval for such studies was gained from
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ARSAC (the Administration of Radioactive Substances Advisory
Committee), based upon tissue distribution data in rat and
subsequent organ radiation dose calculations generated in the
course of this work. These data showed that the radiological
exposure for such studies was within the limits set for a WHO
category 1 project (ie <500 uSv committed effective dose
equivalents) despite the retention of radioactivity in adrenals
14and ovaries. However, radiolabelled studies with [ C]-epostane 
14and [ C]-trilostane in women were not performed.
The lack of a suitable intravenous doseform for trilostane and 
epostane and the fact that these steroids were not approved for 
such use by the regulatory authorities, precluded the assessment 
of absolute bioavailability in humans. Therefore human studies 
centred upon obtaining an oral formulation which gave the optimum 
relative bioavailability.
In order to perform such studies specific, accurate and precise 
analytical procedures for the measurement of the steroids in human 
plasma were required. The HPLC procedure developed for the assay 
of trilostane, met these requirements and also enabled the 
simultaneous measurement of a principal metabolite, 
17-ketotrilostane. The HPLC assay for trilostane had the
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advantage over the radioimmunoassay (55) and cytochemical bioassay 
(1) for trilostane in that the method was specific for the drug 
and metabolite. The assay procedure was also relatively rapid, 
enabling a high throughput of samples for routine analytical use. 
However the cytochemical bioassay revealed that the intrinsic 
activity of 17-ketotrilostane was approximately double that of 
trilostane. Further the comparison of the HPLC assay and 
cytochemical bioassay showed that this metabolite was the only 
active metabolite present in plasma (re 3 hydroxysteroid 
dehydrogenase).
The HPLC assay for epostane in human plasma was developed 
elsewhere (4) and adapted for utilisation within these 
laboratories (81). With these assays potential trilostane and 
epostane formulations for human use could be investigated with 
regard to relative bioavailability.
When a drug is given orally in the form of a tablet or capsule, 
the rate of absorption is often controlled by how fast the drug 
dissolves in the fluids at the absorption site. Since the 
steroids contain at least 17 or more carbon atoms, they are highly 
lipqphillic and tend to be poorly soluble in water. However, 
accurate prediction of solubility is somewhat difficult. The 
solubility of testosterone in water is 24 ug ml”1 (72). The
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solubility of 17-methyl testosterone might be expected to be lower
than testosterone but in fact is not (32 ug ml 1/ ibid), which 
demonstrates the importance of crystalline structure in 
determining solubility. The methyl compound is more soluble 
because of its smaller heat of fusion and thus dissolves more 
readily in aqueous solvents. The same trend in solubility is 
observed with trilostane and epostane. The solubility of 
trilostane in water is less than 10 ug ml”1 (73) whilst that for 
epostane, the methyl derivative of trilostane, is 46 ug ml 1 (74).
Because both compounds are poorly soluble in aqueous media it was 
anticipated that absorption of trilostane and epostane from the 
gastrointestinal tract would be dissolution rate limited. Since a 
substance dissolves more rapidly when its surface area is 
increased the question of particle size is of importance in the 
absorption of poorly soluble drugs. The potential for increasing 
absorption by particle size reduction has been recognised for 
sometime. For example, an increase in the rate and extent of 
absorption of digoxin was observed by reducing the mean particle 
size diameter of drug used in tablet manufacture from 20 - 30 um 
to 3.7 um (92). Similar effects have been noticed for drugs such 
as spironolactone and griseofulvin (93, 94). The gastrointestinal 
absorption of medroxyprogesterone acetate from tablets containing
10 mg of either micronised or non-micronised drug was compared in 
a cross-over fashion in 10 healthy subjects (75). The micronised 
material had 99.9% of the particles smaller than 10 um. The
specific surface areas of micronised and non-micronised
2-1 2-1 medroxyprogesterone acetate were 7.4 m g and 1.2 m g
respectively. Micronisation led to a two fold increase in the
extent of absorption of the steroid.
In fact pharmacopoeial control is now exerted on solid dosage 
forms of many steroids. Thus, betamethasone, cortisone acetate 
and hydrocortisone preparations are all required to be ‘ultra-fine 
powders' for the production of solid dosage forms; an ultra-fine 
powder being defined as a powder of which the maximum diameter of 
90 per cent of the particles is greater than 5 um, and the 
diameter of none is greater than 50 um (76). In addition to the 
potential for increasing the bioavailability of solid dosage forms 
reduction of particle size is also associated with reduced inter 
subject variation. Consequently the effect of particle size on 
the bioavailability of trilostane and epostane formulations was 
investigated with a view to 1) optimising the bioavailability and 
2) minimising intersubject variability.
Whilst particle size reduction is a relatively obvious strategy 
for the delivery of a poorly water soluble drug, the extent of
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micronisation is an important factor which requires investigation 
on an individual compound basis. 'Over' micronisation can lead to 
drug powder aggregation which may lead to a decrease in effective 
surface area and reduced bioavailability.
Initial batches of trilostane and epostane used in animal studies 
were micronised and found to be irregularly shaped crystals from 
less than 2 to about 15 um in diameter, by microscopic evaluation. 
The initial human bioavailability study with trilostane compared 
quite large differences in particle size visa vi 10 um, 45 um and 
100 um. Based upon plasma levels of both trilostane, and the 
active metabolite, 17-ketotrilostane, an approximate 4-fold 
increase in the bioavailability of biologically active components
was demonstrated by decreasing the particle size to 10 um. The
. . . . 2 —1follow-up study utilising 4 um particle size material (7.3 m g
2 —1surface area) and 10 um particle size material (2.2 m g surface
area) demonstrated that additional micronisation had little effect
on the bioavailability of both trilostane and 17-ketotrilostane.
These studies established a working specification for the
production of trilostane solid dosage forms, requiring drug in the
2 -1surface area range of 2-5 m g for optimum oral availability.
The bioavailability study with epostane compared drug within the
2 —1optimum surface area range defined for trilostane (3.8 m g ) with
2-1 . 2 -1 
both lower (0.6 m g ) and higher (7.0 m g ) grade material.
. . . 2 -1There were no significant differences between the 3.8 m g  and
2 —I . 2 —17.0 m g formulations. The surface area range of 2-5 m g was
therefore shown to be appropriate for formulations of epostane.
Although micronisation of both trilostane and epostane led to 
increased bioavailability the inter subject variation at the 
'optimum1 particle size was still very large. For trilostane, 
intra-subject variability was also observed in volunteers who 
received the same formulation on different occasions. Because of 
this high inter and intra subject variability subsequent 
bioavailability studies with trilostane and epostane have utilised 
large panels of subjects (n = 25 to 36) to differentiate dosage 
forms or to suggest equivalency among dosage forms with an
adequate degree of certainty. This variability in systemic
availability of trilostane and epostane clearly has a bearing on 
the clinical use of these drugs and probably contributes to the 
variable efficacy observed in clinical trials.
7.2 Tissue distribution: Although trilostane and epostane are well
absorbed in animals, and the systemic availability of both
compounds has been demonstrated in man, these compounds have to 
reach the site of action to exert a biological effect.
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The tissue distribution of both compounds was therefore examined 
to determine the localisation of drug related material in the 
target organs in which trilostane and epostane have 
pharmacological activity. The data were also required to support 
the application for radiolabelled metabolism studies with 
trilostane and epostane in women and consequently pigmented female 
animals were utilised.
14 . 14[ C]-trilostane and [ C] -epostane had similar patterns of
distribution in pigmented female rats. Both compounds showed
extensive uptake into adrenals such that at 1 h post-dose
radioactivity concentrations were approximately 5 times those
observed in blood. Ovarian concentrations of radioactivity were
similarly 2-3 fold higher than blood concentrations. In both
adrenals and ovaries the elimination of radioactivity was less
rapid than that observed in other tissues. Thus both epostane and
trilostane are located in high concentrations in tissues which are
known to contain the 3 {] -hydroxysteroid dehydrogenase enzyme
system (82). Moreover, in a study which examined the disposition 
14of [ C]-epostane in pregnant rats by whole-body autoradiography 
(83), adrenal radioactivity was localised within the adrenal 
cortex, which reflects the physiological distribution of this 
enzyme (103). However in this same study, placental tissue was
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shown to have only low amounts of radioactivity associated with it
despite the fact that this tissue also possesses the 3-p -hydroxy-
steroid dehydrogenase enzyme system. Similarly in the earlier 
14[ C]-trilostane tissue distribution study in male rat (36) there 
was little evidence of testicular uptake of radioactivity, a 
further tissue known to possess the 3 p -hydroxysteroid 
dehydrogenase enzyme system. These differences may reflect 
various isoenzymes within the tissues which have different 
specificities for each drug^ or be the result of preferential 
uptake by different organs.
The rat tissue distribution studies clearly showed that in both 
adrenal and ovaries the exposure to drug related material was 
the same for both [14C]-trilostane and [14C]-epostane. 
Consequently, the in vivo separation of trilostane and epostane 
activity (with respect to adrenal v ovarian inhibition of 3p - 
hydroxysteroid dehydrogenase) could not be explained by gross 
differences in the distribution of drug related products within 
these tissues. However further studies in dog demonstrated a
difference with regard to the metabolic profiles within the
14 . .tissues. [ C]-epostane concentrations were highest in the ovary,
14whereas [ C]-trilostane and 17-ketotrilostane concentrations were 
highest in adrenal. Thus the metabolic profiles observed in the 
tissues reflected the in vitro organ selectivity noted for these
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compounds. This may be the result of differential metabolism of 
the steroids per se within these tissues or may be a consequence 
of different isoenzymes of 3/3 -BSD with different affinities for 
the two compounds. For example, if an isoenzyme has a higher 
affinity for epostane than for trilostane in the ovary then, more 
epostane would be bound to the enzyme and therefore less would be 
available for metabolism. Evidence for multiple forms of the 3/3 
-hydroxysteroid dehydrogenase enzyme complex from bovine adrenal 
cortex has been suggested on the basis of preferential conversion 
of only one of several possible substrates (84). The question of
differential metabolism or the presence of different isoenzymes
. . .  14 14preferentially binding [ C]-epostane (ovary) or [ C]-trilostane
(adrenal) is worthy of further investigation.
7.3 Trilostane metabolism (rat): Initial metabolism studies with
non-radiolabelled trilostane in the rat identified 
17-ketotrilostane as a major metabolite of trilostane in plasma 
and the glucuronic acid conjugate of 17-ketotrilostane as the main 
metabolite in bile (37). Further metabolites in urine were
postulated as shown in Fig. 7.1.
Subsequent in vitro investigations on the metabolism of trilostane 
using rat hepatocytes have shown that the glucuronide conjugate of 
17-ketotrilostane is the major product of metabolism (99). A high
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proportion of unconjugated 17-ketotrilostane was also observed as 
well as serveral other more polar products. Initial attempts to 
reproduce these results within these laboratories have proved 
unsuccessful - probably due to difficulties in obtaining a high 
yield of viable cells.
In radiolabelled trilostane studies in monkey approximately 65% of 
the urinary radioactivity was accounted for by 5 major 
metabolites, isolated and partially identified by a variety of 
chromatographic and spectroscopic procedures (36). Designated as 
metabolites I-V the relative amounts of these compounds in either 
the free or conjugated (glucuronide) fractions in addition to 
tentative structures are shown in Fig. 7.2. Thus from both rat 
and monkey work the major pathways involved in trilostane 
metabolism were proposed as: oxidation at C-17; reduction at 03; 
hydroxylation and conjugation of most of the metabolites with 
glucuronic acid.
These routes of metabolism are similar to those found in the 
metabolism of androgens, such as testosterone. Testosterone is 
metabolised by reduction in Ring A and at 0 3  by means of the 
4-ene-5Qf-and 5@ -reductases and the 3 a  - and 3f] -hydroxysteroid 
dehydrogenase. The 17-hydroxyl function may be oxidised to a 
17-keto group or additional hydroxylation at 060! , C-6@ , 0 7 a  ,
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receiving an 880 mg/kg oral dose of trilostane
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C-ll/3 and C-16a may occur (82). An overall metabolic pathway for 
testosterone is presented in Fig. 7.3.
Metabolism proceeds by oxidation to 4-androstenedione, saturation 
of the 4,5-double bond to give 5 a: -androstane-3,17-dione and 5(3 
-androstane-3- 17-dione and reduction at G  to give four 17-oxo 
steroids: 3a ,5a (androsterone), 3a , 5@ (etiocholanone), 3@ , 5a 
(epiandrosterone) and 3^ , 5ft -(epi-etiocholanone). In addition 
various isomeric androstanediols of the 5a and 5j$ series can be 
formed. Thus the initial step in testosterone metabolism is the 
conversion to 4 androstenedione; conversion being reversible and 
catalysed by 1 7 -hydroxysteroid dehydrogenase. Although this is 
a reversible reaction the equilibrium lies heavily in favour of 
androstenedione production but occurs to a lesser extent in 
females (85, 86).
In rat trilostane is primarily excreted in faeces (71-81% of the 
dose) following intravenous administration indicating extensive 
biliary excretion (36). A major product of trilostane in rat bile 
has been identified as the glucuronide of 17-ketotrilostane (37). 
In monkey, biliary excretion was less extensive than in rat with 
only 27-39% of the dose excreted in faeces (36). Species 
variation in the extent of biliary excretion of steroids is well 
recognised (90) with rat generally being a more extensive biliary
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secretor of carrpounds than monkey. For testosterone, biliary 
excretion is marked in rat, mouse and cat. As with trilostane the 
major metabolites of testosterone in bile are conjugated.
7.4 Trilostane metabolism (humanV: The isolation and identification
of 17-ketotrilostane in human male plasma confirmed that the 
principal metabolic step in the metabolism of trilostane was 
similar to that which occurred in rats (37) and was identical to 
the first step in the metabolism of testosterone.
However unlike testosterone in which the conversion to 4 
androstenedione is associated with a 10-fold reduction in 
biological activity (87) the metabolism of trilostane to 
17-ketotrilostane represents metabolic activation with respect to 
3 f] -hydroxysteroid dehydrogenase inhibition. The cytochemical
bioassay estimated the potency of 17-ketotrilostane to be 
approximately double that of trilostane. Separately in isolated 
guinea pig adrenal cells, this ratio of activity was confirmed 
(15). Consequently 17-ketotrilostane may be an important 
component with regard to the efficacy of trilostane medication. 
Variable metabolism in different patient groups would markedly 
effect this conversion and this may contribute to the variable 
efficacy observed in clinical studies (23-27).
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The clinical benefit of trilostane in post-menopausal breast 
cancer was suggested to occur via aromatase inhibition (49), 
although in vitro studies had shown trilostane per se not to 
effect aromatase activity (50). Following the identification of 
17-ketotrilostane as a major plasma metabolite of trilostane this 
was tested for inhibition of aromatase activity and; like
trilostane ;no inhibition was observed (101). Thus the efficacy of 
trilostane in breast cancer, if mediated via aromatase inhibition, 
must be the result of further metabolism to another active 
metabolite.
Whilst in animal species the excretion of testosterone occurs via
the bile, renal elimination in man is the principal route of
excretion. The 17-oxo metabolites androsterone and etiocholanone
occur mainly as glucuronides in human urine with about 10% as
sulphates (88). In the same way it is likely that renal
elimination is also a major route of trilostane excretion in man.
The glucuronide conjugate of the major plasma component
17-ketotrilostane was demonstrated as a urinary metabolite, but
only accounted for up to 10% of the administered dose. Further
trilostane metabolites are likely to occur in urine, but would
require a human radiolabelled study to quantify the excretion and
identification of total drug related products. Alternatively the 
14metabolism of [ C]-trilostane in man could be investigated
further by in vitro investigations with human microsomes and 
hepatocytes.
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7.5 Epostane metabolism (rat): Unlike trilostane there was no
evidence for a 17-ketometabolite of epostane in human male plasma. 
The presence of a 17-methyl group in the epostane molecule would 
be expected to prevent oxidation of the 17-hydroxyl group; in the 
same way that 17-methyl testosterone overcomes the first-pass 
metabolism of testosterone (87).
That first-pass metabolism of epostane does not occur, was
indicated by radiolabelled studies in dog which showed the
. . .  14systemic bioavailability of [ C]-epostane to be 99% (80).
. . . 14Preliminary metabolism studies with [ C]-epostane in the dog (89)
suggested that the major urinary metabolites of [14C]-epostane 
were products of hydroxylation, reduction of the A-ring 
cyanoketone function and conjugation (see Fig. 7.4). With regard 
to the metabolites isolated from rat faeces in the present work, 
reduction of the A-ring and cyanoketone function were also evident
i.e. 2 o' — CN, 30! -OH metabolite, and three different isomeric 
triol metabolites were formed (see Fig. 4.27). However unlike dog 
none of the isolated metabolites appeared to be hydroxylated in 
the D-ring.
Further metabolism studies in biliary cannulated rats (79) 
demonstrated a completely different metabolic profile in bile
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F ig . 7 .4  Proposed Structures of Epostane Metabolites In the Dog.
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compared to that observed in faeces in this work. Enzyme
deconjugation studies showed that the majority of the
radioactivity in bile was associated with several glucuronide
conjugates, one of which was tentatively identified as epostane
glucuronide. The presence of mainly free steroids in faeces
therefore indicates that the conjugated metabolites of 
14 . .[ C]-epostane are hydrolysed/metabolised in the gut. These
compounds would therefore be available for reabsorption and may
undergo enterohepatic cycling. The question of biological
activity of these faecal metabolites is therefore of significance
and worthy of further investigation. In an analogous manner the 
14metabolites of [ C]-testosterone in rat faeces were different to 
those observed in bile and attributed to the action of gut
microflora (90).
. . . 1 4Biliary excretion of [ C]-epostane was less extensive in species
other than rat. In dog, pig and monkey, urinary excretion
accounted for 40-50% of the dose compared with the 10-25% of the
dose observed in rat. There was a distinct species variation in
14the urinary metabolites of [ C]-epostane which was evidently
complex. A difference between male and female rat urinary
metabolism was also observed. Female rat urine contained up to 9
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major metabolites compared to only 5 in male animals. Although 
the male metabolites were the same as some of the female 
metabolites the relative proportions between sexes were different.
The presence of greater numbers of metabolic products of
14 . . .[ C]-epostane in female rat urine was consistent with the
observation that twice as much radioactivity was excreted in 
female urine compared to males. In rat sex differences in the 
metabolism of steroids are well documented. Male animals in 
general show a higher hydroxylating activity than females, whereas 
females exhibit a higher 5 a. -reductase (82). Thus for epostane in 
male rats, more extensive hydroxylation might lead to a greater 
amount of conjugation and subsequent elimination via bile.
7.6 Conclusion: Animal studies have demonstrated that the in vivo
organ selectivity of trilostane and epostane may be attributed to 
the site specific localisation of active compounds within adrenals 
and ovaries.
In man, a major plasma metabolite of trilostane was shown to be 
17-ketotrilostane which is intrinsically twice as active as parent 
compound in inhibiting 3 -hydroxysteroid dehydrogenase. A 
specific, sensitive and accurate HFDC assay was developed which 
enabled the measurement of trilostane and 17-ketotrilostane in 
plasma. Plasma concentrations of 17-ketotrilostane in male
-161-
volunteers were approximately 3-fold higher than trilostane and 
thus the metabolite could be an important component with respect 
to the efficacy of the drug.
Micronisation of both trilostane and epostane was shown to be 
important to maximise the oral availability of these compounds. 
However even with micronised formulations considerable inter and 
intra subject variability was noted. For trilostane} variability 
in absorption, coupled with individual differences in the 
metabolism of trilostane to the more active 17-ketotrilostane, may 
in part account for the variable efficacy encountered in clinical 
trials.
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Table 4.1 Excretion of radioactivity following oral administration
14 . -1of r C l -trilostane (ca 20 mg kg ) to female pigmented
rats (n = 3^
1
j Sample/Collection Period
i
Per cent of radioactive dose recovered
1. URINE 167F 168F 169F Mean - SD
| 0-12 h 7.7 28.8 16.5 17.7 + 10.6 |
12-24 h 12.9 4.7 5.3 7.6 + 4.6
24-48 h 2.7 0.7 2.7 2.0 ± 1.2
48-72 h 0.7 0.1 0.7 0.5 + 0.3
Total 24.0 34.3 25.2 27.8 + 5.6
2. FAECES
0-24 h 48.6 59.2 50.8 52.9 + 5.6
24-48 h 14.5 6.1 10.3 10.3 + 4.2
| 48-72 h 4.0 0.9 1.8 2.2 + 1.6
Total 67.1 66.2 62.9 65.4 + 2.2
3. CARCASS (12 h) 1.2 0.4 1.4 1.0 + 0.5
4. CAGE WASHINGS (12 h) 1.8 0.5 5.0 2.4 + 2.3
TOTAL RECOVERY 94.1 101.4 94.5 96.7 + 4.1
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T a b l e  4 -2  E x c r e t i o n  o f  r a d i o a c t i v i t y  f o l l o w i n g  o r a l  a d m i n i s t r a t i o n  o f  
[ ^ C ] - e p o s t a n e  ( c a  2 5  mg kg~~*~) t o  m a le  a n d  f e m a le  r a t s
Per c e n t o f  r a d io a c t iv e  dose reco vered
1M 2M 3M Mean 4- SD 4F 5F 6F Mean 4- SD
ORINE 0 -  12 5 -6 4 -6 5 -6 5 .3 4- 0 .6 1 8 .1 1 7 .1 1 4 .4 1 6 .5 4- 1 -9
1 2 -  24 ‘ 2 -1 3 -3 2 -9 2 .8 4- 0 .6 4 .5 3 .7 4 .1 4 .1 4* 0 .4
2 4 -  48 1 -2 1 .6 3 .5 2 .1 + 1 .2 2 .2 1 .9 2 .4 2 .2 4" 0 .3
4 8 -  72 0 .4 0 -4 1 -0 0 .6 + 0 .3 0 .5 0 .5 0 .9 0 .6 4- 0 .2
7 2 -  96 0 -1 0 .2 0 .4 0 .2 4- 0 .2 0 .3 0 .2 0 .4 0 .3 4- 0 .1
96-120 0 -1 0 .1 0 .2 0 .1 4- 0 .1 0 .2 0 .2 0 .3 0 .2 4- 0 .1
TOTAL 9 -5 1 0 .2 1 3 .6 1 1 .1 + 2 .2 2 5 .8 2 3 .6 2 2 .5 2 4 .0 4- 1 .7
FAECES 0 -  24 6 1 -1 4 8 .7 4 5 .3 5 1 .7 4* 8 .3 4 9 .0 5 5 .3 5 7 .3 5 3 .9 -f 4 .3
2 4 -  48 2 0 -1 2 8 .1 1 7 .0 2 1 .7 + 5 .7 1 9 .1 1 4 .2 1 3 .2 1 5 .5 -r 3 .2
4 8 -  72 2 -6 5 .9 1 4 .7 7 .7 4- 6 .3 1 -9 1 -7 - 2 .1 1 .9 4- 0 .2
7 2 -  96 2 .1 0 .8 3 .2 2 .0 + 1 .2 0 .6 0 .7 0 .7 0 .7 o. 0 .1
96-120 0 .3 ( 2 . 8 ) * ( 0 .8 ) 1 .3 + 1 .3 0 .3 0 .4 0 .3 0 .3 4- 0 .1
TOTAL 8 6 .2 8 4 .3 8 3 .0 8 4 .5 4- 1 .6  • 7 0 .9 7 2 .3 7 3 .6 7 2 .3 4. 1 .4
CARCASS 0 .8 1 .3 1 .7 1 .3 4- 0 .5 0 .7 0 .6 0 .7 0 .7 4- 0 -1
CAGE WASH 0 .8 0 .4 0 .4 0 .5 4- 0 .2 1 .1 0 .2 0 .6 0 .6 -i- 0 .5
TOTAL RECOVERY 9 7 .3 9 6 .2 9 8 .7 9 7 .4 4- 1 .2 9 8 .5 9 6 .7 9 7 .4 9 7 .5 4- 0 -9
R e p e a t  a n a l y s i s  c o n f i r m e d  t h e s e  r e s u l t s -  H o w e v e r ,  m i x - u p  i n  s a m p l e  
c o l l e c t i o n  p r o b a b l e  b a s e d  o n  e x c r e t i o n  r e s u l t s -  V a lu e s  i n t e r c h a n g e d  f o r  
d a t a  a n a l y s i s
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Table 4.3 Mean (- SD) tissue concentrations of radioactivity
. . 14following oral administration of f Cl-trilostane
to female pigmented rats fn = 3)
-l
Cone o f  r a d i o a c t i v i t y  (ug  e q u iv  g  )
1 h 24 h 48  h 72  h
A d re n a ls 1 8 .7 + 3 .0 7 1 0 .3 ± 1 .3 4 6 .7 4 ± 1 .8 0 5 .5 5 ± 0 .6 4
B lo o d 3 .2 7 + 1 .1 8 0 .2 6 ± 0 .0 2 0 .2 0 ± 0 .0 6 0 .2 3 ± 0 .0 6
Bone 0 .7 2 + 0 .1 8 0 .0 5 ± 0 .0 6 M M
Bone m arrow 2 .5 8 + 1 .0 2 0 .0 8 ± 0 .1 0 M M
B r a in 1 .1 0 ± 0 .4 6 0 .1 0 ± 0 .0 9 0 .0 5 ± 0 .0 0 0 .0 6 ± 0 .0 1
Brown a d ip o s e 3 .6 5 -U 1 .5 3 0 .1 3 + 0 .0 4 0 .0 3 ± 0 .0 3 0 .0 1 ± 0 .0 1
D iaph rag m 3 .4 7 + 1 .7 7 0 .1 6 ± 0 .0 4 0 .0 9 ± 0 .0 3 0 .0 8 ± 0 .0 2
E yes 2 .0 8 ± 0 .8 6 0 .2 2 + 0 .0 6 0 .2 0 + 0 .0 9 0 .1 3 ± 0 .0 3
F a l lo p ia n  tu b e s 3 .2 9 + 1 .3 9 0 .4 2 + . 0 .4 7 0 .0 9 ± 0 .0 8 0 .0 4 + 0 .0 2
F a t 1 .8 0 + 1 .0 1 0 .1 7 ± 0 .3 0 M M
H e a r t 3 .1 8 + 1 .0 3 0 .1 3 ± 0 .0 3 0 .1 1 + 0 .0 2 0 .0 9 + 0 .0 1
K id n e y s 8 .4 6 + 2 .2 2 0 .4 3 ± 0 .0 8 0 .3 0 ± 0 .0 8 0 .2 7 ± 0 .0 4
L a rg e  in t e s t i n e 5 .3 4 + 4 .8 2 1 7 .4 + 5 .9 2 5 .3 1 ± 0 .9 0 1 .0 3 + 0 .6 7
L iv e r 2 3 .0 + 5 .0 0 1 .3 3 ± 0 .4 6 0 .8 7 + 0 .1 4 0 .5 7 ± 0 .1 4
Lungs 5 .2 3 + 2 .9 9 0 .1 6 + 0 .0 8 0 .0 7 + 0 .0 1 0 .0 8 + 0 .0 2
M u s c le 2 .5 0 + 0 .7 8 0 .0 9 ± o . ° 2 0 .0 5 ± 0 .0 1 0 .0 2 ± 0 .0 3
O v a r ie s 9 .0 4 + 1 .3 3 3 .9 9 ± 0 .8 5 3 .2 5 + 0 .4 6 2 .5 8 ± 0 .3 5
P a n c re a s 5 .1 8 ± 2 .5 6 0 .3 3 + 0 .3 4 0 .1 1 ± 0 .0 8 0 .0 5 ± 0 .0 1
P i t u i t a r y 1 .3 2 + 0 .6 3 M M M
Plasm a 4 .3 2 + 1 .5 4 0 .1 1 ± 0 .0 2 0 .0 7 + 0 .0 0 0 .0 4 ± 0 .0 0
R e s id u a l c a rc a s s 2 .6 0 + 0 .3 6 0 .1 3 ± 0 .0 1 0 .0 5 ± 0 .0 1 0 .0 5 ± 0 .0 1
S a l i v a r y  g la n d 3 .0 1 + 1 .1 8 0 .0 9 + 0 .0 2 0 .0 4 ± 0 .0 1 0 .0 4 + 0 .0 2
S k in  (n o n -p ig m e n te d ) 1 .8 1 + 0 .7 1 0 .1 3 ± 0 .0 1 0 .1 2 ± 0 .0 5 0 .1 2 ± 0 .0 7
S k in  (p ig m en ted ) 1 .7 4 + 0 .5 8 0 .0 9 ± 0 .0 1 0 .0 6 ± 0 .0 3 0 .0 3 ± 0 .0 3
S m a ll i n t e s t i n e 184 + 3 2 .3 1 3 .2 ± 1 1 .3 4 .4 0 ± 1 .4 3 0 .9 9 ± 0 .7 6
S p le e n 2 .9 0 + 0 .9 9 0 .2 8 ± 0 .1 6 0 .0 6 ± 0 .0 5 0 .0 5 + 0 .0 1
Stom ach 952 ± 2 1 0 0 .4 5 ± 0 .3 1 0 .1 8 ± 0 .1 8 0 .0 3 ± 0 .0 2
Thymus 2 .1 0 ± 0 .5 8 0 .0 8 ± 0 .0 3 0 .0 4 ± 0 .0 2 0 .0 3 ± 0 .0 3
T h y ro id 3 .4 4 + 1 .2 2 M M M
U te ru s 3 .3 6 + 1 .0 8 0 .1 9 ± 0 .1 4 0 .0 5 + 0 .0 2 0 .0 1 + 0 .0 2
M =  le s s  th a n  minimum q u a n t i f ia b le  l e v e l  (=  1 .5  x  b ac kg ro u n d  cpm)
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Table4-4 Mean (- SD) tissue/blood concentration ratio's following
. . .  14 . —loral administration of r Cl -trilostane (ca 2 0  incr ka )
14 -1or T Cl-epostane fca 25 mcr kcr ) to female pigmented rats
Adrenals Ovaries Liver
1 h
14C-Trilostane 5.97 + 1.01 2.93 + 0.70 7.27 ± 0.93
14C-Epostane 4.67 + 1.26 1.57 + 0.32 4.90 + 0.78
24 h
14C-Trilostane 39.9 + 3.64 15.5 + 2.40 5.17 ± 1.59
14C-Epostane 20.2 + 3.86 8.60 + 2.29 8.13 ± 2.93
48 h
14C-Trxlostane 33.8 + 7.65 16.8 + 5.77 4.37 ± 0.50
14C-Epostane 28.4 + 8.75 11.8 + 2.86 8 .57 ± 1.93
72 h
14C-Trilostane 25.4 + 5.33 11.8 + 2.80 2.73 ± 1.15
14C-Epostane 16.9 + 0.90 8.37 + 1.95 5.97 ± 2.03
Table 4,5 Mean tissue concentrations of radioactivity following oral
. . .  14 -1adm inistration o f f Cl -epostane fca, 25 iw  kg ) to
female pigmented rats (n = 3)
T is s u e
. . “I
Cone o f  r a d i o a c t i v i t y  (u g  e q u iv  g  )
1  h 24 h 48  h 72  h
A d re n a ls 3 6 .8 + 2 .6 8 8 .0 6 ± 1 .5 5 5 .0 9 + 0 .1 0 3 .0 6 + 0 .8 3
1 B lo o d 8 .4 4 + 3 .1 0 0 .4 2 + 0 .1 4 0 .1 9 + 0 .0 5 0 .1 8 ± 0 .0 6
Bone 1 .3 7 + 0 .4 0 0 .3 0 ± 0 .5 2 M M
Bone m arrow 4 .5 1 + 1 .6 4 M M M
B r a in 2 .4 9 + 0 .5 2 0 .0 7 ± 0 .0 6 0 .0 1 ± 0 .0 2 0 .0 2 ± 0 .0 4
Brown a d ip o s e 7 .2 7 + 3 .0 8 0 .3 6 ± 0 .2 2 0 .0 4 + 0 .0 6 0 .0 5 ± 0 .0 6
E yes 3 .0 0 + 0 .7 9 0 .2 5 ± 0 .1 0 0 .0 5 + 0 .0 5 0 .0 8 + 0 .0 7
F a t 7 .3 0 + 3 .1 7 0 .2 2 ± 0 .2 5 0 .0 3 + 0 .0 6 0 .0 3 ± 0 .0 6
F a l lo p ia n  tu b e s 6 .5 7 + 1 .3 3 0 .2 3 + 0 .2 1 M 0 .0 3 ± 0 .0 5
H e a r t 6 .7 2 ± 2 .0 6 0 .3 4 ± 0 .0 6 0 .2 4 ± 0 .1 2 0 .1 2 ± 0 .0 4
K id n e y s 1 0 .4 + 3 .0 0 0 .6 0 ± 0 .1 3 0 .2 5 ± 0 .0 7 0 .2 4 ± 0 .0 7
*L a rg e  in t e s t i n e 3 0 .7 + 3 6 .4 1 0 .5 ± 2 .0 9 2 .5 5 ± 0 .7 7 1 .1 0 ± 0 .8 6
L iv e r 3 9 .8 + 7 .3 0 3 .1 2 + 0 .1 5 1 .5 6 + 0 .1 4 1 .0 2 + 0 .0 3
Lungs 7 .3 7 + 2 .2 9 0 .2 5 ± 0 .0 6 0 .1 1 + 0 .0 1 0 .0 9 ± 0 .0 3
M u s c le 4 .1 0 ± 1 .0 4 0 .1 5 + 0 .0 6 0 .0 6 + 0 .0 6 0 .0 2 + 0 .0 4
O v a r ie s 1 2 .4 ± 1 .2 2 3 .3 7 + 0 .4 0 2 .1 5 + 0 .2 2 1 .4 7 + 0 .3 2
P lasm a 1 3 .0 ± 4 .9 3 0 .2 2 ± 0 .0 5 0 .0 5 + 0 .0 5 0 .0 6 ± 0 .0 2
R e s id u a l c a rc a s s 3 .9 4 + 1 .0 1 0 .2 3 + 0 .1 7 0 .0 5 + 0 .0 5 0 .0 5 ± 0 .0 3
S k in  (n o n -p ig m e n te d ) 4 .3 4 + 1 .9 1 0 .3 4 ± 0 .1 8 0 .1 5 + 0 .0 4 0 .2 5 ± 0 .0 7
S k in  (p ig m ented ) 4 .5 3 + 1 .9 5 0 .4 2 ± 0 .1 2 0 .1 0 + 0 .1 1 0 .1 9 + 0 .1 0
*S m a ll  i n t e s t i n e 106 + 6 1 .0 4 .5 1 ± 5 .3 6 2 .8 9 + 0 .9 2 1 .1 7 ± 1 .2 5
S p le e n 4 .5 6 ± 0 .9 6 0 .1 8 + 0 .0 4 M 0 .0 7 ± 0 .0 6
*S tom ach 381 ± 1 0 3 0 .4 5 + 0 .4 1 0 .5 8 ± 0 .2 5 0 .5 0 + 0 .3 7
Thymus 4 .3 8 + 1 .9 3 0 .0 2 ± 0 .0 4 M M
T h y ro id 5 .5 4 ± 1 .7 3 M M M
U te ru s 6 .0 7 + 1 .3 8 0 .1 4 + 0 .1 3 M 0 .1 5 ± 0 .0 6
*  E x c lu d e s  c o n te n ts
M =  L es s  th a n  minimum q u a n t i f ia b le  l e v e l  (=  1 .5  x  b ac kg ro u n d  cpm)
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Table 4.6 Organ radiation dose calculations for f^C]-trilostane 
administration (50 uCi, 1.85 MBcr) in women
J TARGET ORGAN 
! OR TISSUE
DOSE EQUIVALENT 
(uSv)
WT FACTOR WEIGHTED DOSE J 
EQUIVALENT (uSv) |
{ A d re n a l 9 6 .5 0 .0 6 5 .7 9  !
J Bone 2 0 .8 0 .0 3 0 .6 2 *
} Bone m arrow 0 .7 2 0 .1 2 0 .0 9 *  i
i Eye 4 8 .0 0 .0 6 2 .8 8  |
J L iv e r 9 8 .5 0 .0 6 5 .9 1  J
J Lung 6 .0 4 0 .1 2 0 .7 2 *  !
} O vary 170 0 .2 5 4 2 .5 0 *  |
{ T h y ro id 0 .1 7 0 .0 3 0 .0 1 *  |
J F a t  (b re a s t ) 0 .7 2 0 .1 5 0 .1 1 *  J
j Stomach 106 0 .0 6 6 .3 6 *  |
| S m a ll in t e s t in e 173 0 .0 6 1 0 .3 8 *  !
| Upper la r g e  in t e s t in e 1022 0 .0 6 6 1 .3 2 *  !
| Lower la r g e  in t e s t in e 3074 0 .0 6 1 8 4 .4 4 *  J
j U r in a r y  b la d d e r 184 0 .0 6 1 1 .0 4 *  !
*  Named t a r g e t  o r g a n s /t is s u e  = o v a r y , b on e, bone m arrow , lu n g ,  th y r o id
and f a t  (b r e a s t )
5 h ig h e s t  o th e r  o r g a n s /t is s u e s  =  lo w e r la r g e  i n t e s t i n e ,  upper la r g e
i n t e s t i n e ,  s m a ll i n t e s t i n e ,  u r in a r y  
b la d d e r  and stom ach.
WHOLE BODY TOTAL =  3 1 7 .5 9  uSv
Table 4.7 Tissue concentrations of radioactivity 4 h following an
14 -1
oral dose of [ Cl-trilostane (7.1 mg kg ) and 
" 14 =1
f Cl-epostane (5.8 mg kg ) to female dog
Dose
Tissue concentration (ug equiv g”1)
Adrenals Ovaries Liver
14C-Trilostane 5.89 3.71 10.0
14C-Epostane 11.0 9.78 15.6
Table 4.8 Tissue/plasma radioactivity concentration ratios 4 h
14 -1following an oral dose of f Cl-trilostane (7.1 mg kg )
14 -1and f Cl-epostane (5.8 mg kg ) to female dog
Dose
Tissue concentration (ug equiv g ^
Adrenals Ovaries Liver
14C-Trilostane 3.3 2.1 5.6
14C-Epostane 3.7 3.3 5.3
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Table 4.9 Per cent dose excreted in urine (0-24 h) following oral
14
administration of r Cl-epostane
Species Sex Dose level 
-1
(mg kg )
1
Mean (± SD) per cent 
dose recovered in urine 
(0-24 h)
Total
urinary
recovery
Rat 
(n = 3)
male 25 8.1 ± 0.6 11.1 ± 2.2
Rat 
(n = 3)
female 25 20.6 ± 2.1 24.0 ± 1.7
Dog
(n = 3)
female 7.5 25.9 ± 9.0 40.1 ± 6.0
Pig
(n = 3)
female 5 27.3 ± 3.2 44.9 ± 1.0
Monkey 
(n = 4)
female 25 25.6 ± 5.2 47.0 ± 7.4
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Table 4.10 Excretion of radioactivity in urine and faeces following
. . .  14 -1
oral administration of r Cl-epostane fca. 450 incr for )
to female rats
Time
Mean (+ SD) per cent excreted (n = 6)
Urine Faeces
0 - 1 2 1.8
12-24 2.2 10.6*
24 - 48 6.0 37.7
48 - 72 1.7 19.4
72 - 96 0.4 3.1
* 0 - 24 h
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Fig« 4«1 Cumulative excretion of radioactivity in feirale pigmented rats (n = 3) 
following oral administration of [14C]-trilostane (ca 20 mg kg"1)
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Fig. 4.2 Mean (— SD) recovery of radioactivity in urine and faeces following
oral administration of [~^C] -epostane (ca 25 mg kg to male and 
female rats (n = 3)
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Mean tissue concentrations of' radioactivity following oral administration 
of [14C]-trilostane (ca 20 mg kg"1) to female pigmented rats (n = 3)
50.0
10.0
«—t
>•H 5.0
<1) O v) (n•H4-1
-S
4J 1.0
>•W
8 0.5
U
U-lo
6•H4J<0144J
C<uocoo 0.1
s
2
0.05-
0.01
724824
a Mrenals
° Ovaries
• Liver
Kidneys
Blood
a Eyes
Time (h)
-201-
Co
nc
en
tr
at
io
n 
of 
ra
di
oa
ct
iv
it
y 
(u
g 
eq
ui
v 
g‘
Mean tissue concentration of radioactivity following- oral
. . . 14 -1 ;administration of f Cl-epostane (ca 25 mcr kcr ) to female pigmented
rats (n = 3^
200
100-
10-
Adrenals
Ovaries
Small intestine 
Liver1:0 -
Kidneys 
Ji Blood
0*1- Lungs
Eyes
Plasma
Skeletal muscle
001 - Brain
7 20 4 82 4
Time (h)
-202-
Fig. 4.5 TLC profiles of plasma radioactivity following oral
. . . .  14 -1admimstration of r Cl-trilostane ( 7 . 1  mcr ) to
female dog 
2.0 h post-dose
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14 -1
administration of r Cl-epostane (5.8 mcr kcr ) to
female doer
2.0 h post-dose EPOSTANE
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(»») oo;
ft. / TLC profiles of liver radioactivity following oral
. . .  14 -1
administration of r Cl-trilostane (7.1 irer ker ) or
f Cl-epostane (5,8 mcr kcr ) to female doer
144 h post f C]-trilostane dose
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. . .  14 -1
oral administration of r Cl-trilostane f7.1 nrr kcr ) to
female dog
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.10 HPIC profiles of urinary radioactivity following oral
. 1 4  -1
administration of r Cl -epostane (ca 25 mcr kcr ) to male
and female rats
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(5.3 + 0.6% dose);
4020 30o 10
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(16.5 + 1.9% dose)*
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Fig. 4.11 HPLC profiles of faecal radioactivity following oral
14 -1
administration of r Cl-epostane (ca 25 mg kg ) to male
and female rats
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(2af3a,4a,5a,17P)-4,5-Epoxy-3,17-dihydroxy-4,l7-dir2ethyl--
androstane-2-carbonitrile
HO
7*3
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a n d r o s ta n e -2 -c a r b o n it r i le
?«3
C22K33N03 
K.V. 359-5
OOn
80
50- 73
1 3 075
>0-
3 03
1 4 5
f 5 7  2 1 4  2 2 ?
1 5 0  ! 2 0 0  2 3 0  3 0 0
44 63 9 3 446 499
: 105
1-  ptoWfflvjtf1! 
30
3 0 4
4 5 0330 400 300100
-213-
■t1 ig. 4.16 El mass spectrum of the IMS derivative of an epostane analogue
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( 2a, 3?, ka, 5a, 17 P ) - k , 5-Epoxy-lf, 17-dime thylandr os tane -
2,3,17-triol
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Fig. 4.23 El mass spectrum of the IMS derivative of epostane metabolite F2e
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Table 5.1 Trilostane concentrations in prepared human plasm samples
determined by HPDC assay
M Q L = 0.03 Mg/ml.
Concentration added 
(m g/ml)
Concentration found, 
fresh* (Mg/ml)
Concentration found, 
fro zen ** (pg/ml)
0 (0 .0 6 )* * * c
(0 .05 ) N D *
(0 .05 ) (0 .04 )
(0 .07 ) (0 .04 )
0.30 0.28
0.30 0.30
0.29 0.30
0.26 0.32
Mean 0.28 0.31
C.V. (%) 6.1 3.8
Mean percent difference - € .7 3.3
0.51 0.53
0.45 0.50
0.53 0.45
0.48 0.50
Mean 0.50 0.48
C.V. (%) 7.9 6.0
Mean percent difference —2.0 —5.9
0.71 0.69
0.71 0.67
0.67 0.69
0.69 0.68
Mean 0.69 0.68
C.V. (%) 2.4 1.5
Mean percent difference - 2 .8 —4.2
0.91 0.89
0.87 0.92
0.94 0.89
0.90 0.91
Mean 0.90 0.91
C .V. (%) 3.3 1.7
Mean percent difference - 1 .1 0
* Analysed upon preparation.
* *  Analysed after seven-days storage in a laboratory freezer.
* * ‘ Small endogenous components in plasma; mean subtracted from subsequent concentra­
tion levels.
-*ND = not detected.
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Table 5.2 17-ketotrilostane (Concentrations in prepared human plasma
samples determined by HPLC assay
Concentration added
(Mg/ml)
Concentration found, 
fresh* (/ig/ml)
Concentration found, 
fro zen ** (Mg/ml)
0 < M Q L * * *
< M Q L < M Q L
< M Q L (0 .09 )
< M Q L (0 .07 )
0.31 0.31
0.37 0.29
0.31 0.29
0.32 0.28
Mean 0.33 0.29
C .V . (%) 8.8 2.0
Mean percent difference 6.5 - 6 .5
0.76 0.78
0.70 0.72
0.85 0.67
0.75 0.72
Mean 0.77 0.70
C .V . (%) 8.1 4.1
Mean percent difference 1.3 —7.9
1.53 1.51
1.51 1.40
1.47 1.45
1.48 1.43
Mean 1.49 1.43
C .V . (%) 1.4 1.8
Mean percent difference - 2 .6 - 6 . 5
2.29 2.17
2.14 2.27
2.43 2.23
2.24 2.27
Mean 2.24 2.26
C .V . (%) 5.8 1.0
Mean percent difference - 1 .8 - 1 .3
*  Analysed upon preparation.
* *A n a lj’sed after seven-days storage in a laboratory freezer.
* * * M Q L  = 0.05 Mg/ml.
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Table 5.3 Plasma trilostane and 17-ketotrilostane concentrations
determined bv HFLC analysis
(i) trilostane concentrations (ug ml
Time (h) 
Volunteer
0 1.0 2.0 3.0 4.0 5.0 6.0 8.0
Vol. 2 NDa <M2Lb 0.35 0.13 0.12 0.22 0.12 <MQL
Vol. 3 ND <MQL 0.22 0.35 0.54 0.19 <MQL <MQL
Vol. 4 ND 0.17 0.29 0.21 0.10 <MQL <M2L ND
Vol. 6 ND 0.11 0.56 0.24 0.11 <M2L <MQL <MQL
(ii) 17-ketotrilostane concentrations fucr ml
Time (h) 
Volunteer
0 1.0 2.0 3.0 4.0 5.0 6.0 8.0
Vol. 2 ND 0.34 0.79 0.53 0.45 0.73 0.58 0.14
Vol. 3 ND 0.20 0.62 0.79 1.30 0.79 0.28 <MQL
Vol. 4 ND 0.57 0.94 0.60 0.39 0.27 0.14 ND
Vol. 6 ND 0.46 1.73 1.20 0.72 0.50 0.29 0.15
ND = not detected
Minimum quantifiable level = 0.10 ug ml 1
-227-
Table 5.4 Equivalent trilostane plasma concentrations determined by CBA.
analysis
Equivalent trilostane concentration (ug ml b)
Time (h) 
Volunteer
0 1.0 2.0 3.0 4.0 5.0 6.0 8.0
Vol. 2 ND 0.61 1.76 0.86 1.02 1.58 0.95 ND
Vol. 3 ND ND 1.32 1.41 2.11 1.45 0.39 ND
Vol. 4 ND 1.32 2.40 1.05 0.63 ND ND ND
Vol. 6 ND 0.76 3.22 2.27 1.18 0.49 ND ND
ND = not detected
-228-
Fig*. 5.1. Typical HPLC (±iromtocrrams of trilostane and 17-ketotrilostanp. 
in plasma
a . Control plasma
B.Plasma containing internal 
standard, 17-ketotrilostane and 
trilostane
i
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Fig. 5.2 Typical calibration line from HPIjC analysis of trilostane
standards
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Fig. 5.4 Mean (— SD) observed trilostane concentration versus spiked 
trilostane concentration
• Immediate analysis 
o Analysis after storage at -15°C
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samples following oral administration of trilostane to 
human volunteers
Pre-medication urine (non-hydrolysed) , Post-medication urine (non-hydrolysed)
11 m  i r
Pre-medication urine (hydrolysed)
Metabolite •
Trilostane
Post-medication urine (hydrolysed)
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Fig. 5.8 El spectra of IMS derivatives of plasma metabolite and
17-ketotrilostane
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Fig. 5.9 El spectra of IMS derivatives of urine metabolite and
17-ketotrilostane
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Ficr. 5.10 Comparison of c^ rfajcheniical and HPLC assays for the ineasiirement 
of trilostane equivalents in plasma
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Fig. 5.11 Correlation of cvtocihemical bioassav and high pressure
liquid chramatocrraphv analytical methods for the 
measurement of trilostane and 17-ketotrilostane
Cytochemical bioassay (uM)
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Table 6.1 Kiarroacokinetic parameters derived from plasma trilostane
t
and 17-ketotrilostane concentrations in human volunteers (n = 8)
Particle Size
4 urn 10 um 10 um 45 um 100 Um
Trilostane
W  <h>
MJCq (ug nl_1h )
0-74 ± 
2.6 ±
1.54 ±
0.34
1.8
0.44
0.42 ± 
2.3 +
1.26 +
0.16
0.8
0.33
0.65 + 
2.2 +
1.63 ±
0.22
1.1
0.40
0.14 ± 
2.9 +
0.56 +
0.04
1.6
0.23
0.07 + 0.03 
11.3 ± 10.6
0.14 ± 0.18
17-ketotrilostane
cav (ug®3-1)troax (h 
itax ' '
AUCq (ug ml-1h )
.1.54 ± 
2.9 +
4.28 ±
0.56
1.6
0.61
1.12 ± 
3.0 +
3.99 +
0.36
1.2
0.92
1.40 + 
2.3 +
4.98 ±
0.51
1.0
1.67
0.43 + 
3.5 ±
2.71 ±
0.07
1.2
0.49
0.21 + 
3.6 +
1.33 +
0.05
1.2
0.63
Total ADC for
biological
activity*
. 8.86 + 1.14 8.07 + 1.76 10.13 + 3.19 5.20 ± 0.85'*' 2.40 ± 1.18*
Relative
Availability (100%) (100%) (100%) 58% 27%
* tAUCraiiosTANE + ^^C17-KETOTRILDSTANE X 1*71^  
+ P < 0-05
-241-
Table 6.2 Ifoanracokinetic parameters derived from plasma epostane 
concentrations in human volunteers
Parameter
particle size
0.6 m2g 1 3.8 m2g_1 2 -1 7.0 m g
^
w (h)
0.38a± 0.27 
3.5 + 0.8
0.78 ± 0.43 
3.3 ± 1.9
0.61 ± 0.23 
2.5 ± 1.8
MJC1® (ug ml-1!!-1) 2.12b ± 1.36 4.15 ± 2.77 3.03 ± 0.71
a = p < 0.01 
b = p < 0.02
-242-
concentrations.
MEAN PLASMA TRILOSTANE CONCENTRATIONS
SUM OF SQUARED DEVIATIONS <F) = 2.531424E-02
THE LAG TIME = .32693 H
COEFFICIENT OF DETERMINATION (r-2) ( .2 ) = .8617894
TIME C (O B S ) C (E S T ) 7. DEV
. 5 .146 .12 -17.739
1 .274 . 303 10.639
1.5 .354 .346 -2.127
O
jL .428 707 - *— / -23.524
-C. m Z* 70 1 . *_> A. OC4- -25.367
T 17 L.. jL- / N -14.446
3-5 .202 .191 -5.499
A —r .152 -24.884
5 .095 . 093 -2.018
Cj .052 .056 7. 546
o . 02 .02 -1.507
tEAN FLASMA 17-KETOTRILOSTAWE CONCENTRATIONS
SUM OF SQUARED DEVIATIONS (F) = .075846
THE LAG TIME - .4791799 H
COEFFICIENT OF Db 1tFllINATIGN (r-A2) ( 2 ) = .9418196
TIME C(OBS) C(EST) 7DEV
.3 .202 .048 -76.371
1 .687 .811 18.052
1.5 .969 1.086 12.026
1.122 1.11 -1.065
2.5 1.091 1.018 -6.734
T .875 .88 .564
3.5 .723 .735 1.593
4 .708 .599 -15.381
5 .456 .382 -16.285
6 .238 .235 -1.199
8 .088 .085 -3.361
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Table 6.4 Mean - SD pharmacolcinetic parameters derived from plasma
trilostane and 17-ketotrilostane concentrations in human 
volunteers following a 240 mcr oral dose (n = 7)
Parameter Trilostane 17-ketotrilostane
C (ug ml"1) max '  ^ J 1.19 ± 0.31 2.43 ± 0.90
t (h) max v ' 2.64 ± 1.60 2.71 ± 1.25
AUC1® (ug ial_1h ) 4.09 ± 1.20 11.0 ± 6.10
-244-
Table 6.5 Comparison of C and AUC parameters after 120 mcr and
max
240 mcr oral trilostane doses (normalised for body weights
120 mg (n = 25) 240 mg (n = 7)
Trilostane
i H 1 H
(ug na ) 0.0085 ± 0.0040 0.0172 ± 0.0062
AUC (ug ml "^ ikg 1) 0.0203 ± 0.0066 0.0597 ± 0.00238
17-ketotrilostane
Suax ^  ^  V 1) 0.0198 ± 0.009 0.0353 + 0.016
AUC (ug ml ^hkg 1) 0.0673 ± 0.027 0.1652 ± 0.109
Ratio 240 mcr dose/120 mg dose Trilostane 17-ketotrilostane
2.0 1.8max
AUC 2.9 2.5
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Table 6.6 Urinary excretion of free trilostane and 17-ketotrilostane 
(inert following a 120 mcr oral dose of trilostane
(i) Trilostane
s^ime (h) 
Voluntee^
2 h
Premedication 0-2 2-4 4-6 6-8 8-24 0-24 %Dose
1
a
(0.04) ND ND ND ND ND ND ND
2 ND 0.06 ND 0.09 ND ND 0.15 0.1
3 (0.13) ND ND ND ND ND ND ND
4 ND 0.03 ND ND ND ND 0.03 <0.1
5 ND ND ND ND ND ND ND ND
6 ND ND ND ND ND ND ND ND
7 ND ND 0.03 0.04 ND ND 0.07 0.1
8 ND ND 0.04 0.02 ND ND 0.06 0.1
(ii) 17-ketotrilostane
<Time (h) 
Volunteer^
2 h
Premedication 0-2 2-4 4-6 6-8 8-24 0-24 %Dose
1 (0.02) 0.07 0.25 0.09 0.03 ND 0.44 0.4
2 (0.01) 0.23 0.09 0.96 ND 0.06 1.34 1.1
3 ND 0.20 0.96 0.09 0.02 ND 1.27 1.1
4 ND 0.64 0.24 0.34 0.02 0.42 1.66 1.4
5 ND ND 0.16 0.08 0.10 0.56 0.90 0.8
6 ND 0.23 0.61 0.68 0.17 0.82 2.51 2.1
7 ND 0.11 0.32 0.62 0.04 0.08 1.17 1.0
8 (0.01) 0.01 0.35 0.44 0.13 0.20 1.13 0.9
MEAN 1.1
SD 0.5
ND = none detected
a Figures in brackets subtracted from subsequent post-medication samples.
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Table 6.7 Urinary excretion of conjugated trilostane and 17-ketotrilostane
(rca) following a 120 mcr oral dose of trilostane 
(derived freon the difference between total and free values)
(i) Trilostane
s^ime (h) 
Volunteer''"
2 h
Premedication 0-2 2-4 4-6 6-8 8-24 0-24 %Dose
1 ND ND ND ND ND , ND ND ND
2 ND ND 0.14 ND ND ND 0.14 0.1
3 ND ND ND ND ND ND ND ND
4 ND 0.04 0.03 ND ND ND 0.07 0.1
5 ND ND ND ND ND ND ND ND
6 ND ND ND ND ND ND ND ND
7 ND 0.08 0.06 0.10 ND 0.49 0.73 0.6
8 ND 0.06 0.04 0.03 NS ND 0.13 0.1
(ii) 17-ketotrilostane
\Tlme (h) 
Volunteer^
2 h
Premedication 0-2 2-4 4-6 6-8 8-24 0-24 %Dose
1 ND 0.29 0.62 2.71 1.23 0.06 4.91 4.1
2 ND 0.25 1.98 ND 0.21 ND 2.44 2.0
3 ND ND 0.64 ND ND ND 0.64 0.5
4 ND 3.18 1.68 1.48 0.85 2.81 10.00 8.3
5 ND ND 0.11 0.61 0.42 ND 1.14 1.0
6 ND ND ND 0.12 ND ND 0.12 0.1
7 ND 0.18 0.61 1.45 0.57 ND 2.81 2.3
8 ND 0.06 0.42 1.03 NS 0.96 2.47 2.1
MEAN 2.6
SD 2.6
ND = none detected 
NS = no sample
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Fig 6.3 Mean (— SD) plasm trilostane concentrations in male volunteers 
(n = 8) following a single oral dose of trilostane (120 mcri , 
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Fig. 6.9 Plasma trilostane and 17-ketotrilostane concentrations following
120 mcr fn = 25) and 240 mcr (n = 7) oral doses of trilostane in man
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Fig, 6.10 Plasma cxmcentration-tiine profiles for trilostane and 17-ketotrilostane 
when a dose of 240 mcr of trilostane is given every 6 hours
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Fia. 6.12 Plasma trilostane and 17-ketotrilostane concentrations in
hypertensive patients following various doses of trilostane
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Trilostane [ (4a ,5a ,17(3 )-4,5-epoxy-3,17 -dihydroxyandrost-2-ene-2-carbo- 
nitrile, I, Fig. 1] is a synthetic steroid which has been shown to be a competi­
tive inhibitor of the 3/3-hydroxysteroid dehydrogenase—A 5 -3-oxosteroid 
isomerase (3(3-HSD) enzyme system in laboratory animals [1—3] and humans 
[4 ] .  The drug has been used to modify adrenal steroidogenesis in conditions 
such as Cushing’s syndrome [4 ] ,  primary aldosteronism [5 ] ,  various forms of 
hypertension [ 6 ] ,  and recently it  has been found to be of benefit in the 
treatment of some forms of cancer of the breast [ 7 ] .
High-performance liquid chromatographic (HPLC) examination of extracts 
of plasma from dosed healthy male volunteers indicated that chromatograms 
contained two peaks, due to trilostane and a metabolite, which were absent
NC-
HO'
■*o
NC-
HO
(I) Ob
Fig. 1. Structures of trilostane ( I )  and ketotrilostane ( I I ) .
0378-4347/84 /$03 .00 © 1984 Elsevier Science Publishers B .V.
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from extracts of control plasma. This communication reports the isolation and 
identification of the metabolite as the 17-keto analogue of trilostane (keto­
trilostane, I I ,  Fig. 1) using various chromatographic techniques including thin- 
layer chromatography (TLC ), HPLC and gas chromatography—mass 
spectrometry (GC—MS), and describes an HPLC procedure for the quantitative 
analysis of trilostane and ketotrilostane in human plasma.
E X P E R IM E N TA L
Reagents and standards
Modrenal capsules (Modrestane, U.S.A.) containing 60 mg trilostane were 
supplied by Sterling Research Labs. (Guildford, U .K .). Trilostane was obtained 
from Sterling Organics (Dudley, U .K .), ketotrilostane from Sterling-Winthrop 
Research Institute (Rensselaer, New York, N Y , U.S.A.) and ethisterone (the 
internal standard) from Sigma (St. Louis, MO, U.S.A.). The reagent for silyla- 
tion, N,0-bis(trimethylsilyl) trifluoroacetamide (BSTFA), containing 1% 
trimethylchlorosilane (TMCS), was purchased from Pierce (Rockford, IL ,  
U.S.A.). A ll other chemicals and solvents were of analytical or chromatographic 
grade, as appropriate.
High-performance liquid chromatography
The HPLC system consisted of a Waters Model 6000A pump, a Waters Model 
710B WISP automatic sample injector, a 5-jum Hypersil ODS column (150 X  
4.6 mm I.D .) obtained from HPLC Technology (Macclesfield, U .K .), a Waters 
Model 440 detector operating at 254 nm, and a Spectra Physics SP4100 data 
system. For quantitative analysis and for monitoring separations the mobile 
phase consisted of methanol—0.1 M  formic acid (1 :1) at a flow-rate of 2 m l/m in. 
Both column and mobile phase were maintained at 30° C. Under these condi­
tions the retention times for trilostane, ketotrilostane and the internal standard 
were approx. 6 , 7 and 12 min, respectively.
Two additional mobile phases, methanol—water (55:45) and methanol— 
water—1.3 M  ammonium acetate (45:40:15), were used for metabolite 
characterisation.
Thin-layer chromatography
For the examination of plasma extracts and purified metabolite by TLC , 
samples were spotted on 0.25-mm precoated layers of silica gel G-60 F 2 5 4 
(E. Merck, Darmstadt, F.R .G .) together with standards of trilostane and keto­
trilostane. Development was carried out at room temperature in the solvent 
systems chloroform—water—acetic acid—tert.-butanol (65:20:10:5 , lower 
phase), chloroform—methanol—formic acid (80:10:10) and dichloromethane— 
diethyl ether—acetic acid (80:15:5).
The separated components were visualised by fluorescence quenching of 
254-nm radiation and by charring at 100°C after spraying with 3.75 M  
sulphuric acid. With the latter procedure trilostane and ketotrilostane yielded 
characteristic grey—brown-coloured products. The approximate R p  values of 
trilostane and ketotrilostane in these systems were 0.52 and 0.60, 0.37 and 
0.50, and 0.36 and 0.52, respectively.
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Gas chromatography—mass spectrometry
The GC—MS system was a Finnigan 4000 gas chromatograph—quadrupole 
mass spectrometer monitored by a Data General Nova 3 computer. The gas 
chromatograph contained a 15 m X 0.4 mm I.D . fused-silica capillary column 
coated with OV 73 (Phase Separations, Deeside, U .K .). For capillary operation 
the gas chromatographic oven was held at 80° C for 1 min and then 
programmed to 305° C at 25°C/m in. Injection port, separator and transfer line 
temperatures were set at 260° C, 280° C and 280° C, respectively. Helium was 
used as carrier gas with a flow-rate of 4.0 ml/m in.
Isolation and derivatisation o f metabolite
Four male volunteers were each dosed with Modrenal capsules (4 X 60 mg). 
Blood sampes (50 m l) were taken 2, 3 and 4 h after dosing into tubes con­
taining lithium-heparin as anticoagulant. The plasma samples obtained by 
centrifugation were pooled and stored below —15°C until required.
A  100-ml aliquot of plasma was adjusted to approx. pH 5 by the addition 
of 50 ml acetate buffer (0.5 M , pH 5.0) and extracted with diethyl ether 
3 X 200 ml). Extracts were pooled, dried over sodium sulphate and evaporated 
to dryness.
The residue, taken up in 0.5 ml chloroform, was applied to a glass column 
containing a bed of silica gel (Activity I I I ,  Woelm Pharma, F.R.G., 100 mm X 
13 mm I.D .) made up and eluted with chloroform (25 ml) followed by 
chloroform—methanol (9 :1 ) at approx. 1 ml/m in. Fractions were collected and 
those found to contain the metabolite were taken down to dryness and re­
chromatographed on a 5-pm Hypersil ODS column (250 mm X 10 mm I.D .) at 
ambient temperature using the mobile phase methanol—water (55:45) at a 
flow-rate of 4 ml/m in.
Those fractions of the eluate containing the metabolite were again pooled, 
evaporated to dryness under reduced pressure and dried over P2O 5 for 1  h. 
The residue was reconstituted in 15 pi toluene and 15 pi BSTFA—TMCS  
reagent and heated at 60° C for 15 min. A  1-pl aliquot o f the reaction mixture 
was injected directly into the GC—MS system. A  small sample o f ketotrilostane 
was derivatised and chromatographed in a similar manner for comparative 
purposes.
Preparation o f analytical standards and samples
Plasma standards were prepared in duplicate by supplementing 2.0 ml of 
control human plasma (obtained from blood with lithium-heparin as the 
anticoagulant) with aliquots o f solutions of trilostane and ketotrilostane in 
1 mM  potassium hydroxide to produce concentrations of 0 and 0.2—1.0 
pg/ml trilostane and 0 and 0.25—2.5 pg/ml ketotrilostane.
Two sets of randomised and coded plasma samples with trilostane and keto­
trilostane concentrations within the ranges described above, to be analysed 
under single-blind conditions, were prepared in a similar manner. One set 
prepared in quadruplicate was analysed upon preparation, the other prepared 
in triplicate was stored in the laboratory freezer for seven days before analysis.
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Analytical procedure
In a tube containing 2.0 ml of human plasma, were added 1.0 ml acetate 
buffer (0.5 Af, pH 5.0) and 10 ml chloroform containing the internal standard 
(0.2 pg/ml). After mixing and centrifugation the upper aqueous phase was 
carefully removed by aspiration and discarded, leaving the lower organic phase 
which was dried over sodium sulphate. An aliquot (5 ml) was evaporated to 
dryness under a stream of nitrogen in a dry-block heater at 45° C. The residue 
was dissolved in 50 pi ethanol and 20 pi injected into the liquid chromatograph 
for analysis.
Extraction efficiency
The percentage recoveries of the extraction procedures for trilostane and 
ketotrilostane were determined at five concentrations, ranging from 0 . 2  to 1 . 0  
pg/ml for trilostane and from 0.25 to 2.5 pg/ml for ketotrilostane, by 
comparing the peak heights obtained from extracted plasma samples with those 
obtained by injection o f unextracted samples.
Calculation o f results
Regression analyses of the peak height ratios (trilostane internal standard, 
ketotrilostane internal standard) obtained for the standards were performed 
to determine the linearity o f the response with respect to concentration. 
The resulting regression lines were used to estimate the concentrations o f 
trilostane and ketotrilostane in the prepared samples. The minimum  
quantifiable level (M Q L) of the assays were estimated as the concentration 
whose lower 80% confidence lim it just encompassed zero [ 8 ] .
RESULTS A N D  DISCUSSION
Identification o f ketotrilostane in plasma extracts
HPLC examination of extracts of plasma from dosed individuals revealed 
that chromatograms contained two peaks, assigned to trilostane and a metab­
olite, which were absent from extracts of control plasma. Typical 
chromatograms are shown in Fig. 2A and B. Since Mori et al. [9 ] had previous­
ly reported that significant quantities of the 17-keto analogue of trilostane 
(ketotrilostane) were present in the plasma of rats dosed with the drug it 
seemed possible that this compound might be responsible for the additional 
peak noted in extracts of human plasma. This view was strengthened when it  
was demonstrated that the human metabolite had identical chromatographic 
properties to ketotrilostane in a range of TLC and HPLC systems.
Confirmation was obtained when it  was shown that the trimethylsilyl (TMS) 
derivatives of the isolated metabolite and ketotrilostane eluted as sharp peaks 
with similar retention times of around 11.5 min under the GC conditions 
described in the experimental section and that both gave essentially identical 
mass spectra (Fig. 3A  and B). The molecular ion at m/e 399 indicated the for­
mation of the mono-TMS derivative.
Assay o f trilostane and ketotrilostane in human plasma
Preliminary investigations suggested that the plasma concentrations of
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Fig. 2. Typical chromatograms o f extracted plasma samples obtained from  a volunteer 
before (A ), and after (B ) 120-mg oral dose o f trilostane (see text for chromatographic con­
ditions) Peaks: K  = ketotrilostane (concentration 2.3 Mg/ml); T  = trilostane (concentration 
1.0 pg/m l), I  = internal standard (ethisterone, 0.2 pg/ml).
trilostane and ketotrilostane after a standard dose used in volunteer studies 
(120 mg) were likely to be in the ranges 0—1 pg/ml and 0—2.5 pg/ml, respec­
tively. Regression analysis on the standards indicated a linear relationship 
between peak height ratio and concentration over these ranges (coefficient of 
regression >  0.99 in both cases).
The control plasma used to prepare the standards and samples contained an 
endogenous component which gave rise to a small peak at the same retention 
time as trilostane. When this contribution was subtracted the slope for 
trilostane was typically 0.484 and the Y-intercept —0.001 pg/ml. For keto­
trilostane the slope was 0.463 and the Y-intercept —0.006 pg/ml.
The concentrations o f trilostane and ketotrilostane in the prepared plasma 
samples, estimated by inverse prediction from the regression equation, and 
allowing for the contribution o f the endogenous component, are summarised in 
Tables I  and I I .  The accuracy o f the assay, defined by the ranges of the mean 
percent differences from the nominal concentration values, varied from —6.7%  
to 7.9% for trilostane and —7.9% to 6.5% for ketotrilostane. The respective 
M QL values were 0.03 and 0.05 pg/ml. Extraction efficiencies (± S.D.) were 
82 ± 6% for trilostane and 76 ± 12% for ketotrilostane and were independent 
of concentration.
The HPLC assay procedure described in this communication is simple, 
relatively rapid and has the advantage over radioimmunoassay [10] in that it
f439
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Fig. 3. Mass spectra o f the (mono-)TMS derivatives o f the metabolite isolated from  human 
plasma (A ), and o f ketotrilostane (B ).
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TA B LE  I
RESULTS O F T H E  A N A L Y S IS  OF PREPA RED H U M A N  PLASM A SAMPLES F O R  
T R IL O S T A N E
M Q L = 0.03 pg/ml.
Concentration added 
(Mg/ml)
Concentration found, 
fresh* (pg/m l)
Concentration found, 
frozen** (pg/ml)
0 (0 .0 6 )* * * c
(0 .05 ) NDS
(0 .05 ) (0.04)
(0 .07 ) (0 .04 )
0.30 0.28
0.30 0.30
0.29 0.30
0.26 0.32
Mean 0.28 0.31
C.V. (%) 6.1 3.8
Mean percent difference - 6 .7 3.3
0.51 0.53
0.45 0.50
0.53 0.45
0.48 0.50
Mean 0.50 0.48
C .V . (%) 7.9 6.0
Mean percent difference —2.0 - 5 . 9
0.71 0.69
0.71 0.67
0.67 0.69
0.69 0.68
Mean 0.69 0.68
C .V . (%) 2.4 1.5
Mean percent difference —2.8 - 4 .2
0.91 0.89
0.87 0.92
0.94 0.89
0.90 0.91
Mean 0.90 0.91
C .V . (%) 3.3 1.7
Mean percent difference —1.1 0
*  Analysed upon preparation.
* *  Analysed after seven-days storage in a laboratory freezer.
** *S m a ll endogenous components in plasma; mean subtracted from subsequent concentra­
tion levels.
-*ND = not detected.
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TABLE II
RESULTS O F T H E  A N A L Y S IS  OF PREPA RED H U M A N  PLASM A SAMPLES F O R  
K E T O TR ILO S TA N E
Concentration added 
(Mg/ml)
Concentration found, 
fresh* (/ug/ml)
Concentration found, 
fro zen ** (ng fm l)
0 < M Q L * * *
< M Q L < M Q L
< M Q L (0 .09 )
< M Q L (0.07 )
0.31 0.31
0.37 0.29
0.31 0.29
0.32 0.28
Mean 0.33 0.29
C .V . (%) 8.8 2.0
Mean percent difference 6.5 - 6 .5
0.76 0.78
0.70 0.72
0.85 0.67
0.75 0.72
Mean 0.77 0.70
C .V . (%) 8.1 4.1
Mean percent difference 1.3 —7.9
1.53 1.51
1.51 1.40
1.47 1.45
1.48 1.43
Mean -1.49 1.43
C .V . (%) 1.4 1.8
Mean percent difference - 2 . 6 —6.5
2.29 2.17
2.14 2.27
2.43 2.23
2.24 2.27
Mean 2.24 2.26
C .V . (% ) 5.8 1.0
Mean percent difference - 1 .8 —1.3
*  Analysed upon preparation.
**Analysed after seven-days storage in a laboratory freezer. 
* * * M Q L  = 0.05 Mg/ml.
allows for the simultaneous quantitation of both trilostane and ketotrilostane. 
The recently developed cytochemical bioassay [11] measures total trilostane- 
like bioactivity (i.e. inhibition of 30-HSD activity by trilostane and its bioactive 
metabolites) but gives no information on their relative concentrations. This
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ability to measure trilostane and ketotrilostane separately is important for 
determining the pharmacokinetics of the drug and for studying the effects of 
dose, formulation and disease states on metabolism.
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Summary—High pressure liquid chromatographic (HPLC) analysis of plasma taken over 8 h from ten 
normal male subjects medicated with 120 mg of trilostane revealed that the drug is rapidly metabolised 
into at least one metabolite, 17-keto trilostane. Both compounds were detected in the blood stream at 
concentrations >  2 x 10-7 M  within an hour and were cleared from the blood by 6-8 h. Approximately 
3 times the concentration of metabolite was detected compared to the parent compound in most samples 
analysed. There were large subject to subject variations in the handling of drug.
Standard curves of pure 17-keto trilostane and trilostane were parallel as assessed by cytochemical 
bioassay. This assay is based upon the inhibition of 3/3-hydroxysteroid dehydrogenase activity in unfixed 
tissue sections of the dioestrous rat ovary. The relative potency of the metabolite compared to trilostane 
was 1.71 (95% confidence 1.5-2.0) over the dose range 0.15-1.5 fi M. Thus, the metabolite may be the 
major active agent when trilostane is administered for clinical purposes.
In a further 4 volunteers, who also received 120 mg trilostane and were sampled over an 8 h period, 
plasma was analysed independently by HPLC and cytochemical assays. In the majority of cases the 
bioactivity recorded (relative to a trilostane standard curve) was substantially higher than the molar sum 
of circulating trilostane and 17-keto-trilostane (as assessed by HPLC). However, if the relative potency 
of 17-keto-trilostane is taken into consideration, correlation between the two assays was excellent 
(r =  0.947, n =  18, P <  0.001). This also suggests that no further active metabolites were present in the 
plasma samples. The drug profiles seen in the second study were essentially the same as described for the 
first 10 volunteers.
The combination of a bioassay, which detects trilostane-like bioactivity, and HPLC, which reveals the 
type of metabolism, should aid our understanding of the clinical value of this potentially important drug.
INTRODUCTION
Trilostane is an orally active steroid analogue which 
is active in vitro and in vivo as an inhibitor of 
3/i-hydroxysteroid dehydrogenase activity [1-5]. To 
date its value as a modulator of adrenal steroido­
genesis has been variable both in normal subjects and 
in patients [6-14]. Recently, the drug has been shown 
to be of benefit in the treatment of advanced breast 
cancer [15]. In an attempt to understand the reasons 
for the variable efficacy of the drug, two assays have 
been developed for its analysis in plasma. The first, a 
quantitative cytochemical bioassay, is based upon the 
inhibition ofi'3/5-hydroxysteroid dehydrogenase (3/? 
HSD) activity in unfixed tissue sections of the di­
oestrous rat ovary. This bioassay is accurate, precise
tTo whom correspondence should be addressed. 
fCurrent address: Department of Chemical Pathology, 
Stepping Hill Hospital, Poplar Grove, Stockport SKE 
7JE, U.K.
and specific for trilostane and any metabolite(s) 
of trilostane which is active in inhibiting 3/5 HSD  
activity [16]. Strictly speaking, as developed at 
present it is an assay which measures trilostane-like 
bioactivity in plasma. However, the system could also 
be modified for the assay of any other drugs which 
also act by inhibiting 3/5 HSD activity e.g. the steroid 
analogue W IN  32,729 (Epostane) which is "currently 
being investigated as an anti-fertility agent [5]. The 
second assay, based upon HPLC techniques [17]. is a 
structural assay which allows for the separate mea­
surement of plasma trilostane and its metabolite 
although it gives no information about the biological 
expression of the molecules. The combined use of 
these two entirely different types of assays should be 
a powerful tool in aiding our understanding of the 
biological as well as chemical fate of this drug.
In the present communication the bioavailability 
of trilostane and its metabolite, 17 keto-trilostane, 
has been studied in 14 normal male subjects given a 
single oral dose (120 mg) of the drug. Analysis of the
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plasma concentrations of the two compounds was 
performed by structural and bioassays and the rela­
tive biological potency of the metabolite has been 
assessed.
MATERIALS AND METHODS
Subjects and blood sampling
The subjects (n =  14, ages 22-40, weights 60-87 kg) 
were normal, healthy male volunteers, who were 
aware of the purpose of the study and had given 
signed consent. Trilostane (2 x 60 mg capsules) was 
taken orally between 0900 and 1000 h. The subjects 
were fasted. A  heparinised blood sample was taken 
before dosing and at various times (up to 8 h) post­
medication. Plasma was prepared and 2-5 ml aliquots 
were snap frozen and stored at — 20°C.
In four of the volunteers duplicate samples were 
also extracted for the bioassay and assayed at two 
dilutions in two separate assays. All the samples were 
analysed by HPLC. The assays were performed inde­
pendently in different laboratories (the bioassay at 
Manchester, the HPLC at Sterling-Winthrop Re­
search and Development, Alnwick) and without prior 
knowledge of any results obtained by the other 
technique. Plasma cortisol was also assayed by radio­
immunoassay in those samples (Amerlex Kit, Am- 
ersham International).
Extraction of trilostane from plasma
A simple chloroform extraction procedure was 
employed. The most efficient extraction of trilostane 
is achieved using acidified plasma, and the protocol 
outlined below leads to 80-90% of the drug being 
extracted. Sodium acetate buffer (1 ml of 0.5 mol/1, 
pH 5.0) was added to 2.0 ml plasma and thoroughly 
mixed in a stoppered tube. Ten ml of chloroform 
were dispensed into the mixture, which was then 
mixed for 5 min on a rotating mixer. The tubes were 
centrifuged at 2000 rpm for 5 min followed by the 
removal of the top aqueous layer. The chloroform 
layer was now dried with 1 g anhydrous sodium 
sulphate, after which 5 ml were transferred to clean 
glass vials before evaporation to dryness in vacuo at 
45°C.
Cytochemical bioassay [16]
The cytochemical bioassay is based upon the dose 
related inhibition of 3/? hydroxysteroid dehy­
drogenase activity in the corpus luteum of unfixed 
cryostat sections of the rat ovary. Enzyme activity 
was measured by microdensitometry. Standard 
curves were constructed in the presence of plasma 
extract taken from a control plasma pool lacking 
trilostane. Equal volumes of the stock enzyme sub­
strate (epiandrosterone, 4 x l O -3 M )  the control 
plasma extract and graded doses of pure trilostane 
(all in dimethyl formamide) were placed into clear 
glass vials. The enzyme incubation medium (contain­
ing buffer, polyvinyl alcohol, EDTA, nitroblue tet-
razolium and N A D +) was then added to each vial 
and mixed thoroughly. The final concentrations of 
trilostane were 1.5, 5, 10 and 25 x 10-7 mol/1. The 
procedure for incorporating plasma extracts (both 
test and quality control samples) into the incubation 
medium is as described above for the standard curve 
except that the pure trilostane solution was replaced 
by solvent alone.
The detection limit of the plasma assay is 2 p mol/1 
trilostane after allowing for dilution effects and re­
covery losses. This level gives a significantly different 
response from the zero quality control (P  <  0.05) and 
has an inter-assay coefficient of variation of <  15%. 
Intra- and inter-assay coefficients of variation using 
both plasma quality controls and unknown samples 
are 4% (n =  15) and 13.9% (n — 27) respectively. 
Recovery is 80 ±  9%(n =  13) and 79 ±  10%(n =  10) 
for plasma quality controls containing 12 and 
4.8 p mol/1 trilostane respectively. Dilutions (up to 
1:5) of plasma extracts are parallel to the standard 
curve and the assay throughput is approx 16 
samples/week/technician.
The relative potency of 17-keto trilostane was 
assessed in three experiments by the preparation of 
standard curves (ranging from 0.15 to 2.5 /xM) of the 
metabolite and the parent compound. Potency esti­
mates were calculated by computer analysis of the 
relative slopes and errors around each dose point by 
courtesy of D r J. Zanelli (National Institute of Bio­
logical Standards and Control, Holly Hill, Hamp­
stead, London).
H PLC  assay [17]
The high performance liquid chromatographic sys­
tem consisted of a Waters Model 6000A pump, a 
Waters Model 710B WISP automatic sample injector, 
a 5/xm Hypersil ODS column (150x4 .6  mm i.d.) 
obtained from HPLC Technology (Macclesfield, 
England), a Waters 440 detector operating at 254 nm, 
and a Spectra Physics SP4100 data system. For 
quantitative analysis and for monitoring separations 
the mobile phase consisted of methanol-0.1 M  formic 
acid (1:1, v/v) at a flow rate of 2 ml/min. Both 
column and mobile phase were maintained at 30°C. 
Under these conditions the retention times for tri­
lostane, ketotrilostane and the internal standard (eth- 
isterone) were approx 6, 7 and 12 min, respectively.
Two additional mobile phases, methanol-water 
(55:45, v/v) and methanol-water-1.3 M  ammonium 
acetate (45:40:15, by vol), were used for metabolite 
characterisation.
RESULTS
It  can be seen from HPLC analysis (Fig. 1 a,b,c) 
that different subjects absorbed the drug at different 
rates, the highest level of trilostane (T) being recorded 
at 2, 3 and 4h  respectively. The data from 10 
volunteers is summarised in Fig. Id. The profiles had 
two features in common. First, the metabolite
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Fig. 1. The determination of the plasma concentrations of 
trilostane [ • ]  and 17-keto trilostane [O] by HPLC in 
normal subjects following a 120 mg oral trilostane dose, (a), 
(b) and (c) are three individual profiles, (d) is the 
mean ±  SEM of 10 volunteers: where SEM’s are not shown 
the trilostane (or 17-keto trilostane) levels were undetectable 
in >  5 out of the 10 subjects.
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(17-keto-trilostane, 17-K-T) was present in each sam­
ple in a ratio of approx 3:1 (17-K-T:T) on a molar 
basis. Second, both compounds were cleared (i.e. 
<0.2  fiM  detected) from the blood by 6-8 h.
The relative potency of 17-K-T was assessed by 
bioassay (Fig. 2). Both T  and 17-K-T exhibited 
parallel dose response lines (over the range 
0.15-2.5 f iM)  and the metabolite was 1.71 times (95% 
confidence, 1.4-2.1) more potent in inhibiting 3)3 
HSD activity than the parent molecule.
In four further subjects who had taken the drug 
under similar circumstances plasma T and 17-K-T 
concentrations were again estimated by HPLC assay, 
and plasma trilostane-like bioactivity was measured 
by the cytochemical bioassay. In addition, plasma 
cortisol was assessed. It  can be seen (Fig. 3 a,b,c,d
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Fig. 2. The relative inhibition of rat ovarian 
3)3-hydroxysteroid activity by trilostane [ • ]  and 17-keto 
trilostane [■]. The results are expressed as the mean ±  SD 
(« =  4).
Fig. 3. Total plasma trilostane and 17-keto trilostane levels 
in four normal volunteers, a comparative study by cyto­
chemical bio and HPLC structural assays. [A] plasma 
cortisol (nmol/l). [O] molar sum of trilostane and 17-keto 
trilostane ( x 1.71 to allow for increased potency) as deter­
mined by HPLC. [■ ] Trilostane-like bioactivity as deter­
mined by cytochemical bioassay. The lower limits of de­
tection of the cytochemical bioassay and HPLC assay are 
indicated by the solid and dot/dash horizontal lines. Where 
no data are presented, the levels were below the lower limit 
of detection of the assay.
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Fig. 4. The correlation between the cytochemical and HPLC 
assays of plasma trilostane and its metabolite. Total 
trilostane-like bioactivity was determined by cytochemical 
bioassay. The molar sum of trilostane and 17-keto-trilostane 
( x 1.71 to account for its increased potency) were calcu­
lated from the HPLC assays.
and Fig. 4) that the agreement between the bioassay 
of trilostane-like activity and the molar sum of T  and 
17-K-T ( x 1.71 to account for its increased potency) 
assayed by HPLC was in excellent agreement with a 
correlation coefficient of 0.947 (n =  18, P  >  0.99). A  
further feature of these profiles is the clear re­
lationship between the concentration of active drug 
and cortisol in the plasma. Thus, when there are clear 
sustained peaks of T  and 17-K-T, cortisol secretion 
was suppressed, recovering only when the drug levels 
decline.
DISCUSSION
In view of the fact that plasma drug levels may 
more accurately reflect pharmacologic effect than 
administered dose which may only be poorly related 
to the drugs efficacy due to great differences between 
^individuals with regard to absorption, metabolism 
and clearance rate, there has been an upsurge in the 
development of drug assay techniques [18]. Thus, as 
well as being pre-requisite for the study of pharma­
cokinetics and dynamic characteristics of a particular 
dosing schedule, the determination of plasma drug 
concentrations may allow for the correlation of these 
levels with both therapeutic and toxic effects on the 
patient.
To date no pharmacokinetic studies have been 
published for trilostane and its clinical efficacy has 
been variable. The confusion about its value is best 
typified by the experiences with Cushing’s Syndrome 
where the clinical response has varied from no effect 
[13] to positive effects in some cases [14] and finally 
to the provocation of an Addisonian crisis [8]. It may 
be that for this drug, as with many others, an initial 
screening of the plasma bioactive levels of the com­
pound (and its metabolite) may be desirable.
A single dose of trilostane (120 mg) given to nor­
mal volunteers is readily absorbed (although with 
considerable subject to subject variation), is rapidly
metabolised into a plasma metabolite (17-K-T) and 
cleared from the blood within 6-8 h. In normal 
subjects at least, the metabolite is the major circu­
lating form of the drug. Further, its potency, as 
assessed by the cytochemical bioassay, is 1.7 x that 
of the parent compound. Plasma cortisol levels were 
acutely suppressed when the concentrations of tri­
lostane and 17-keto-trilostane were at their highest. 
This is in marked contrast to that experienced with 
normal volunteers treated with increasing doses 
(240 mg-»960 mg/day) over a 4 week period [11]. In 
that study, 24 h urinary free cortisol excretion rose 
slightly and early morning serum cortisol levels re­
mained unchanged whilst the subjects were on tri­
lostane. Furthermore adrenocorticotrophin levels 
(assayed by radioimmunoassay) were unaffected.
In conclusion the combined use of a biological 
assay which measures the bioactive molecules, and of 
an HPLC assay which provides information on the 
metabolism of the drug, is a powerful combination 
when attempting to understand the efficacy and fate 
of any particular compound.
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